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The prevalence of chronic Lyme disease (CLD) remains relatively unknown in 
Connecticut because there is not an agreement on what CLD is and how it should be 
diagnosed in addition to which pathological agent causes CLD. The aim of this 
quantitative study was to assess whether there were significant differences between two 
groups of primary care physicians (PCP) working in Connecticut from two different 
points in time regarding their knowledge in the diagnosis, treatment, and management of 
CLD. A knowledge, attitude, and practice model was used as the underlying theoretical 
framework for this study. A random cross-sectional survey was mailed out to the 1,726 
PCPs found in the list of certified medical doctors in Connecticut of 2015. One hundred 
and forty-five PCPs responses (11.9% response rate) were received and compared to 
responses from previous data (a 2010 study) of 285 PCPs (39.1% response rate) from the 
list of certified medical doctors in 2006. The PCP estimated mean number of patients 
diagnosed and treated for CLD was not significantly different between 2006 and 2015. 
However, a significantly higher number of PCPs in 2015 reported knowing Lyme disease 
(LD) symptoms but not feeling comfortable diagnosing LD (χ² = 536.83, p < 0.001), and 
significantly more PCPs in 2015 reported knowing LD symptoms and feeling 
comfortable diagnosing CLD (χ² = 265.41, p < 0.001). This study can promote social 
change by encouraging Connecticut PCPs to recognize CLD as a diagnosis to enable the 
development of registries and case-control assessments. The findings of this study may 
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Chapter 1: Introduction to the Study 
Introduction 
In this study, I used knowledge from epidemiology, microbiology, and public 
health to investigate chronic Lyme disease (CLD) also known as post treatment Lyme 
disease syndrome (PTLDS), a probable but unreported new health condition that affects 
humans (Centers for Disease Control and Prevention [CDC], 2019a; Johnson, Shapiro, & 
Mankoff, 2018). I describe how frequently primary care physicians (PCPs) diagnosed and 
treated Lyme disease (LD) and CLD/PTLDS in Connecticut; however, there has been no 
agreement on what CLD/PTLDS is, how it should be diagnosed, and certainty regarding 
the pathological agent that causes CLD. There is speculation that CLD/PTLDS may be a 
health condition disseminated through the bites of vector-borne pathogens, and many 
researchers associate CLD/PTLDS with LD (Van Hout, 2018).  
Therefore, this study was conducted as a validation of the previous research done 
on the same topic by Johnson and Feder (2010), who were pioneers investigating 
CLD/PTLDS in Connecticut among PCPs. Johnson and Feder found the differences in 
the knowledge, attitudes, and practices (KAP) of physicians who diagnosed and treated 
CLD/PTLDS, who were undecided on CLD, and who did not believe that CLD/PTLDS 
existed in the last 3 years. Johnson and Feder found that a few physicians (less than 3%) 
diagnosed patients with CLD/PTLDS, and 49% of physicians did not treat their patients 
with CLD/PTLDS because they believed that it did not exist. Data from Johnson and 
Feder’s study (PCP survey responses from 2006) were compared to data in this current 
study (PCP survey responses in 2015).  
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I aimed to collect data and use descriptive and analytical epidemiological 
knowledge to examine CLD/PTLDS, a potential new health challenge, as well as study 
how PCPs diagnose and treat patients for CLD/PTLDS. This research is a quantitative 
cross-sectional study on how frequently Connecticut PCPs have diagnosed and treated 
patients for LD and CLD/PTLDS in the last 3 years. Results were compared to the 2006 
distributions of PCP found in the historical population published in 2010 from a study on 
the same topic. Chapter 1 continues with presenting the problem, background, purpose, 
research question, theory, and rationale for the selection of the theory frame design, 
concise definitions, assumptions, limitations, potential contributions, and a study 
summary. 
Background 
CLD/PTLDS is a health challenge (Ali, Vitulano, Lee, Weiss, & Colson, 2014; 
Cameron, 2010; Johnson & Feder, 2010, Johnson, Wilcox, Mankoff, & Stricker, 2014). 
However, physicians and other health professionals have not developed a protocol to 
diagnose and treat CLD/PTLDS. Numerous physicians do not believe that CLD/PTLDS 
is a real illness affecting humans because no one has found valid evidence-based medical 
knowledge about the causal agent and databases collected to confirm or corroborate 
CLD/PTLDS as a new disease (Baker, 2008; Cameron, 2010; Feder et al., 2007; Johnson 
& Feder, 2010; Lantos, 2011; Lantos, 2015a; Wormser & Shapiro, 2009). Despite the 
lack of primary evidence (e.g., origin, mode of transmission, prevalence, incidence rates, 
and risk factors) to identify a possible new or emergent infectious illness, epidemiology 
can be used as a deductive science to gather new insights when the pathogen is unknown 
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to the medical community. It is also advantageous to compare past and present cases 
when investigating a disease that affects the members of a community, which is further 
supported by PCPs’ knowledge that can provide insights for epidemiological and 
evidence-based medical investigations.  
Various scientists have contributed to the origin of evidence-based medicine 
without being aware they used the field principles of epidemiology. With such 
epidemiological applications as data collection and the use of statistical analysis, they 
were able to contribute to the cure for many infectious diseases in the past. For example, 
Hippocrates (the prescription of a form of aspirin and the introduction of how the 
environment may be a risk factor for diseases), Edward Jenner (the vaccination of 
Smallpox), Ignaz Semmelweis (prevention of the transmission of puerperal fever), Joseph 
Lister (the use of antiseptic), Robert Koch (germ theory), and Alexander Fleming (the 
discovery of penicillin) made profound contributions in the field of medicine (Gaynes, 
2017; Hajar 2015).  
Some new advances in epidemiology include clinical epidemiology (Mullan, 
1984; Young, Naude, Brodovcky, & Esterhuizen, 2017), foundations for microbiomics 
(Foxman & Martin, 2015), molecular epidemiology (Carroll et al., 2015), primary care 
epidemiology (Hannaford, Smith, & Elliott 2006), and public health informatics (Friede, 
Blum, & Mc Donald, 1995). Because of these epidemiological advances and the use of 
electronic primary care records, surveillance, and public health informatics, medical 
doctors and other health practitioners (e.g., epidemiologists) can help prevent, eliminate, 
and control diseases. For example, Koch had applied data collection and surveillance 
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practices with his discovery of Mycobacterium tuberculosis in 1882, which has the major 
symptoms of a fever, severe coughing, and chest pain (Fogel, 2015). Koch observed how 
patients with tuberculosis had similar symptoms, and with microscopic laboratory 
techniques was able to recognize the bacteria that caused their symptoms. Koch’s 
discovery established the importance of case definitions in preventing diseases (Cambau 
& Drancourt, 2014). Additionally, Koch’s work set the precedent for evaluating diseases 
with epidemiological applications, creating follow-up for effective treatment techniques, 
and using laboratory techniques as support for clinical diagnoses (Cambau & Drancourt, 
2014). However, there are not always methods for data collection and surveillance 
because there are no accepted case definitions, international classification of disease 
(ICD) codes, or clear guidelines for diagnosis and treatment, which is the case for 
CLD/PTLDS.  
Though not all health conditions are recognized, the CDC has a surveillance 
system—the standardization of the list of reportable diseases across the United States and 
territories (CDC, 1990a). Additionally, after the 1990s, the developed guidelines for 
surveillance by telecommunications systems required public health agencies to relay 
reportable diseases to the CDC. Consequently, standardized case definitions for 
reportable diseases were needed (CDC, 1990a, 1990b). Once a disease’s case definition is 
established and reported, term standardization enables epidemiologists to calculate 
incidence, prevalence, and risk factors affecting humans and animals. The case definition 
process begins after a new disease is found and aids in the collection of epidemiological 
information. Therefore, epidemiologists focus on determining and monitoring the 
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distribution and determinants of diseases within susceptible populations via public health 
surveillance (Choi, 2012; Kuller, 2016). Moreover, after case definition usage is 
established, researchers can track incidence rates and monitor temporal or long-term 
trends in disease occurrence. Epidemiologists also examine factors such as whether the 
disease is seasonal, acute or chronic, and infectious or noninfectious. The Council of 
State and Territorial Epidemiologists in the United States (CDC, 1990a, 1997) started to 
use case definitions to classify and survey diseases in 1990: 
• Confirmed case: a case that is classified as confirmed for reporting purposes.  
• Probable case: a case that is classified as probable for reporting purposes.  
• Laboratory-confirmed case: a case that is confirmed by one or more of the 
laboratory methods listed in the case definition under “Laboratory criteria for 
diagnosis.” Although other laboratory methods may be used in clinical 
diagnosis, only those listed are accepted for laboratory confirmation for 
reporting purposes. 
• Clinically compatible case: a clinical syndrome generally compatible with the 
disease, but no specific clinical criteria need to be met unless they are noted in 
the case classification.  
• Supportive laboratory results: specified laboratory results consistent with the 
diagnosis but not meeting the criteria for laboratory confirmation.  
• Epidemiologically linked case: a case in which the patient has/has had contact 
with one or more persons who have/had the disease, and transmission of the 
agent by the usual modes of transmission is plausible. A case may be 
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considered epidemiologically linked to a laboratory-confirmed case if at least 
one case in the chain of transmission is laboratory confirmed.  
• Meets the clinical case definition: meets precisely the clinical case definition. 
Although in clinical practice the diagnosis may be made with the use of other 
criteria, for reporting purposes the stated criteria must be met. (Wharton, 
Vogt, & Buehler, 1990).  
In the field of public health (i.e., epidemiology) the number of individual illness 
cases is significant, and the data enable epidemiologists to calculate incidence rates. This 
information is vital for health practitioners, such as PCPs and local health directors, to 
monitor diseases in their communities. Most disease investigations are initiated once the 
incidence exceeds expected occurrence levels for the specific condition and time. In some 
cases, there is a well-organized system for collecting data from ill community members, 
which is the case for CLD/PTLDS. It is frequently not reported by local health 
departments because it is a health condition without a standardized case definition and 
unknown etiological origin. Therefore, PCPs may have no easy way to share 
CLD/PTLDS patient information with health agencies such as the Connecticut 
Department of Health (CT DPH). Further, access to data from epidemiological research is 
limited to public health officers, which results in a lack of disease prevention and control 
efforts (Bach et al., 2017; Choi, 2012; Kuller, 2016). Thus, understanding the importance 
of public health data collection and surveillance will help analyze quantitative 
information, which may lead to health policies to reduce mortality and morbidity 
(Wetterhall, Pappaioanou, Thacker, Eaker, & Churchill, 1992).  
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Defining and Diagnosing Chronic Lyme Disease 
In the United States, LD is a major disease caused by B. burgdorferi and B. 
mayonii (Dolan et al., 2017). LD is transmitted to humans through the bites of infected 
blacklegged ticks (Citera, Freeman, & Horowitz, 2017; Moore et al., 2016). The CDC 
estimates that there are more than 300,000 LD cases in the United States annually 
(Rebman et al., 2017). The most common symptom is the erythema migrans (EM) rash 
(Nadelman et al., 2012). However, not all patients who contract LD develop this red rash 
(Citera et al., 2017). Table 1 presents the basis for different diagnoses, and Table 2 
presents the ICD codes for Lyme Disease.  
Table 1 
 
Categories for Diagnosis 
Patient Category Basis for Diagnosis 
Undisputed Lyme disease Diagnosed on appropriate clinical grounds in early disease or 
by reference laboratory testing in disseminated Lyme disease. 
Post-Treatment Chronic 
Lyme syndrome 
Diagnosed as above but failing to experience complete 
symptom resolution after standard antibiotic therapy. 
Alternatively, diagnosed 
chronic Lyme syndrome 
Diagnosed on clinical grounds supported only by alternative 
tests, the validity of which is questioned by major reference 
laboratories and the CDC. 
Seronegative Lyme 
disease 
Diagnosed on purely clinical grounds (a controversial 
category outside of early disease). 







ICD-10 Codes for Lyme Disease 
Diagnosis Code Description Category 
A69.2 LD Other spirochetal (A69) 
A69.20 LD, unspecified Other spirochetal (A69)  
A69.21 Meningitis due to 
LD 
Other spirochetal (A69). Meningitis in LD · 
Meningitis (basal) (basic) (brain) (cerebral) (cervical) 
(congestive) (diffuse) (hemorrhagic) (infantile) 
(membranous) (metastatic) (nonspecific) (pontine) 
(progressive) (simple) (spinal) (subacute) 
(sympathetic) (toxic) 
A69.22 Other neurologic 
disorders in LD 
Other spirochetal (A69).  
Cranial neuritis · Meningoencephalitis · 
Polyneuropathy · Cranial neuritis due to LD · Lyme 
cranial neuritis · Lyme meningoencephalitis · Lyme 
polyneuropathy · Meningoencephalitis due to LD 
A69.23 Arthritis due to 
LD 
Other spirochetal (A69). Lyme arthritis · Arthritis, 
arthritic (acute) (chronic) (nonpyogenic) (subacute) 
M19.90 due to or associated with LD 
A69.29 Other condition 
associated with 
LD 
Other spirochetal (A69). Lyme myopericarditis · 
Myocarditis (with arteriosclerosis) (chronic) (fibroid) 
(interstitial) (old) (progressive) 
Note. Information from http://www.icd10data.com/ICD10CM/Codes/A00-B99/A65-
A69/A69-/A69.20. CLD/PTLDS does not have an ICD code so patients can be diagnosed 
and have their health insurance paying such medical process like in the case here with 
LD.   
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In 2019, the International Lyme and Associated Diseases Society (ILADS) 
defined CLD (also known as PTLDS) as “an ongoing infection with any of the 
pathogenic bacteria in the Borrelia burgdorferi sensu lato group that is poorly understood 
and often mischaracterized.” Associated with this definition in 2018, the International 
Lyme and Associated Diseases Society recognized that symptoms of fibromyalgia, 
chronic fatigue syndrome, and depression were often misdiagnosed in patients with 
CLD/PTLDS (ILADS, 2018, p. 8). Other symptoms for CLD/PTLDS include peripheral 
neuropathy, motor neuron disease, neuropsychiatric presentations, cardiac presentations 
with electrical conduction delays and dilated cardiomyopathy, and musculoskeletal 
problems (ILADS, 2004). 
Many health organizations, including the CDC (2019) and the National Institute 
of Allergy and Infectious Diseases (2019), do not accept the term CLD/PTLDS as a 
standard medical diagnosis. These health organizations prefer the term PTLDS. PTLDS is 
a known disease related to LD in patients who previously had EM or recurring symptoms 
(CDC, 2019a; Horowitz & Freeman, 2018). The CDC defines PTLDS (also known as 
CLD) as a health condition in which patients treated for LD continue to have symptoms 
of fatigue, pain, or joint and muscle aches after two to four weeks (CDC, 2017c). 
However, the cause of PTLDS remains unknown (Marques, 2008). Consequently, an 
ICD-10 diagnosis code is designated for PTLDS and not for the term CLD alone because 
the International Lyme and Associated Diseases Society  definition does not fit a 
diagnosis among PCPs. Therefore, the controversial health condition of CLD/PTLDS 
may never be reported or will be under- or mis-reported by the CDC, National Institute of 
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Health, Infectious Diseases Society of America, and International Lyme and Associated 
Diseases Society. Additionally, these health organizations do not agree on billing and 
legislation guidelines for appropriately treating LD patients (Naktin, 2017). Therefore, 
there are many gaps in the medical field regarding CLD/PTLDS.  
There is also controversy surrounding the diagnosis of CLD/PTLDS (Lantos, 
2015a; Maloney, 2016). The Infectious Diseases Society of America, ILADS, and the 
CDC have differing perspectives on the existence of CLD/PTLDS. Many medical doctors 
do not believe that CLD/PTLDS is a chronic form of LD, and epidemiologists are not 
sure of its origins. Researchers have not identified a biological agent that causes 
CLD/PTLDS, and there is no reliable laboratory test to detect it, which have impeded the 
empirical study of CLD/PTLDS (Lantos et al., 2015c; Maloney, 2016).  
To address the lack of knowledge on CLD/PTLDS, Johnson and Feder (2010) 
conducted a study on physicians’ KAP regarding CLD/PTLDS. They collected KAP data 
from a sample of 285 PCPs practicing in the state of Connecticut. Johnson and Feder 
found that less than 3% of the 285 PCPs in their study had diagnosed patients with 
CLD/PTLDS, 49.8% of the PCPs did not treat their patients for CLD/PTLDS because 
they did not believe the condition existed, and 48.1% of the PCPs reported being 
undecided as to whether CLD/PTLDS existed. However, little KAP knowledge of 
CLD/PTLDS has been obtained in the 10 years since Johnson and Feder’s study, the only 
exception being a study by Ferrouillet, Milord, Lambert, Vibien, and Ravel (2015). 
Ferrouillet et al.’s (2015) study was similar in nature and scope to that of Johnson and 
Feder but was focused on both LD and CLD/PTLDS. Ferrouillet et al. found that there 
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were significant differences in the knowledge and practices of physicians regarding LD 
diagnosis and treatment. Additionally, Ferrouillet et al. discovered that physicians had 
diverse responses to the diagnosis, treatment, and management of LD and CLD/PTLDS. 
Ferrouillet et al.’s findings demonstrate the necessity of this research because they may 
be relevant in improving physician’s knowledge toward the latest trends of CLD/PTLDS 
in Connecticut.  
Another survey implemented in this study could address the informational gaps 
related to CLD/PTLDS to build on the data collected by previous researchers. A new 
study may help broaden the understanding of CLD/PTLDS in Connecticut. This study 
expands the fields of medicine and epidemiology by applying both nonparametric and 
parametric statistical analyses to gather evidence-based medical research when 
encountering a health challenge (Levman & Takahashi, 2016; Roy et al., 2009). 
Therefore, I conducted the same survey used by Johnson and Feder (2010) with a 
statistical application to allow for the assessment, measurement, and evaluation of 
whether awareness and treatment by PCPs have changed in Connecticut. All independent 
variables pertain to the two study groups of Connecticut PCPs (2006 vs. 2015). I 
employed Chi-square (χ²) goodness-of-fit tests when the dependent variables were 
categorically coded and one-sample t tests when the dependent variables were ratio 
coded.  
This study filled the gap by investigating the KAP of PCPs’ positions on 
CLD/PTLDS in Connecticut. The CT DPH currently does not collect epidemiological 
information about CLD or PTLDS as distinctive from LD reporting, which is expected 
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from the Council of State and Territorial Epidemiologist’s surveillance across the U.S. 
States and Territories. This study is therefore limited because I was unable to ask PCPs in 
Connecticut to utilize any of the ICD A69 subcodes to characterize the cases into specific 
CLD/PTLDS categories epidemiologically. Therefore, the ability to collect 
epidemiological data on CLD cases is limited in this study.  
This study also contributes new knowledge to address gaps in communication 
among PCPS in Connecticut regarding the status of CLD in Connecticut by comparing 
two different PCP profiles (2006 vs. 2015). Lapses in communication between health 
professionals about a critical issue of concern can create poor awareness of the magnitude 
of the health problem, inefficiency in financing, and lack of adequate health policies to 
benefit the members of a community (Mallonee, Fowler, & Istre, 2006). Therefore, I 
aimed to assess, evaluate, and compare the differences in the KAP among PCPs who (a) 
diagnose and treat CLD/PTLDS, (b) are undecided about it, and (c) do not believe that it 
exists. These correlations were used to validate (yes or no) the outcomes found in 
Johnson and Feder’s (2010) study.  
After the position of PCPs is known regarding CLD/PTLDS, this study may have 
scientific merit if the data obtained can enhance the necessity for the creation of a 
baseline electronic system that will collect and document data from cases of 
CLD/PTLDS. The study may also lead to equal guidelines across medical doctors to use 
same standard care practices for diagnosing and treating CLD/PTLDS. As Moffett and 
Moore (2011) stated, a competent physician treats patient equally under similar 
circumstances. However, it is difficult to expect the same care from PCPs when they 
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diagnose and treat patients without standardized care and guidelines (Cameron et al., 
2014, Infectious Diseases Society of America, 2006). When comparing the PCPs’ 
responses from the previous study (Johnson & Feder, 2010) and this study, it was 
expected that the outcomes of the Chi-square (χ²) goodness-of-fit and the one-sample t 
test will help PCPs to find new and constructive data that can be utilized to infer solutions 
to improve their medical practices and approaches to better serve LD and CLD/PTLDS 
patients. As Skela-Savič, Macrae, Lillo-Crespo, and Rooney (2017) stated in their study, 
“Healthcare improvement science is the generation of knowledge to cultivate change and 
deliver person-centered care that is safe, effective, efficient, equitable and timely. It 
improves patient outcomes, health system performance, and population health” (p. 1) 
The results of the study have the potential to contribute to social change by 
presenting the position of PCPs regarding CLD/PTLDS in Connecticut as a new disease, 
which may encourage future research and validation of CLD/PTLDS as a diagnosis. This 
conflict around CLD/PTLDS may affect numerous patients who are or were severely sick 
with CLD in Connecticut. Patients with CLD have found no much medical support for 
their illness status (Ali et al., 2014; Johnson et al., 2014). Patients with CLD/PTLDS have 
felt neglected without any medical help and paid more money out of their pocket when 
they visited physicians in the state of Connecticut (Johnson et al., 2014). Patients with 
CLD/PTLDS also lost their jobs and are or were experiencing a higher degree of 




There was a need to conduct a validation study to assess, evaluate, and determine 
whether there are changes in Connecticut PCPs’ knowledge about the diagnosis, 
treatment, and management approaches for CLD/PTLDS. LD could be associated with 
the pathology of CLD/PTLDS; however, that association is currently unproven. Although 
the pathological agent, transmission, and treatment of LD are well known, questions 
remain regarding the best medical treatment practices for CLD/PTLDS (Bernard et al., 
2016; Delong, Blossom, Maloney, & Phillips, 2012). LD mimics other conditions, and 
patients are not always aware that they have contracted the disease (Marzec et al., 2017). 
There are few guidelines for the diagnosis, treatment, documentation, and management of 
CLD patients.  
There is  also gap in the knowledge regarding significant differences in the KAP 
of physicians on the diagnosis, treatment, and management of LD and CLD/PTLDS 
among physicians who diagnose and treat CLD/PTLDS, physicians who are undecided 
on CLD/PTLDS, and physicians who do not believe that CLD/PTLDS exits. Thus, I 
surveyed these physicians by using Chi-square test (χ²) and t tests. The problem is current 
and significant to the discipline because new knowledge on this topic may contribute to 
social changes that will improve strategies in protocols needed for PCPs to deal with 
CLD/PTLDS patients.  
Purpose of the Study 
The purpose of this quantitative study with a nonexperimental cross-sectional 
comparative research design was to assess, exanimate, and determinate (for validity 
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purposes) whether there were significant differences between two groups of PCPs 
working in Connecticut regarding their KAP in the diagnosis, treatment, and management 
of LD and CLD/PTLDS. In this study, the CT DPH medical doctors/Doctor of 
Osteopathic Medicine (MD/DO) of 2015 was the independent variable for all study 
questions. The complete data set for the Connecticut PCPs group from the list of certified 
medical doctors in 2006 or CT DPH MD/DO of 2006 could not be obtained from 
Johnson and Feder (2010). Therefore, I used the data presented in their study, and this 
group of physicians is treated as a population with frequency and mean level data that 
was compared to the data obtained from the sample of physicians in this study.  
The first research question acted as a validation check, and it was expected that 
the two groups would have similar frequencies of PCPs with general or family practice, 
internal medicine, pediatric, and other primary care specialties since the two cluster 
groups were withdrawn from the original lists of CT DPH MD/DO of 2006 and 2015. 
The dependent variable for the second research question is the knowledge of LD, 
measured categorically, and the dependent variable for the third research question was 
the knowledge of CLD/PTLDS, the categorical variable. For the fourth and fifth research 
questions, one-sample t tests were conducted to determine whether the two groups of 
PCPs significantly differ concerning the number of patients diagnosed with and treated 
for CLD/PTLDS, as well as the average course of antibiotic treatment for patients 
diagnosed with CLD/PTLDS, the respective dependent variables. This study allowed for 
a priori assumption and/or premise for the existence of CLD/PTLDS as defined by  
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International Lyme and Associated Diseases Society(Cameron et al., 2014; ILADS, 
2004).  
Research Questions and Hypotheses 
Research Question 1: Are the frequency distributions of the 2015 sample of 
Connecticut PCPs across the four primary practice specialty areas (i.e., family medicine, 
internal medicine, pediatrics, other) significantly different from the distributions of the 
2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?  
H01: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the four primary practice specialty areas (i.e., family medicine, internal medicine, 
pediatrics, other) are not significantly different from the distributions of the 2006 
(Johnson & Feder, 2010) sample of Connecticut PCPs. 
Ha1: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the four primary practice specialty areas (i.e., family medicine, internal medicine, 
pediatrics, other) are significantly different from the distributions of the 2006 (Johnson & 
Feder, 2010) sample of Connecticut PCPs.  
Research Question 2: Are the frequency distributions of the 2015 sample of 
Connecticut PCPs across the two knowledge of LD categories (i.e., know symptoms of 
LD and feel comfortable diagnosing and treating LD vs. know LD but do not feel 
comfortable diagnosing and treating LD) significantly different from the distributions of 
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs? 
H02: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the two knowledge of LD categories (know symptoms of LD and feel comfortable 
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diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and 
treating LD) are not significantly different from the distributions of the 2006 (Johnson & 
Feder, 2010) sample of Connecticut PCPs. 
Ha2: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the two knowledge of LD categories (know symptoms of LD and feel comfortable 
diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and 
treating LD) are significantly different from the distributions of the 2006 (Johnson & 
Feder, 2010) sample of Connecticut PCPs. 
Research Question 3: Are the frequency distributions of the 2015 sample of 
Connecticut PCPs across the three knowledge of CLD/PTLDS categories (do not believe 
CLD exists, do not feel comfortable diagnosing and treating CLD/PTLDS, and feel 
comfortable diagnosing and treating CLD/PTLDS) significantly different from the 
distributions of the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs? 
H03: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the three knowledge of CLD/PTLDS categories (do not believe CLD exists, do not feel 
comfortable diagnosing and treating CLD/PTLDS, and feel comfortable diagnosing and 
treating CLD/PTLDS) are not significantly different from the distributions of the 2006 
(Johnson & Feder, 2010) sample of Connecticut PCPs. 
Ha3: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the three knowledge of CLD/PTLDS categories (do not believe CLD/PTLDS exists, do 
not feel comfortable diagnosing and treating CLD/PTLDS, and feel comfortable 
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diagnosing and treating CLD/PTLDS) are significantly different from the distributions of 
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.  
Research Question 4: Is the estimated average number of patients diagnosed as 
having CLD/PTLDS within a 3-year period by the 2015 sample of Connecticut PCPs 
significantly different from the average number of patients diagnosed as having 
CLD/PTLDS within a 3-year period by the 2006 (Johnson & Feder, 2010) sample of 
Connecticut PCPs?  
H04: The estimated average number of patients diagnosed as having CLD/PTLDS 
within a 3-year period by the 2015 sample of Connecticut PCPs is not significantly 
different from the average number of patients diagnosed as having CLD/PTLDS within a 
3-year period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs. 
Ha4: The estimated average number of patients diagnosed as having CLD/PTLDS 
within a 3-year period by the 2015 sample of Connecticut PCPs is significantly different 
from the average number of patients diagnosed as having CLD/PTLDS within a 3-year 
period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs. 
Research Question 5: Is the estimated average course of antibiotic treatment (in 
weeks) for patients diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut 
PCPs significantly different from the average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample 
of Connecticut PCPs? 
H05: The estimated average course of antibiotic treatment (in weeks) for patients 
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is not 
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significantly different from the average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample 
of Connecticut PCP 
Ha5: The estimated average course of antibiotic treatment (in weeks) for patients 
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is 
significantly different from the average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample 
of Connecticut PCP. 
The KAP survey used in this study was relevant to measure how many PCPs 
diagnose and treat CLD/PTLDS, are undecided on CLD/PTLDS, or do not believe that 
CLD/PTLDS exists. Abdullah et al. (2013) have established the reliability and validity 
for the KAP questionnaire. The Cronbach’s alpha coefficients were 0.96 (knowledge), 
0.63 (attitude), and 0.79 (practice). The alpha coefficients were acceptable (Nyunnally, 
1978).  
Theoretical Framework 
In 1962, Rogers developed the diffusion of innovations theory (Chien-Yun, Wan-
Fei, Yu- His, & Chia-Hung, 2012; Rogers, 2004). This innovations theory is a systematic 
research investigation tool that can be applied to support how new concepts or ideas are 
distributed and adopted by groups within society over time. Researchers in the modern 
medical field have utilized diffusion of innovation theory to promote an understanding of 
health challenges and to incorporate innovation adoptions into KAP for societal benefit 
(Agyeman et al., 2009; Chien-Yun et al., 2012; Launiala, 2009).  
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Examples of researchers who use the KAP theory to change physician behavior 
include AI-Dharrab, Mangoud, and Mohsen (1996) and Magri, Johnson, Herring, and 
Greenblatt (2002). Al-Dharrad et al. administered a KAP study to physicians and nurses 
to collect data on hypertension in Saudi Arabia. Magri et al. described a KAP 
questionnaire that was administered to New Hampshire PCPs to obtain insights into LD 
diagnoses. Recently, Awad and Aboud (2015), Chien-Yun et al. (2012), and Ferrouillet et 
al. (2015) also used a KAP survey to investigate health concerns.  
In this study, I used the KAP model as the underlying theoretical framework in 
this cross-sectional epidemiological study as a quantitative research method (Launiala, 
2009). The KAP model served as a standard for this study because I collected significant 
quantitative data to identify insights related to physician care for CLD/PTLDS patients 
based on medical knowledge and practices. These data were beneficial to prove or 
disprove this study’s hypotheses. 
There are currently many knowledge gaps regarding the underlying agents that 
may cause CLD/PTLDS in Connecticut residents. New information regarding what has 
been or needs to be performed to identify possible risk factors about the disease’s origin 
in Connecticut is important to discover the etiological agent, determine the distinctive 
symptoms, and develop corroborative tests that yield an accurate diagnosis and treatment 
by PCPs. However, the application of the KAP model was not used to answer questions 
regarding the causative agent for CLD/PTLDS. Instead, the questionnaire focused on 
obtaining documentation regarding the KAP of Connecticut PCPs who treat CLD/PTLDS 
patients. PCPs (e.g., family/general, pediatrician, and internal medicine physicians) were 
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chosen because they are typically the first resource for patients (Eldein, Mansour, & 
Mohamed, 2013). The testable Research Questions and hypotheses were used to 
determine if there are methods to improve the doctor-patient relationship in potential 
CLD/PTLDS cases. This study’s findings may be useful if CLD/PTLDS is identified as a 
distinct disease with a functional case definition in the future (Souri et al., 2017; Stricker 
& Fesler, 2018). The survey data may produce significant information on the medical 
care needs of CLD/PTLDS patients. Additionally, it is essential to determine whether 
there are significant differences in the duration of prophylaxis given to CLD/PTLDS 
patients. In this study, I applied the KAP model to test the hypotheses.  
Nature of the Study 
In this quantitative study, I employed a comparative cross-sectional research 
design to determine whether there were significant differences regarding LD and 
CLD/PTLDS KAP between the group of 285 Connecticut PCPs in Johnson and Feder’s 
(2010) study and the 145 PCPs in this study. The comparison element of the study 
pertained to the differences in categorical and ratio-coded dependent variables between 
the two groups of PCPs. The study design was cross-sectional because the data were 
collected from PCPs. 
This study’s independent variable was the PCP groups—that is, those in Johnson 
and Feder’s (2010) study and those in this study. This study had five dependent variables. 
The first three dependent variables were categorically coded. The first three dependent 
variables measured (a) the type of PCP (i.e., family/general practice, internal medicine, 
pediatrics, other), (b) knowledge levels of LD, and (c) knowledge levels of CLD/PTLDS. 
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The last two dependent variables were ratio coded and measured the estimated number of 
patients diagnosed with and treated for CLD within 3 years and the estimated average 
course of antibiotic treatment (in weeks) for patients with CLD(PTLDS).  
As the researcher of this study, I made similar attempts to replicate Johnson and 
Feder’s (2010) sampling and methodological (i.e., recruitment, data collection, 
measurement) procedures to make valid and appropriate comparisons between the data in 
this study and that reported in their study. The participant inclusion criteria were the same 
as those previously used. The criteria required that the physician (a) was certified to 
practice medicine in the state of Connecticut, (b) currently practiced medicine in the state 
of Connecticut, and (c) was a PCP with an identified PCP specialty (i.e., family medicine, 
internal medicine, pediatrics, and others that included emergency medicine). 
I utilized Johnson and Feder’s (2010) KAP survey and developed a survey packet 
that included a KAP survey, a letter of introduction outlining the purpose of the study, an 
informed consent form, and a stamped, addressed envelope for returning the 
questionnaire. In alignment with Johnson and Feder, the study packet was mailed to 33% 
of the PCPs whose work contact information was available from the CT DPH. Surveys 
were expected to be returned from an equivalent number of PCPs  
SPSS 24.0 software was used to enter and analyze the survey data. However, 
because I was unable to obtain the entire data set used by Johnson and Feder (2010), it 
was treated as the population when compared to the sample obtained in this study. 
Sample-to-population comparisons require the use of specific statistical tests for 
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hypothesis testing, which included Chi-square (χ²) goodness-of-fit tests and one-sample t 
tests.     
There are differences between LD and CLD (Crowder et al., 2014). There are also 
differences between CLD, which is given the name PTLDS. However, I combined CLD 
and PTDS as CLD/PTLDS to be inclusive for the purpose of this investigation. Other 
definitions to clarify my use of terms are provided in this section. 
Antibiotics: Antibiotics are classes of drugs prescribed to patients by a medical 
doctor with the purpose to kill or inhibit the growth of disease-causing microorganisms. 
Antibiotics (e.g., penicillin, streptomycin) must be given after a bacterial infection 
(Hamilton & Wenlock, 2016).  
Bias: Bias is the presence of systematic errors in the study design, conduct, or 
analysis (Althubaiti, 2016). 
Beliefs: Beliefs are traditional ideas that one can have regarding an issue. For 
example, a medical procedure can be informed by what people believe is the right choice 
of treatment (Launiala, 2009).  
Chronic diseases: Chronic diseases are chronic illnesses classified as 
noncommunicable diseases or degenerative diseases characterized by an uncertain 
etiology, multiple risk factors, long latency period, prolonged time, and non-contagious 
origin with some degree of degeneration and disability (Fradgley, Paul, & Byrant, 2015).  
Chronic Lyme disease (CLD): CLD is the occurrence of a constellation of 
persistent symptoms in patients with or without evidence of previous Borrelia 
burgdorferi infection (Ali et al. 2014; Johnson & Feder, 2010). Though there are varying 
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definitions for this term, CLD occurs when patients are diagnosed with and treated for 
LD and may continue to experience worsening symptoms after treatment is received. In 
other cases, there is no known etiologic agent or sign of the typical rash of LD or 
information about laboratory testing related to Borrelia burgdorferi or B. mayonii 
(Lantos, 2015a). In this study this term is used as CLD/PTLDS. 
Erythema Migrans (EM): EM is a circular skin lesion that outwardly looks like a 
red patch (rash) with a central clearing and appears as a bullseye after a deer tick bite 
(Allen, Vin, Warner & Joshi, 2016; 2016; Torbahn et al., 2016).  
Evidence-based medicine: Evidence-based medicine is the integration of the 
current best research using clinical expertise, pathophysiology knowledge, and patients to 
make the best medical decisions from observations and data obtained from clinical 
studies (Cameron et al., 2014). 
Immunity: Immunity is protection against a disease. There are two types of 
immunity status: passive and active. The immunity protection status of a person is 
indicated by the presence of antibodies in the blood and can usually be determined by a 
laboratory test (Warrington, Watson, Kim, & Antonetti, 2011). 
Infectious diseases: Infectious diseases are caused by pathogenic microorganisms 
(e.g., bacteria, viruses, parasites, or fungi) that can be transmitted directly or indirectly 
from one person to another (Nii-Trebi, 2017). 
Lyme disease (LD): LD is the most common vector-borne infectious disease in the 




Multi-system infectious disease syndrome: Multi-system infectious disease 
syndrome is a term used mainly by Horowitz in treating patients for CLD (Horowitz & 
Freeman, 2018).  
Primary care epidemiology: Primary care epidemiology represents applications 
and methods to collect the data of health problems encountered in a primary care 
diagnosis setting (e.g., etiology, prevention, and diagnosis to improve their management). 
(Mullan, 1984).  
Physician: A physician is a certified medical doctor who is qualified to practice 
medicine and take care of people or patients (e.g., conduct examinations, prescribe 
medications, and order, perform, and interpret diagnostic tests; U.S. Labor Department, 
2017).  
Post-treatment Lyme disease syndrome (PTLDS): PTLDS is a term established by 
the CDC in 2006 (Maloney 2016; Lacout, El Hajjam, Marcy, & Perronne, 2018) to refer 
to a health condition in patients with LD who maintain symptoms for more than six 
months after the first presentation of LD. In some cases, PTLDS is recognized by other 
organizations and researchers as CLD. In this study this term will be apply as 
CLD/PTLDS. PTLDS is accepted by the CDC and the Infectious Diseases Society of 
America as a diagnostic term for patients whose symptoms persist after the typical 2 to 4 




Public health surveillance: Public health surveillance is the ongoing practice of 
conducting the systematic collection, analysis, interpretation, and dissemination of health 
data for planning, implementation, and evaluation (Choi, 2012, p. 1). 
Risk factors: Risk factors are conditions or measurements associated with the 
probability of disease or death and not necessarily recognized by people or patients 
(Willadsen et al., 2016).  
Surveillance: Surveillance within a medical domain refers to the continuous 
methodical and systematic collection, analysis, and interpretation of health data essential 
for the planning, implementation, and evaluation of public health practice. It is 
thoroughly integrated with the timely dissemination of these data to those who need to 
know (Adokiya, Awoonor-Williams, Beiersmann & Müller, 2015).  
Zoonotic diseases: Zoonotic diseases are infectious diseases that can be 
transmitted from animals to humans or vice versa (Scoth, Mattocks, Rabinowitz, & 
Brandt, 2013).  
Zoonotic infection agents: Zoonotic infection agents are viruses, bacteria, fungi, 
and parasites that cause zoonotic diseases (Walter-Toews, 2017).  
Assumptions 
One of the main assumptions pertained to the use of CLD/PTLDS. For this study, 
a priori existence of CLD/PTLDS as defined and diagnosed by the International Lyme 
and Associated Diseases Society was accepted (Cameron et al., 2014), although the  
International Lyme and Associated Diseases Society  (2004) definition of CLD/PTLDS 
contained no link to the etiologic agent of LD (e.g., through documentation of serologic 
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evidence; Johnson & Feder, 2010). The International Lyme and Associated Diseases 
Society asserts that a bacterium causes LD and can persist in patients after the traditional 
28-day antibiotic treatment (Cameron et al., 2014; Johnson & Feder, 2010; Marzec et al., 
2017; Stricker & Johnson, 2008). They (ILADS)  supported two main reasons why the 
CLD/PTLDS term is preferred among health care providers as (a) patients with 
CLD/PTLDS suffer from inclusive constitutional symptoms as musculoskeletal, and 
neuropsychiatric symptoms, and (b) patients had used a multiples treatment (i.e., 
medicines and long courses of intravenous antibiotics). 
I also assumed that the growth or reduction of the population of PCPs (family 
physician, pediatrician, and internal medicine physicians) in Connecticut drastically 
changed over time in the last 10 years but stays stable within less than 20% of variation 
(Appendix C). In addition, I assumed that the external validity and the internal validity in 
this study have limitations because the results were not representative for all medical 
doctors in Connecticut that were listed in the CT DPH MD/DO of 2015 (i.e., all PCPs) 
when comparing it with the CT DPH MD/DO of 2006 (Appendix E). However, I 
assumed that PCPs survey responses in this study (2015) would be a representative of the 
PCPs distribution (or responses) of 2006 because I followed the same sampling frame 
that Johnson and Feder (2010) used. Additionally, I assumed that the data obtained from 
this study could not be generalized to medical doctors working in other states in the 
United States.  
Despite these assumptions, I assumed that the study was appropriate to evaluate 
the KAP of PCPs in regard to LD and CLD/PTLDS. I also assumed that the results of this 
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study have a proper level of construct validity because I used the same survey, same 
sample frame, and same protocols as Johnson and Feder (2010). The only variations were 
the length of the invitation to participate or cover letter. Previous researchers used just 
one short paragraph, whereas I used a whole page to comply with the Walden 
Institutional Review Board (IRB). I also added two other questions at the end of the 
questionnaire used in this study (Appendix A).  
Scope and Delimitations  
I sought information that can be used to help to resolve current disagreements 
between PCPs and patients with CLD/PTLDS in Connecticut. Having a consensus among 
PCPs about CLD/PTLDS may bring benefits to their medical practice and patients. The 
data were from PCPs working in Connecticut in 2006 and 2015. The purpose of the study 
was to identify whether there were significant differences after 10 years on the position of 
PCPs on the KAP concerning the diagnosis and treatment of CLD/PTLDS in Connecticut 
and to validate the results of Johnson and Feder’s (2010) study. Johnson and Feder 
limited questions on LD and CLD/PTLDS to 3 years before the survey’s distribution, and 
I followed the same procedure despite potential concerns for recall bias (Althubaiti, 
2016).  
This study had volunteer participation drawn from randomly selected certified 
Connecticut PCPs to answer a mail survey related to LD and CLD/PTLDS. Many PCPs 
in Connecticut may have differing positions in attentiveness to CLD/PTLDS as to how 
they diagnose and treat patients with LD and CLD/PTLDS. To make this study as 
objective as possible, I defined CLD/PTLDS in the survey cover letter, which was mailed 
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with the survey as “the persistence (more than six months) of Borrelia burgdorferi 
infection, despite multiple standard courses of antibiotics.” The term LD was not defined 
in the cover letter or survey because this was not the focus of this study. Another reason 
why I did not define LD is because I wanted to compare the outcomes published by 
Johnson and Feder (2010) with the same questions (including one two questions about 
LD in the survey) plus two more questions at the end to be in compliance with the 
Walden IRB requirements for consent. Thus, I assumed that all study PCPs were 
considering the same clinical definition of CLD/PTLDS when completing the survey. 
The sample size for this study included randomly selected participants with 
available mailing addresses. For this quantitative KAP survey, the subjects were medical 
doctors from the active list of the Connecticut State Health Department Certified Medical 
Doctors/Surgeons in 2015 (CT DPH, 2015). The exact number of CT DPH PCPs of 2015 
who took part is discussed in Chapter 3. The CT DPH MD/DO of 2015 was made up with 
the names of physicians, their work or practice addresses, medical license numbers, the 
expiration of their medical license numbers, and their specialty.  
The study was limited to PCPs working in Connecticut. Therefore, the criteria for 
this target population included medical doctors who actively practiced medicine in 2015, 
were licensed by the state of Connecticut, and practiced as pediatricians, family doctors, 
or internal medicine doctors. PCPs’ names were collected from the certified list of 
physicians working in the following categories in 2015: family doctors or general 
medicine, pediatrics, and internal medicine. A purposeful selection (nonrandom) 
identified the participants for this study within the three categories because it was the best 
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method to find a representative volunteer sample of Connecticut physicians whose 
practices were most likely to diagnose CLD/PTLDS or related conditions. Computer 
randomization was used to eliminate selection bias and to obtain the correct number of 
necessary participants. The variables studied were drawn from a population of health care 
practitioners that worked as medical doctors. Johnson and Feder (2010) studied a similar 
population in 2006 and selected participants using random selection. The investigative 
period lasted no longer than 2 months and involved a one-time mailed survey. Thus, it 
was essential to obtain the correct mailing addresses from the list of selected participants.  
The exclusion criteria were medical doctors with a specialization in categories 
other than the study’s specified groups of family or general physicians, pediatricians, and 
internal medicine physicians. However, emergency physicians were accepted in this 
study because the previous study also included them in the statistical analysis (Johnson & 
Feder, 2010). Emergency physicians have a crucial role when dealing with prospective 
LD patients since in some occasions many of them may show up at the hospital 
emergency room looking for someone to remove ticks found on themselves or with EM 
manifestations (Applegren & Kraus, 2017). Additionally, physicians have the best 
intentions to help patients with the diagnosis and treatment of LD from the exposures of 
ticks on individuals or with the rash to eliminate LD complications especially if such 
patients may be living in geographical areas of endemic of Ixodes scapularis ticks 




The study was limited because I could not control all potentially confounding 
factors if there were present in this cross-sectional research. Confounding variables or 
confounders are often defined as the variables correlate (positively or negatively) with 
both the dependent variable and the independent variable (Pourhoseingholi, Baghestani, 
& Vahedi, 2012). Therefore, confounding factors can cause a false relation between an 
exposure and an outcome, especially in clinical trials. Even though this study was not a 
clinical trial, there is a study design limitation because the associations of exposure and 
outcomes are simultaneously evaluated or measured. It is impossible to assess any 
temporal relationships between exposures and outcomes in cross-sectional studies 
(Carlson, 2009; Salem, 2015). Without longitudinal data, it is not possible to establish an 
exact cause and effect relationship (Salem, 2015). However, cross-sectional studies are 
less expensive than longitudinal studies.  
The design of this study may have also produced selection bias because cross-
sectional studies rely on one-time responses and no other personal risks, behaviors, or 
confounders. Another critical consideration is selection bias if proper randomization is 
not achieved. A nonresponse from selected participants may produce bias because the 
survey’s population was reduced (Thorpe et al., 2008).  
Another important limitation is recall bias, which occurs when there are differing 
levels of accuracy from the point from the informant (Althubaiti, 2016). Recall bias in 
epidemiological and medical research may be due to difficulty in remembering previous 
significant details related to the participant’s disease when responding to self-reporting 
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surveys (Althubaiti, 2016). The recall period in this study was 3 years ago. Thus, this 
period may cause less reliable recalled information given by the PCPs who participated in 
this study. The study design in the questions used in the survey was 3 years ago because 
it was stated in the survey used by the previous researchers (Johnson & Feder, 2010).  
Self-selection is another form of bias that occurs when a complex decision is 
made quickly by the respondents. In this study, a few survey responses stated indicated 
that the PCPs had participated in the previous survey. In PCPs’ responses, there were a 
large number of PCPs who did not believe in CLD/PTLDS as well others who stated they 
believe in CLD as a new disease.  
Other limitations pertained to the method of data collection. One of the 
disadvantages of mailed surveys is that correct addresses are required for each participant 
in addition to resources to cover delivery costs (Edwards, 2010). Consequently, an 
individual other than the intended respondent may answer the survey. Participants 
answering the questions in a retrospective survey may find that recalling previous actions 
or past details related to their disease is challenging. The day and season period when the 
survey was mailed out may also have caused limitations (PRA, n.d.). Another 
disadvantage was that the cover letter was a whole page, which may have affected the 
response rate. Medical doctors do not have much free time to read while serving their 
patients; they work long hours, and the surveys were mailed at their workplaces 
(Pedrazza, Berlanda, Trifiletti, & Bressan,2016). 
Social desirability bias may also occur in administering questionnaires or surveys 
when the data or responses to questions are affected by social desirability, approval, or 
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the inability to be guaranteed anonymity or confidentiality (Althubaiti, 2016). The survey 
responses of the instrument used in this study were to be answered without the name of 
the PCPs participants to eliminate social desirability by using a previously conducted 
survey for data collection of this study (Althubaiti, 2016). It is essential to avoid social 
desirability bias when constructing a data collection method (Althubaiti, 2016). Social 
desirability bias should not have affected this study because the survey was random and 
was to be answered anonymously.  
Another limitation of this study was the inability to corroborate the medical data 
reported from the CT DPH and the CDC because there is not an approved case definition 
for CLD (PTLDS). At this time, there is the confusion about how to employ the term 
CLD/PTLDS. Consequently, there was a lack of known published reported surveillance 
data on the term CDL or PTLDS. PTLDS is a term appropriate to be used to identify 
patients afflicted with CLD (CDC, 2019a) for reasons that are explained in detail in 
Chapter 2. Therefore, in this study both terms were considered similar as CLD/PTLDS to 
be in accordance with the CDC, even residents in Connecticut preferred the term CLD 
(Johnson & Feder, 2010).  
Significance 
Researchers from several scientific disciplines are currently investigating 
CLD/PTLDS, which may lead to discoveries and knowledge about it and the health 
controversy surrounding it. One of the primary areas of study in this research is the 
potential close relationship between CLD/PTLDS and documented cases of LD in 
Connecticut. LD can be a serious health problem if unrecognized and untreated (Ljøstad 
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& Mygland, 2013). However, although there is a potential relationship with CLD/PTLDS 
and LD, there is also a potential that CLD/PTLDS occurs without clinical or diagnostic 
evidence of B. burgdorferi infection. Therefore, some researchers think that it is 
inappropriate to use the term CLD, which implies a B. burgdorferi’s etiology (National 
Institute of Allergy and Infectious Diseases, 2019).  
This study may enable future researchers to identify a possible link between LD 
and CLD/PTLDS. This may inform Connecticut residents about the severe health 
implications that may affect them if a relationship between LD and CLD/PTLDS is 
found. The number of LD cases in Connecticut has increased over the last 30 years. The 
CT DPH has reported 2,108 confirmed and 810 probable cases of LD since 2013 
(Garnett, Connally, Stafford, & Carter, 2011). Therefore, there is a need to determine 
whether there is a relationship between misdiagnosis (or failure to receive an early 
diagnosis and management) of LD and the presumed onset of CLD/PTLDS. The 
prevention of CLD/PTLDS onset will protect patients from neurological complications, 
central nervous system effects, and other complications such as arthritis (Bratton, 
Whiteside, Hovan, Engle & Edwards, 2008). The results of this study may provide 
physicians with knowledge for diagnosing, managing, and treating patients with LD and 
CLD/PTLDS so that patients will not be misdiagnosed, poorly maintained, or 
undertreated. This study may provide significant insights on this complex health issue 
because it addresses information gaps (besides the intents of validation of the previous 
research) about CLD/PTLDS as a potential persistent and contemporary public health 
concern and how to avoid disability and morbidity. Additionally, many patients have 
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become frustrated when they did not receive an accurate diagnosis and treatment for an 
illness that they believed was CLD/PTLDS (Lantos, 2015a).  
The potential benefits of this study also include increasing the awareness of 
CLD/PTLDS within the Connecticut health professional community and to improve the 
diagnosis barriers (e.g., lack of case definition, ICD-10 code, standardized medical 
guidelines, better practices) that PCPs face when working with CLD/PTLDS patients. 
This is significant because the doctor–patient relationship is the core of care in collecting 
data, diagnosing, and helping patients heal (Dorr Goold & Lipkin, 1999, p. 27). This 
study may result in benefits and social changes that will improve communication between 
PCPs, public health organizations (e.g., CDC, World Health Organization, Council of 
State and Territorial Epidemiologists, CT DPH, Connecticut Medical School), 
professional medical societies, and people with presumed cases of LD and CLD/PTLDS. 
It is essential that these public health organizations see the need to collect more 
information and to create a database for surveillance purposes to document what is 
happening to potential CLD/PTLDS patients. 
The study may also advance current medical knowledge and show whether a 
belief in CLD/PTLDS affects a physician’s KAP regarding the diagnosis, treatment, and 
management of LD (within the context of the survey) and CLD/PTLDS. This study may 
advance medical practices by providing an opportunity for PCPs to reach a consensus of 
what they should do to help CLD/PTLDS patients. The study may also contribute 
positive and constructive ideas for social change within the health care field by 
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influencing PCP outcomes. Additionally, the findings of this study may encourage 
changes in the protocol presently used by PCPs to help CLD/PTLDS patients.  
Summary 
CLD/PTLDS is a new health condition without a case definition (CDC, 2019a), so 
it has not been defined, classified, or accepted as a reportable disease in Connecticut. It is 
common practice in Connecticut for all certified physicians who examine or treat 
patients’ reportable infectious diseases to report to the director of the DPH on any 
notifiable mandated infections encountered. Researchers agree that CLD/PTLDS has not 
garnered sufficient attention from health care professionals and that many people who 
stated that they had CLD/PTLDS did so because of conflicting information as well as 
because of the lack of a case definition for CLD/PTLDS (Henry & Carr, 2012; Johnson & 
Feder, 2010; Lantos, 2015a; Stricker & Johnson, 2008; Stricker & Fesler, 2018).  
This study was conducted to acquire new evidence-based knowledge to help the 
medical community (particularly PCPs) determine whether there is a need to create better 
practices to evaluate, diagnose, and treat potential CLD/PTLDS patients. The findings of 
this study may also encourage PCPs to develop a case definition for CLD/PTLDS. 
Additionally, if CLD/PTLDS is considered a distinct condition, a new surveillance 
system could be used for chronic Lyme spectrum illness prevention. The study could 
advance knowledge in the discipline by exploring the differences in KAP of two PCPs 
distributions (2006 vs. 2015) in Connecticut. 
Chapter 2 provides the literature review regarding the latest findings related to 
CLD/PTLDS and why it is not currently a reportable disease. Chapter 3 describes the 
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primary methodology used in this quantitative study. Chapter 4 contains the results and 
includes statistical data analyses with corresponding figures and tables. Finally, Chapter 5 
provides information about the public health implications, recommendations, and 




Chapter 2: Literature Review  
Introduction 
The prevalence of CLD/PTLDS remains relatively unknown in Connecticut. 
Furthermore, there is currently a significant division between two professional medical 
societies, the Infectious Diseases Society of America and the International Lyme and 
Associated Diseases Society, about the guidelines for the diagnosis and treatment of 
CLD/PTLDS (Davidsson, 2018; Feder et al., 2007; Johnson & Feder, 2010). The 
diagnosis and treatment of CLD/PTLDS is now one of the most debated medical health 
challenges in Connecticut and the rest of the United States (Feder et al., 2007; Lantos, 
2015a). The controversy centers on whether CLD/PTLDS is a separate illness (Feder et 
al., 2007; Johnson & Feder, 2010, Lantos, 2015a). The argument is caused by the lack of 
information about the etiological agent, as well as a lack of reliable clinical testing, no 
ICD code, and no standardized clinical guidelines for treatment. Medical doctors, 
especially PCPs, may have different KAPs on the most appropriate treatment for 
CLD/PTLDS (Johnson & Feder, 2010). A significant point of conflict among medical 
doctors is over the practice of long-term treatment with IV therapy.  
Another part of the debate is the many stories from CLD/PTLDS patients who 
had positive and negative outcomes after receiving IV treatments with antibiotics such as 
individuals afflicted with CLD/PTLDS who have contributed testimonials via social 
media (e.g., Facebook, YouTube, blogs). An example on YouTube is the story of Monica 
Amore (Amore, 2009). In Monica Amore’s testimonial, she reported the success of long-
term IV antibiotic therapies, and she has been healthy and recovered. However, there are 
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also negative stories about the adverse effects of long-term IV antibiotic therapy for 
individuals diagnosed with CLD/PTLDS. In 2000, Patel, Grogg, Edwards, Wright, and 
Schwenk (2000) presented a testimonial from a 30-year-old female who was diagnosed 
with CLD/PTLDS. The woman received 27 months of IV treatments with cefotaxime and 
died from septic thrombus infection that was not caused by CLD/PTLDS but rather from 
a secondary infection from IV Groshong catheters that caused a fatal infection with 
Candida parapsilosis (Patel et al., 2000).  
To address these issues regarding the diagnosis and treatment of CLD, I 
conducted this study to compare a sample of PCPs to those in a seminal study published  
in 2010. In this chapter, I introduce for the consideration of the literature reviews these 
subtopics as  literature search strategy, theoretical foundation, problems with the case 
definition of chronic lyme disease, controversy with the diagnosis of chronic Lyme 
disease,  controversy with bacteria and chronic Lyme disease diagnosis, relationship 
between Lyme disease and Chronic Lyme disease , disagreement on treatment for Lyme 
disease and Chronic Lyme disease,  persistence of Borrelia burgdorferi after antibiotic 
treatment, diagnosis, treatment, and management of Lyme Disease, Chronic Lyme 
disease , diagnosis, treatment, and management of Post-Treatment Lyme Disease 







Literature Search Strategy 
The literature for this study was discovered with ProQuest Dissertations and 
Theses, EBSCOHost, Google, Google Scholar, the Walden University Library, the 
University of Connecticut’s Lyman Medical Library, and YouTube. Sources included in 
the literature review were primarily published from 2006 to 2018. Search terms included 
knowledge, attitudes, and practices of physicians; Lyme disease; chronic Lyme, 
treatment, and management of LD and CLD/PTLDS; physicians who are undecided on 
CLD/PTLDS; physicians who do not believe that chronic LD exists; and knowledge, 
attitudes, and practices (KAP) theory. Statistical applications of SPPS used in public 
health research were identified for this section of the literature review. 
Additionally, the literature search was undertaken to collect information regarding 
CLD and PTLDS, and CDL/PTLDS. The literature review included research on the 
definitions of CLD and PTLDS; controversial issues regarding diagnosis; variability of 
treatment for CLD or PTLDS; associations between LD and CLD; the persistence of the 
B. burgdorferi after treatment with antibiotics; available clinical testing for CLD/PTLDS 
and LD; problems for primary, family, and general care physicians, including 
pediatricians and internal medicine physicians reporting on CLD/PTLDS; the latest 
CLD/PTLDS research; research gaps for CLD/PTLDS; the relationship between biofilms 
and CLD/PTLDS; and a review of research methods, including surveys, conducted on the 




Public health researchers have used the diffusion of innovations theory to ground 
their research for adopting innovative procedures (e.g., taking antibiotics or medications, 
accepting treatment for diseases like diabetes, etc.), which may lead to concrete, desired 
changes in societal behavior for improving wellness in a community (Abdullah, Aziz, 
Harum, & Burhanuddin, 2013; AL-Dharrab, Mangoud, & Mohsen,1996; Lien & Jiang, 
2016; Zhang et al., 2015). In addition to the diffusion of innovations theory, I used the 
KAP approach to understand PCPs’ KAP when they treat LD and CLD/PTLDS. The 
diffusion of innovations theory can be applied to research assessing participants’ KAP in 
public health settings (Launiala, 2009). KAP can also be applied when examining 
physician behavior to improve health status (Awad & Aboud, 2015; Chien-Yun et al., 
2012; Fauman, 2006).  
The KAP approach was the most appropriate method to examine the difference in 
the KAP of PCPs concerning LD and CLD/PTLDS. This approach was informed by the 
research questions and helped identify the research design decisions (i.e., the method of 
inquiry, data collection, and analysis). Thus, for this study, the KAP approach was used 





Figure 1. The knowledge, attitude, and practice (KAP) diagram. Adapted from “A study 
on Modification of Knowledge, Attitude, and Practice on Vocational High School 
Electronic Courses Integrated with Nanotechnology Concept,” by Chien-Yun et al., 2012, 
International Journal of Thermal & Environmental Engineering, 4, p. 74.  
Problems with the Case Definition of Chronic Lyme Disease 
PCPs are required to have a comprehensive knowledge of toxicology, pathology, 
and clinical sciences to diagnose and treat patients following the laws and ethics of the 
state in which they practice medicine (Grudniewicz et al., 2015). This study was focused 
on the applications used in epidemiology with inductive and deductive applications to 
gather new insights about CLD/PTLDS as a possible new health issue affecting residents 
in Connecticut. The International Epidemiological Association (2017) defined 
epidemiology as the “study of the occurrence and distribution of health-related events, 
states, and processes in specified populations, including the study of the determinants 
influencing such processes, and the application of this knowledge to control relevant 
health problems.” This epidemiology definition emphasizes big data, genealogy, and 
personalized medical therapies (Kuller, 2016).  
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The initial step in conducting an epidemiological investigation on contagious 
diseases or chronic diseases is to formulate a case definition . This initial step helps 
identify the disease’s potential infectious agent or the risk factors, leading to a definite 
diagnosis by a certified medical doctor or laboratory staff. A case definition identifies the 
risk factors and may allow disease trends to be documented in most cases with electronic 
reporting records or geographic information systems of ill patients. Once a disease has a 
case definition, it can be reported to local, state, and federal agencies (Coggn, Martyn, & 
Evanoff, 2005).  
The next step requires physicians to diagnose and report details about the results 
of physical and pathological examinations, diagnostic tests, and treatments administered 
to patients (Rajkomar & Dhaliwal, 2011). A correct diagnosis helps health care 
professionals identify the source, mode of transmission, and cause of the investigated 
disease (Rajkomar & Dhaliwal, 2011). Without a case definition, professionals cannot 
perform an effective analysis of the data obtained from the current or previously afflicted 
members of the community.  
Although CLD does not have an approved case definition, the CDC recognizes 
PTLDS as a health condition (Borchers, Keen, Huntley, & Gershwin, 2015). Borchers et 
al. (2015) described PLDS as a health condition found in patients treated with antibiotics 
who continue to have persistent symptoms from a previous LD infection. The Infectious 
Diseases Society of America accepts this definition of PLDS (also known as PTLDS). 
Other researchers have defined CLD/PTLDS as a persistent infection caused by B. 
burgdorferi that may or may not have laboratory or clinical evidence and that requires a 
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more extended treatment period that uses intravenous and/or oral therapies (Johnson & 
Feder, 2010). For example, Lantos et al. (2015b) described CLD/PTLDS as a health 
condition present in some patients with prolonged, medically unexplained physical 
symptoms and/or uncorroborated alternative medical diagnoses. Lantos and Wormser 
(2014) and Chan et al. (2013) also found that a small group of individuals who thought 
that they had CLD/PTLDS were also treated for coinfections, such as with Babesia, 
Anaplasma and Bartonella. However, there is still an issue with defining CLD without 
clinical laboratory evidence (Klempner et al., 2012).  
There are many definitions of CLD/PTLDS, which reflects the issue of whether it 
is a health condition or a disease and whether it deserves a new classification. For 
instance, Ścieszka et al. (2015) suggested that PTLDS and PLDS are interchangeable 
terms. Most people living in Connecticut are familiar with the terms CLD or PTLDS 
(Feder et al., 2007; Johnson et al., 2014). Moreover, before the CDC, researchers have 
rejected the CLD term and preferred the term tick-associated poly-organic syndrome 
(Borchers et al., 2015; Clarissou et al., 2008). Regardless, ILADS (2004, 2005) defines 
CLD as a blend of recurrent symptoms with debilitating subjective physical 
manifestations that include extreme fatigue, arthralgia, myalgia, vague memory and poor 
concentration, strong headaches, and irritability. However, the Infectious Diseases 
Society of America (2017) does not acknowledge CLD term alone and has rejected this 
definition (Johnson et al., 2014; Johnson & Feder, 2010; Johnson & Stricker, 2010). 
Despite disagreements, one suggestion for a case definition for CLD is that it must meet 
the following criteria: (a) the illness is present for at least a year, (b) there are persistent 
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and significant neurologic involvements or active arthritic manifestations, and (c) patients 
must still be infected with the B. burgdorferi bacteria following antibiotic treatment 
(Burrascamo, 2008). 
In Connecticut, CLD/PTLDS is currently a health condition without an acceptable 
epidemiological case definition. CLD/PTLDS is not accepted, recognized, or reported in 
the United States. Further, CLD/PTLDS patients in Connecticut and across the nation 
struggle to obtain treatment for the disease, mainly due to a lack of acceptance by the 
medical community. Therefore, evidence-based medical knowledge may yield scientific 
information on the possible relationship between CLD/PTLDS and LD, which could 
affect Connecticut residents.  
Though there is no official definition to report cases of CLD/PTLDS, the latest 
statistics from the CT DPH in 2017 show a decrease in the number of cases reported and 
documented in the state (see Figure 2). Additionally, the latest statistics from the CT 
DPH (2018) show a total of 1,363 confirmed cases and an overall incidence rate of 56.6 





Figure 2. Lyme disease cases and rates (per 100,000) by count.  From “Lyme Disease 
Statistics,” by CT DPH, 2018 (https://portal.ct.gov/-/media/Departments-and-
Agencies/DPH/dph/infectious_diseases/lyme/stats/CTLDStats2017.pdf?la=en) 
In addition to the cases of CLD in Connecticut, the ILADS (2004) estimated the 
prevalence of CLD/PTLDS to be between 34% and 64% of studied cases in 1994 for 
patients who were seen by a physician and thought they might have LD. It is suggested 
that 10% to 20% of patients who underwent 2 to 4 weeks of treatment for LD had 
persistent symptoms with or without the presence of B. burgdorferi (Adrion et al., 2015, 
Maloney, 2016). However, the limited amount of scientific data on the topic has resulted 
in differing physician opinions about the duration or the therapeutic window to treat 
CLD/PTLDS patients (Feder et al., 2007; Lantos et al., 2015b; Ścieszka et al., 2015). But 
De Long, Hsu, and Kotsoris (2019) estimated that in 2020, the prevalence of 
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CLD/PTLDS in the United States will be higher than in 2016, with as many as 1,944,189 
(95% CI: 1,619,988- 2,304,147) CLD/PTLDS cases. As indicated by this prevalence rate, 
CLD/PTLDS is a concern not just for Connecticut, but the United States as a whole. 
Controversy with the Diagnosis of Chronic Lyme Disease  
A group of scientists and health professionals have suggested that CLD/PTLDS 
occurs due to inappropriate antibiotic treatment of the LD-causing bacteria (ILADS, 
2004, 2015). These health care professionals believe that the most efficient method to 
treat and cure CLD/PTLDS is the use of long-term antibiotics (Cameron et 2014; ILADS, 
2004, 2015). Most physicians who belong to the health professional group support 
extended antibiotic treatment if needed by CLD/PTLDS patients (ILADS, 2004, 2015). 
However, another group of scientists and health professionals consider CLD/PTLDS to 
be multiple spectrum diseases that result from unknown causes and are unrelated to the 
persistence of B. burgdorferi (Baker, 2012; Infectious Diseases Society of America, 
2017; Marques, 2008). These professionals do not recommend long-term antibiotic 
treatment for potential CLD/PTLDS patients (Infectious Diseases Society of America, 
2006, 2015, 2017, 2019). These different perspectives and treatment approaches indicate 
the need for a resolution to assist those with CLD/PTLDS such as identifying a pathogen 
that causes CLD/PTLDS.  
One of the reasons CLD/PTLDS is a controversial diagnosis is the absence of an 
identified pathogen or other noninfectious agents that can show causation (Ali et al., 
2014; Auwaerter et al., 2011; Feder et al., 2007; Marques, 2008; Wormser, 2007). If the 
pathogen or other noninfectious agents that cause CLD/PTLDS are unknown, it is 
48 
 
impossible to determine which laboratory tools should be used to identify unknown 
agents, particularly if they are biological in origin. Additionally, the lack of standardized 
diagnostic criteria within the medical community makes it challenging for physicians to 
provide treatment and manage CLD/PTLDS (Feder et al., 2007; Lantos, 2011; Ljostad & 
Mygland, 2012; Stricker & Johnson, 2008). Another challenge associated with 
CLD/PTLDS is the lack of information about the role of the autoimmune system 
(residual or persisting antigens) and toxins produced in CL/PTLDS patients (Miklossy, 
2012; Miller, 2016). 
Controversy with Bacteria and Chronic Lyme Disease Diagnosis 
When a bacteria diagnosis is needed, a patient’s blood sample is the standard for 
obtaining and examining bacteria culture samples (direct cultures or indirect plus serum 
analysis; Villa et al., 2017). Gold standard testing in microbiology is derived from Koch’s 
work, which documented the protocols necessary to isolate pathogens and relate the 
pathogens to a specific disease or to prove their microbial etiology or infectious origin in 
outbreak cases (Mortimer, 2003). Koch’s protocols are the contemporary basis for direct 
pathogen identification from cultures using microscopic and xenodiagnostic techniques 
(Fredricks & Relman, 1996; Hess, 2017; Mortimer, 2003). Koch’s Postulates include the 
following: (a) the bacterial agent must be present with every case of the disease, (b) the 
microorganism must be isolated from a host source and grown purely by means of 
laboratory in vitro techniques, (c) the same grown microorganism must be confirmed as 
the symptom-causing agent when it was introduced into a healthy susceptible host, and 
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(d) the same pathogen should be recovered again from the infected host (Fredricks & 
Relman, 1996; Hess, 2017; Mortimer, 2003).  
Other serology and immunology testing used to identify bacteria, parasites, 
viruses, and diseases include agglutination methods, precipitation methods, 
electrophoresis methods, labeling techniques in immunoassays and complement fixation, 
and fluorescent antibodies (Villa et al., 2017). Measuring the levels of antibodies is 
possible when identifying the bacteria that is resulting in the illness; the identification of 
these antibodies is often used to prescribe the proper antibiotic treatment. Other 
identification methods for disease-causing parasites in humans include using blood 
smears and serology testing. Parasites are sensitive to antibiotics, and viral infections 
require more complex methods than bacterial infections to be identified by DNA or RNA 
cultures. Viral infections cannot be eliminated or cured with antibiotics. 
A related issue is that PCPs need to have confidence in laboratory test results 
because they are clinically relevant to giving the correct and precise diagnoses and 
treatments to patients (Infectious Diseases Society of America, 2017). There is currently 
no corroborating evidence regarding the relationship between bacterial infections and 
CLD/PTLDS. Some scientists support the notion that two possible central pathways lead 
to CLD/PTLDS in patients: (a) the persistent presence of bacteria following traditional 
antibiotic treatment for LD or (b) late or delayed treatment of LD and other tickborne 
infections. Due to the debate surrounding CLD/PTLDS, most physicians in the United 
States, as well as Connecticut are divided as to whether CLD/PTLDS is a new disease 
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distinct from other conditions or if it is related to B. burgdorferi, which results in LD 
(Johnson & Feder, 2010). 
Relationship Between Lyme Disease and Chronic Lyme Disease  
LD is a tickborne disease that was discovered in 1977 in Connecticut when a 
group of children and several adults suffered from swollen joints (Berndtson, 2013; 
Johnson & Feder, 2010; Herrington et al., 1977). B. burgdorferi is a spirochete that 
causes LD (Johnson & Feder, 2010; Owen, 2006) and was discovered by William 
Burdgdorferi (Berndtson, 2013; Johnson et al., 1984; Tilly, Rosa, & Stewart, 2008). In 
1977, LD became the most reported vector-borne disease in the United States (Johnson & 
Feder, 2010; Magriet al., 2002; Hickling & Stromdahl, 2012). In 2010, there were more 
than 30,158 reported cases of contracted LD in the United States (Overstreet, 2013). 
However, LD is more prevalent in the Northeastern region of the United States  
(Overstreet, 2013). LD was classified as a reportable disease in Connecticut in 1991, 
according to the CDC (Bratton et al., 2008). In 2017, the age groups most affected by LD 
in Connecticut were those who were older than 60 and younger than 10 (see Figure 3). 
Unlike CLD/PTLDS, LD has a known etiological agent, and its early diagnosis followed 




Figure 3. Lyme disease incidence rates by age group, 2017. From “Lyme Disease 




Researchers who argue for the existence of CLD/PTLDS believe that 
CLD/PTLDS patients are infected with the same bacterium that causes LD (Auwaerter, 
2007). However, as cases of CLD /PTLDS continue to emerge in Connecticut (Johnson et 
al., 2014) even after antibiotic treatment, physicians believe that the bacteria remain 
active (Branda et al., 2018). This belief suggests that the traditional regimen of two to 
four weeks of oral antibiotics (typically doxycycline or amoxicillin) is ineffective in 
eliminating the bacteria (Ljostag & Mygland, 2013). Other researchers believe that it is 
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possible to contract CLD/PTLDS without a visible tick bite or without having presented 
the EM rash—a hallmark indicator of LD. 
Biofilm Formation and Borrelia burgdorferi 
Biofilms are produced by bacteria responsible for infections such as periodontitis, 
chronic otitis, endocarditis, and lung and gastrointestinal infections (Stricker & Johnson, 
2011). According to Barthold (2014), B. burgdorferi does not form a biofilm as it grows 
in the collagenous connective tissue. However, other researchers have discovered that 
CLD/PTLDS is related to the formation of biofilms in humans after an infection with B. 
burgdorferi at the “persister stage” (Sapi et al., 2012; Stricker & Johnson, 2011). Sapi et 
al. (2016) suggested that B. burgdorferi may initiate a biofilm response due to the 
presence of motile spirochetes that transform into cystic, granular, or “cell-wall-
deficient” forms when it encounters various unfavorable environmental conditions. Sapi 
et al. (2012) hypothesized that B. burgdorferi can form a biofilm during in vitro and in 
vivo studies.  Moreover, Theophilus et al. (2015) indicated the possible presence of 
antibiotic-resistant B. burgdorferi persister cells. Theophilus et al. (2015) claimed that 
biofilms explain the LD relapse after antibiotic treatments. There is no effective treatment 
for biofilms (Stricker & Johnson, 2011).  
Disagreement on Treatment for Lyme Disease and Chronic Lyme Disease  
There is no universal agreement within the medical community on how to treat 
CLD/PTLDS (Maloney, 2016). Numerous questions were raised by Barbour (2015) and 
other health professionals concerning the treatment practices for LD and CLD/PTLDS, 
including (a) the effectiveness of shorter or longer periods of antibiotic treatment, (b) 
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whether one antibiotic is more effective than a combination of two medicines delivered 
simultaneously, (c) whether patients without typical symptoms or a confirmed bacterial 
agent present should be treated, and (d) whether conventional methods are better to treat 
people with LD or CLD/PTLDS than unconventional methods of modern medicine. 
Although CLD/PTLDS is assumed to be a bacterial infection-based disease, there is no 
conclusive evidence regarding its origin. The ingestion or inhalation of pathogens, as well 
as trauma, needle sticks, arthropod bites, or sexual transmission are all bacterial infection 
routes. The most common hypothesis for CLD/PTLDS transmission is that it is related to 
an arthropod bite, which is typical for in medically important diseases with rare or 
unknown cures (e.g., malaria) (Duron & Hurst, 2013).  
The most commonly documented treatment practices for patients with 
CLD/PTLDS are related to persistent symptoms of the LD bacteria. Some researchers 
and health professionals assert that LD and other tick-borne coinfections may be 
connected to the etiological agent(s) of CLD/PTLDS (Cameron, 2010; ILADS, 2015). 
Most known bacterial diseases are cured with the use of antibiotics; however, it is also 
essential to take steps to prevent antibiotic resistance (Foxman & Martin, 2015).  
Antibiotics (antibacterial or bactericidal agents) are selective toxicity chemical 
substances produced by microorganisms or plants with the ability to kill or inhibit 
another type of organism. There are antibiotics that kill the bacteria (i.e., bactericidal) and 
those that inhibit bacterial growth but do not kill bacteria (i.e., antibacterial) (Davies & 
Davies, 2010). Antibiotics that kill bacteria use the following mechanisms of action: (a) 
inhibition of bacterial cell wall synthesis (i.e., cephalosporin, carbapenems, 
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monobactams, vancomycin, cyclosserine, and bacitracin), (b) inhibition of protein 
synthesis (i.e., aminoglycosides, tetracyclines, chloramphenicol, erythromycin, 
clindamycin, and linezolid),(c) inhibition of nucleic acid synthesis (i.e., sulfonamides and 
trimethoprim), (d) inhibition of the DNA synthesis of quinolones and flucytosine, and (e) 
inhibition of mRNA synthesis (i.e., rifampin) (Davies & Davies , 2010).  
Certain antibiotics act as agents that alter cell membrane function (e.g., 
polymyxins) (Brown, & Dawson, 2017), whereas other antibiotics have a mechanism for 
altering fungal cell membranes (Ost et al., 2016). The latter include amphotericin B, 
nystatin, and azoles (Serhan, Stack, Perrone, & Morton, 2014). In 1928, Alexander 
Fleming discovered penicillin, one of the most common antibiotics (Davies & Davies, 
2010). 
 Penicillin is bactericidal but only kills when the infected cells grow; this occurs 
through inhibiting the peptidoglycan biosynthesis for the bacteria’s cell walls. Penicillin 
has been an effective treatment for Gram-positive bacteria and some spirochetes (e.g., 
syphilis), as well as some Gram-negative bacteria (Zaffiri, Gardner, & Toledo-Pereyra, 
2012). Penicillin has also been used to treat patients with LD (Wormser et all., 2000; 
Wormser et al., 2006). The traditional treatment for LD at the early stages, however, is 
with oral antibiotics, such as doxycycline (100 mg twice per day), cefuroxime (500 mg 
three times per day), or amoxicillin (500 mg twice per day) for a period of 21 days in 
patients who exhibit EM (Wright et al., 2012; Gasmi et al., 2017). Physicians who treat 
those with late-stage LD prefer to use ceftriaxone (2 g intravenously per day) and 
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penicillin G (Wright et al., 2012). Some researchers have stated that doxycycline cannot 
be used as an effective oral antibiotic to cure late-stage LD (ILADS, 2004).  
The preferred antibiotic to treat LD in children and pregnant women is 
amoxicillin (Wormser et al., 2006), although intravenous ceftriaxone or penicillin have 
been found to be most satisfactory in treating patients in the late stages (ILADS, 2004). 
Patients treated with proper antibiotics in the early stages usually recover rapidly and 
completely. Antibiotics commonly used in oral treatment include doxycycline, 
amoxicillin, cefuroxime axetil, azithromycin, and penicillin (Torbahn et al., 2016). 
Patients with certain neurological or cardiac illnesses may require intravenous treatment 
with antibiotics, including ceftriaxone or penicillin (Barbour, 2015; Burrascano, 2008; 
Cameron, 2009; ILADS, 2014; Wills et al. 2016). 
Studies suggest that the presence of the bacteria that causes LD may persist after 
treatment (Cameron, 2009; Wills et al., 2016). Gene mutation is a potential explanation 
for why the B. burgdorferi strain is resistant to certain antibiotics (Barbour, 2015). For 
example, it can change its morphology (i.e., pleomorphic) depending on surrounding 
environmental conditions, as does B. burgdorferi sensu lato, which creates complications 
for the development of an effective vaccine (Meriläinen et al. 2015). There is controversy 
regarding the safety levels and protocol of antibiotic use against tickborne diseases, 
including LD and CLD/PTLDS (Barbour, 2015). 
Researchers and patients advocate for extended antibiotic use for CLD/PTLDS 
patients (Wright et al., 2012). These supporters believe that the prolonged symptoms of 
late LD, CLD/PTLDS are related to autoimmune responses triggered by an association 
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with B. burgdorferi and reactions with human leukocyte antigen haplotypes (Wright et 
al., 2012). Researchers and patients who advocate for extended antibiotic use for people 
with CLD/PTLDS also advocate for prolonged antibiotic use in late stage LD patients; 
these people are often members of ILADS (2004; 2015). However, the American 
Academy of Neurology, the American Academy of Pediatrics, the College of 
Rheumatology, and the Infectious Diseases Society of America do not support the use of 
prolonged antibiotic treatment (Wright et al., 2012). Questions remain regarding the safe 
lengths of time that humans should receive prolonged antibiotics for LD, CLD/ PTLDS 
(Cameron, 2006, 2010; Delong et al., 2012; Klempner et al., 2001; Klempner et al., 2013, 
Krupp et al., 2003; Stricker, 2007). 
The National Institute of Allergy and Infectious Diseases (2019), as part of the 
National Institute of Health, sponsored four placebo-controlled clinical studies to 
evaluate the effectiveness of prolonged antibiotic treatment following standard 
recommended treatment regimens in patients with persistent symptoms related to those 
caused by B. burgdorferi (National Institute of Allergy and Infectious Diseases, 2019) 
The National Institute of Health (2019) showed that prolonged antibiotic treatment in 
these patients was not more beneficial than the short-term therapy given to patients by 
most U.S. doctors. According to Klempner et al. (2013), the findings suggest that there is 
no justification for the medical community to treat patients with extended periods of 
antibiotics administered by intravenous routes (Klempner et al., 2013).  
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Persistence of Borrelia burgdorferi after Antibiotic Treatment 
LD is the most common arthropod vector-borne disease in the United States and 
is transmitted to humans through the bite of an infected I. scapularis tick (Stricker & 
Fesler, 2018, Wright et al., 2012). However, not all I. scapularis ticks carry B. 
burgdorferi. The CDC (2017b) issued a press release on the discovery of another type of 
bacteria, Borrelia mayonii, which causes LD. I. scapularis acquires the infected 
spirochete through blood contact with small mammals, particularly Peromyscus leucopus, 
a white-footed mouse (Bratton et al., 2008; Tracy & Baumgarth, 2017; Vuong et al., 
2017). The spirochete grows in the tick’s midgut and is transmitted to humans through 
the tick’s salivary glands (Patton et al., 2011; Talwani, & Gilliam, 2012; Tabbasam, 
Malik, Asghar, Paracha, & Nazir, 2016; Wright et al., 2012).  
Infected individuals commonly have early flu-like symptoms, such as headache, 
muscle and joint pains, fever, and malaise (Torbahn et al., 2016); therefore, it is helpful if 
they are aware of a previous bite. In other cases, the best tool that physicians and health 
professionals have at their disposal to diagnose LD is an early visual sign of the EM rash 
(Gasmi et al., 2017; Lantos et al., 2015c; Wright et al., 2012). This EM rash is not visible 
or present in all individuals infected with B. burgdorferi (Allen et al., 2016). 
Furthermore, EM is not easy for all physicians and health professionals to identify if the 
patient has multiple skin rashes (Kemperman, Bakken, & Kravitz, 2008). 
The recognition of EM by physicians and other health care professionals is 
essential, as there are no certified clinical serology tests that identify the spirochete in 
patients’ blood or the antibodies produced when B. burgdorferi is present during the first 
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two weeks of infection (Gasmi, 2017; Kemperman et al., 2008). It is possible to perform 
additional testing for LD between the third and sixth week after a B. burgdorferi 
infection. Testing would include an enzyme-linked immunoassay (ELISA) to show 
positive cases and a Western blot to corroborate these cases (Aguero-Rosefield, Wang, 
Schwartz & Worsmer, 2005; Dessau, Bangsdborg, Ejlertsen, Skarphedinsson, &, 
Schonheyder, 2010; Ogden et al., 2017).  
B. burgdorferi persists in patients with continuous LD or PLTDS, which others 
may argue is a CLD/PTLDS symptom (Cameron, 2010). There are key aspects to 
consider when conducting clinical or epidemiological investigations regarding the 
persistence of B. burgdorferi and its relationship to late LD and CLD/PTLDS. It is 
necessary to assess the following: (a) the history of tick exposure, (b) the history of living 
in or having traveled to an endemic area for ticks, and (c) the history of the presence of 
the EM rash (Fallon et al., 2008).  
There are concerns regarding the persistent presence of B. burgdorferi after early 
and late-stage treatment (Berndtson, 2013; Cameron, 2010; ILADS, 2014; Middelveen et 
al., 2018). Scientists have found that B. burgdorferi can evade the immune system in 
mammals making its eradication difficult in later stages (Barbour, 2012; Norris, 2014). 
Some patients have alluded to this reason for why they became sick; this assertion is also 
consistent with the opinion of CLD/PTLDS (Allen et al., 2016; Berndtson, 2013). B. 
burgdorferi possesses unique properties related to its virulence genes and outer bacterial 
membrane protein, making its eradication more difficult than other known spirochete 
infections (Tilly et al., 2008).  
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Several studies on laboratory animals (e.g., mice, dogs, and monkeys) document 
the persistence of B. burgdorferi after antibiotic treatment (National Institute of Health, 
2015). Some of these studies on laboratory animals found the presence of its DNA after 
antibiotic treatment. However, this presence of its DNA cannot indicate a genetic product 
of an active bacterial infection (Feder et al., 2007; Tabbasam et al., 2016).  
Embers et al. (2012) used toxicological techniques of xenodiagnoses and indirect 
fluorescent antibody staining to test the hypothesis that the spirochete in animal tissue 
persists after antibiotic treatment. Embers et al. (2012) performed two experiments using 
xenodiagnoses. The results of those two xenodiagnoses studies show the presence of 
debris or DNA material from B. burgdorferi. Although this DNA material was found, and 
pieces of the spirochete were hidden in the tissue, it is not entirely certain whether the 
same DNA material was viable, attenuated, or dormant (Lyer et al., 2013). Additionally, 
B. burgdorferi was found to integrate unique properties into its bacterial loci to create 
genetic changes that interfere with antibiotic treatment effectiveness (Lyer et al., 2013).  
Molecular biology studies can be used to help researchers understand certain 
behavioral aspects of B. burgdorferi when an antibiotics regimen is used to eradicate the 
infection. These molecular biology studies shine a light on LD patients under treatment, 
the effectiveness of late treatment, and the possible relationship between CLD/ PTLDS. 
In conclusion, a significant debate continues on the existence of B. burgdorferi and its 
ability to cause chronic symptoms in untreated or undertreated patients, whether at the 
early or late stages of LD (Stricker & Johnson, 2013).  
60 
 
Clinical Testing to Diagnose Infections of Lyme Disease and Its Relationship to 
Testing for Chronic Lyme Disease  
Although CLD/PTLDS has no known etiological agent, testing may be 
challenging and may not be specific, nor is there a diagnostic for it (CDC, 2019). Many 
PCPs may diagnose and treat a late LD infection (ILADS, 2014, Lantos, 2015a). LD has 
signs and symptoms that are less specific than other bacterial infections; thus, it is 
inevitably difficult to diagnose. Laboratory testing is recommended only for patients who 
notice the typical symptoms of LD (Gasmi et al., 2017). To understand the complexity 
and irregularity of testing for LD, it is essential to discuss its etiological agent, B. 
burgdorferi (Burrascano, 2008; Hyde, 2017; Wormser et al., 2006). 
B. burgdorferi is a motile (Sultan et al., 2013, 2015) spirochete with the following 
attributes: irregular, loosely coiled, helical, weakly Gram-negative, size range from 0.20 
to 0.30 µm in diameter, and 10 to 40 µm in length (Aberer & Duray, 1991; Marquez, 
2015; Meriläinen et al. 2015). This spirochete has complex nutritional demands and is 
very challenging to cultivate in vitro using Barbour-Stoener Kelly (BSK) medium 
(Aberer & Duray, 1991; Marques, 2008; Sultan et al., 2015). Isolation of B. burgdorferi 
from the EM rash is possible, but there is less opportunity for isolation in late-stage LD 
infections (Moore et al., 2016).  
Not all people exposed to the spirochete will develop an infection or present with 
the typical EM rash (Gasmi et al., 2017). Therefore, people may be unaware of a B. 
burgdorferi infection in the early stages. The longer an infection with LD continues, the 
more difficult it is to find the most suitable clinical and serology tests to facilitate its 
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diagnosis. Consequently, there is a need to have well-trained medical and laboratory staff 
in areas where LD persists until new medical advances can corroborate the etiological 
agents for CLD/PTLDS.  
The microscopic examination of blood or tissues from patients with LD is not 
recommended because B. burgdorferi is rarely found in clinical specimens (Wormser et 
al., 2006). Culturing is not a common practice for clinical samples obtained from patients 
because B. burgdorferi is difficult to isolate and observe under a microscope and because 
it has a low growth process (Marques, 2008; Sultan et al., 2015). B. burgdorferi is also 
difficult to grow in vitro (Marques, 2018), as it requires special media or nutrients. 
Molecular diagnostic techniques for the diagnosis of LD, such as the use of nucleic acid 
amplification techniques for DNA or RNA, have lower sensitivity than the culture 
techniques for special properties, such as the motility of B. burgdorferi (Eshoo et al., 
2012; Marques, 2015; Sultan et al., 2015). Unlike other bacterial infections where 
pathogen detection is performed directly or indirectly from a culture, LD diagnosis is not 
determined using the direct presence of the bacteria (Marquez, 2015).  
LD has three distinct stages of pathogenic development on a patient after a 
positive tick bite (Applegren & Kraus, 2017). The first stage or early stage is described 
mainly as the recognition of symptoms as fever, headache, fatigue, pain in the joins and 
the present of the EM (Nadelman et al, 2012). The second stage is described as when B. 
burgdorferi spreads throughout the whole body of the sick person. At this second stage, 
patients may exhibit symptoms like arthritis, meningitis, myocarditis, from weeks to 
months from the initial infection (Applegren & Kraus, 2017). In the third stage of LD, 
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patients have chronic symptoms as chronic arthritis, neurologic defects, or skin lesions 
(Applegren & Kraus, 2017).  
In the early stage of LD infection, the bacteria hide (move) into the inner cells 
(inside the cell membrane) of the human host (Eshoo et al., 2012; Porcella & Schwan, 
2001). This movement causes the bacteria not to be free in the bloodstream as many other 
infections (i.e., syphilis). Thus, a direct blood test to identify the infection by morphology 
of B. burgdorferi is not applicable at early stages and late stages of LD where the bacteria 
has moved to the organs of the central nervous systems (Applegren & Kraus, 2017). The 
early stage of LD diagnosis is based on the presence of antibodies found in the serum of 
samples from patients during the early stages of infection (Borchers et al., 2015; 
Burrascano, 2008).  
However, if the serology testing of antibodies is conducted early when the EM 
rash is present or immediately after the tick bite, the results may have very low sensitivity 
and may occasionally be reported as negative (see Figure 4). Lantos et al. (2015c) also 
discussed the validity of serology testing in low-prevalence regions where the prevalence 
of ticks and LD is low and in which health professional may have a greater difficulty in 




Figure 4. Sensitivity/specificity of commercial two-tier testing for convalescent/late state 
Lyme disease in the United States. Adapted from “Two-Tiered Lab Tests Miss More 
Than 50% Of The Cases Of Lyme Disease,” by L. Johnson, n.d. 
(https://www.lymedisease.org/lyme-basics/resources/two-tiered-lab-tests-miss-50-
percent-of-lyme/) 
Due to these difficulties, Connecticut physicians cannot diagnose early LD based 
on laboratory testing of patient blood samples. Clinical testing used in most of the United 
States and Connecticut is based on the presence of the EM rash and immunological and 
DNA applications. Some of these clinical tests are based on elevated sedimentation, 
elevated IgM levels, and mildly elevated hepatic transaminase (SGPT/ALT) levels. 
Common immunological assays used after two weeks of LD infection include 
indirect fluorescent antibody staining, staining methods, and the enzyme-linked 
immunosorbent assay (ELISA), as well as western blot for corroboration (Aguero-
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Rosenfeld et al., 2005; Liu et al., 2016). The most common tests used to diagnose LD are 
the indirect immunofluorescence assay and enzyme-linked immunosorbent assay (Liu et 
al., 2016). ELISA is the most sensitive test for most stages of LD because it uses purified 
or recombinant antigens. Serology testing is weak and unreliable for testing the early 
stages due to problems with sensitivity, cross-reaction activity from bacteria other than 
those being screened, and the need to create a single method to detect infection (Liu et 
al., 2016).  
The ELISA test kit, also called the C6 peptide test (Chan et al., 2013; Wright et 
al., 2012), has been used since 2000, but the sensitivity is higher (60%) in patients and 
may still yield false positives. This ELISA test kit has better sensitivity than the two-tier 
ELISA test, although it was not tested in children (Chan et al., 2013; Lipsett et al., 2015). 
Lloyd and Hawkins (2018) reported that the C6 peptide test had a different sensitivity of 
66.7% to 75%. Lloyd and Hawkins (2018) suggested that the reason for the variation may 
be due to the ribosomal spacer type (RST) genotype.  
The ELISA test has been used as a screening assay, as it has a specificity rating of 
90%-100% (Ljøstad & Mygland, 2013). The infection must be older than two weeks to 
measure the level of antibodies raised against the pathogens. Health care practitioners 
recommend that people test for IgM antibodies after the second week of exposure, as they 
may last up to four weeks post infection (Gasmi et al., 2017). Western blot is used to 
confirm a positive ELISA reaction (CDC, 1995, 2005; Ogden et al., 2017).  
Antigenic heterogeneity B. burgdorferi and other species affect the test’s 
sensitivity (Bonin, 2016; Branda, Linskey, Kim, & Steere, 2011). The variability of 
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ELISA and Western blot kits to test for LD depends on the infection’s stage and the 
species of Borrelia. Various types of ELISA have been validated and approved by the 
FDA and accepted by the CDC (CDC, 1995; CDC, 2005).  
This form of antibody testing uses blood serum samples from people presumed to 
have LD; however, it is not as sensitive as other serum commercial kits that are currently 
used for other diseases (e.g., syphilis). A commercial kit with two-tier testing often 
includes two steps: an EIA or immunofluorescent assay indirect fluorescent antibody 
staining that is followed by supplemental IgM and IgG immunoblots or western blot that 
use antibodies for LD. These antibodies depend on the manufacturer and location due to 
the geographic variability of the Borrelia species (Bonin, 2016; Branda et al., 2011; 
Gasmi et al., 2017; Wormser et al., 2013). However, in the United States, two-tier testing 
for LD according to the CDC’s established criteria has a sensitivity close to or higher 
than 68% with a specificity of 99.5% (Wormser et al., 2013).  
Branda et al. (2011) examined an alternative two-tiered strategy. The purpose of 
Branda et al.’s (2011) study was to investigate the sensitivity of the three testing 
strategies. Branda et al. (2011) randomly selected 1,246 healthy people and 54 patients in 
a hospital. Specificity was measured, and the study found that the positive predictive 
value was 70%.  
However, internal validity should have been examined. The mortality threat may 
occur when uncommitted participants withdraw from a study (Branda et al., 2011). A 
total of 1,246 healthy individuals and 54 patients were randomly selected in the hospital; 
consequently, the results and findings cannot be generalized to other hospitals. 
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Nonetheless, this study was reported two decades after the testing for LD was initiated; 
the two-tiered testing with immunoblotting remains the standard for evaluation in testing 
patients for LD. 
A clinician cannot accept ELISA and Western Block molecular test outcomes in 
two-tier testing for LD alone because they may yield false positive results (Marquez, 
2015). These false positive results may be due to pre-existing conditions, such as Epstein-
Barr virus or Helicobacter pylori. A false positive result is an issue because patients who 
do not have LD may show a positive test.  
People who are aware of tick bites may be tested again for an increase in the B. 
burgdorferi antibodies after the first two weeks since ELISA and western blot tests may 
cause false negatives (Marquez, 2018). The proper time for testing with a two-tier kit for 
LD is between two and four weeks after the bite; this is when the antibodies for Borrelia 
species will develop and produce higher IgM than IgG. The low sensitivity of most two-
tier testing systems commercially used in the United States for testing LD remains an 
issue because uninfected individuals may yield a positive test result. Additionally, others 
with early B. burgdorferi symptoms can be missed.  
Testing should never be performed in the absence of appropriate history and 
clinical LD symptoms (Erthel, Nelson, & Carter, 2012). However, most laboratory 
clinicians prefer to use molecular biology tests with blood samples for bacteria diagnosis. 
Problems remain for testing serum samples from patients. Tests using serum samples 
from patients may yield a false positive due to issues with the specificity and sensitivity 
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of these tests, which can have cross-reacting antibodies against spirochetes in the normal 
flora (Ljøstad & Mygland, 2013).  
Additionally, a polymerase chain reaction test is available to detect the tickborne 
bacteria (Greenwich Press, 2017; Hickling & Stromdahl, 2012). A polymerase chain 
reaction positive test performed on ticks is not a direct indication of LD infection. 
Instead, tick polymerase chain reaction testing for B. burgdorferi (Maurin, 2012) can 
provide valuable information about the probability of contracting an illness, especially if 
the tick was fully engorged and attached to a human host for over 48 hours (Marquez, 
2015; Gasmi et al., 2017).  
Although the CDC does not support the testing of ticks (CDC, 2017b), the 
Connecticut Agricultural Station (2019) and the Greenwich Health Department in 
Connecticut (2015) provide this service to the public. It may be beneficial to investigate 
whether the number and results of tick tests in Connecticut correspond with the highest 
incidence of LD. Borrelia DNA can be detected by a polymerase chain reaction test of 
synovial fluid and cerebrospinal fluid (e.g., CSF, synovial fluid, and blood) with varying 
levels of success (Bratton et al., 2008; Ljøstad & Mygland, 2013; Wright et al., 2012). It 
is important to note that B. burgdorferi is challenging to consistently cultivate from the 
synovial fluid (Marquez, 2015).  
Polymerase chain reaction tests help identify bacteria species that are causing an 
infection (Maurin, 2012; Scott et al., 2017). The incubation period is 3 to 30 days after an 
infectious tick bite (CDC, 2017b; Kemperman, Bakken, & Kravitz, 2008). There is no 
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evidence for the person-to-person transmission of LD. There are some claims of 
maternal-to-child transmission, although there is little evidence (CDC, 2017b). 
It is challenging to use microscopy, serology, or molecular testing to yield an 
accurate CLD/PTLDS diagnosis due to the lack of consensus between medical 
communities, as well as a lack of scientific evidence regarding its etiological agent(s). 
Scientists believe that CLD/PTLDS develops due to various factors related to the 
antibiotic treatment of B. burgdorferi in patients who were either undertreated, untreated, 
or treated late (Cameron, 2006; Wright et al., 2012). It is inappropriate and complicated 
to apply the same criteria used by most certified clinical labs to test for late-stage LD 
with a combination of ELISA and western blot tests (Ogden et al., 2017). Laboratory 
testing for B. burgdorferi is not standardized at the national level (Auwaerter, 2007). 
There is no known distinct testing method for CLD/PTLDS apart from the limited 
relationship to the approved serological testing for traditional cases of LD (Sigal, 2003; 
Strasheim, 2014).  
Most patients with CLD/PTLDS have been accurately diagnosed based on the 
continuous symptoms that they have presented to a Lyme-literate medical doctor (Baker, 
2012). The ILADS favors the use of long-term antibiotics and refers to many patients 
with CLD/PTLDS to Lyme-literate medical doctors, which is opposed by the Infectious 
Diseases Society of America. Infectious Diseases Society of America-affiliated 
physicians believe that long-term antibiotics are not a beneficial treatment for those who 
have late LD or CLD/PTLDS (Infectious Diseases Society of America, 2006, 2012, 2017; 
Marquez, 2008). Patients suffering from late cases of LD and CLD/PTLDS continue to 
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be symptomatic and seek a correct diagnosis and appropriate treatment for their condition 
at considerable personal and financial cost.  
Problems for Physicians Reporting Chronic Lyme Disease  
Unanswered questions remain regarding the existence of CLD/PTLDS. Therefore, 
the medical community is divided on the best approach for a diagnosis when presented 
with CLD/PTLDS symptoms. The root of the controversy lies in the fact that CLD lacks 
reliable biological markers and diagnostic tests to identify its origin. 
Most patients visit a health professional for two reasons: to follow up with health 
plan appointments (e.g., annual checkups, surgeries, births) or to address immediate 
sickness. In both circumstances, patients may leave a health professional’s office with a 
known diagnosis and an appropriate treatment to follow. In Connecticut, patients who 
believe that they have CLD/PTLDS do not encounter a fair process when visiting health 
care professionals and complain that they were denied or received limited or improper 
health care.  
Physicians face difficulties in diagnosing CLD/PTLDS due to the lack of a 
clinical definition, symptom continuity, and systematic evidence that B. burgdorferi is 
associated with the etiology of CLD/PTLDS. Lantos (2011) found no proof that the 
bacteria that causes LD were present in certain patients who claimed to have 
CLD/PTLDS. These patients who claimed to have CLD/PTLDS had pre-existing 
conditions, such as rheumatoid arthritis, degenerative diseases of the spine, multiple 
sclerosis, or amyotrophic lateral sclerosis. Lantos’s (2011) study also noted late-stage 
symptoms of LD, including severe pain in the joints and knees (e.g., in patients with 
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arthritis), chronic neurological complaints, short-term memory loss, cognitive issues, 
shooting pain, or numbness and tingling in the hands and feet. Lantos (2011) randomly 
selected patients who may have had CLD/PTLDS in the United States and successfully 
tested the research question; however, validity was mentioned in the study.   
According to the Infectious Diseases Society of America (2017), patients who 
suffer from CLD/PTLDS have symptoms similar to the degenerative effects of untreated 
long-term LD. Therefore, there is confusion among Connecticut physicians as well as 
patients who believe that their illness is related to CLD/PTLDS or other diseases 
associated with LD. Many patients complain that their doctors refuse to diagnose and 
treat CLD/PTLDS and thereby withhold care. Patients’ firsthand feelings are a result of 
their doctors’ lack of knowledge about CLD/PTLDS and coinfections from I. scapularis 
bites (Cameron, 2010). If this is the case for health professionals who treat CLD/PTLDS 
patients, addressing physician education and training to ensure medical practice 
consistent with preventive care guidelines may be essential to aid in accurate diagnoses 
and to keep patients healthy (Gasmi et al., 2017; Strumpf, 2011). 
Diagnosis, Treatment, and Management of Lyme Disease, Chronic Lyme Disease  
There have been limited studies demonstrating the frequency of health 
practitioner diagnosis, treatment, and management of tick-borne disease, and, specifically 
for this study’s purpose, about LD and CLD/PTLDS. PCPs may have difficulty in 
treating LD patients despite confirmation of the etiological agent and established 
antibiotic treatment regimens. Many areas remain open to exploration on how to control 
an LD infection that went untreated. CLD/PTLDS has many gaps and unanswered 
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questions, and there is a lack of information regarding the frequency of PCP diagnoses 
that use reliable and distinct laboratory testing.  
 Johnson and Feder (2010) found that fewer than 3% of physicians diagnosed 
patients with CLD/PTLDS in Connecticut. Johnson and Feder (2010) also discovered that 
49% of physicians did not treat their patients for CLD/PTLDS because they did not 
believe it existed. Johnson and Feder (2010) performed descriptive statistics (but did not 
conduct MANOVA or t-tests). MANOVA is the most appropriate tool to measure 
differences between physicians because it assesses the effects of dependent variables 
simultaneously. T-tests can be valuable when using continuous data if the studied 
population is normally distributed (Parab & Bhalerao, 2010). If it not normally 
distributed, the data analysis should be complemented with non-parametric tests.  
Ferrouillet et al. (2015) conducted a 2012 descriptive cross-sectional study to 
determine the knowledge and practices (in regards to the diagnosis and management of 
cases of LD using serology testing) of family physicians in two settings: (a) in one region 
with known infected ticks (Montérégie) and (b) in regions without infected ticks (Estrie 
and Lanaudière) in Southern Quebec, Canada. Ferrouillet et al. (2015) invited family 
participants to take part in the study by in-person invitations. A self-survey with 19 
questions on two pages was given to those who accepted the invitation to participate. The 
survey questions were divided into three sections: (a) their experience with LD in the 
previous year, (b) questions regarding their knowledge, and (c) questions regarding their 
need for information.  
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A descriptive analysis on the two regions compared them using Fisher’s exact test 
with SAS version 9.4. The participation rate in this study was 59% of the 201 
participants. Ferrouillet et al. (2015) concluded that 201 participants were appropriate for 
representing the population of family physicians since the response rate of the survey was 
significant as a high response (n= 151 out of 201) among the primary care family 
physicians of   Montérégie (p. 1). Some of the results were as follows: 56% never 
considered the diagnosis of LD, and 80% never prescribed antibiotics for LD patients. 
These results showed the based for internal validity. Ferrouillet et al. (2015) by 
conducting this study stated the importance that PCPs’ knowledge and practices needed 
optimize the management of individual patients with LD.  
Moreover, Ferrouillet et al.’s (2015) study’s results were similar to Johnson and 
Feder’s (2010) results. Johnson and Feder’s (2010) study had identical conclusions 
regarding the differences in the KAPs of physicians related to LD and CLD/PTLDS. 
Johnson and Feder (2010) tested the assumption that there were significant differences in 
the KAP of physicians regarding the diagnosis, treatment, and management of LD. The 
hypothesis stated that there would be significant differences between PCPs concerning 
the diagnosis, treatment, and management of LD.  
To test the hypothesis, Johnson and Feder (2010) performed descriptive statistics. 
Johnson and Feder (2010) randomly selected 3091 physicians and asked them to 
complete a mail survey. However, Johnson and Feder’s (2010) study did not publish how 
the survey was developed, and its validity published.   
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Both Johnson and Feder’s (2010) study and Ferrouillet et al.’s (2015) study focus 
on the differences in the KAPs of physicians regarding the diagnosis, treatment, and 
management of LD and CLD/PTLDS. The former discovered that there were significant 
differences. The latter also found that there were significant differences in the way 
physicians diagnosed and prescribed antibiotic treatment to potential LD patients. As 
evident in the study by Magri et al. (2002), most physicians preferred to recommend the 
LD vaccine to patients when the vaccine was still in use; it is essential to note that the 
vaccine is no longer prescribed to patients in the United States.  
Magri et al.’s (2002) conclusion differs from Johnson and Feder’s (2010) study 
and Ferrouillet et al.’s (2015) study. Magri et al. (2002) tested if there were significant 
differences in the KAPs of physicians concerning the diagnosis, treatment, and 
management of LD by performing Chi-square tests. Magri et al. (2002) randomly 
selected 600 physicians in New Hampshire and asked them to complete a survey.  
However, internal validity should have been examined. Selection bias can occur 
when there are differences between physicians who return their questionnaires and 
physicians who do not answer their surveys. The mortality threat may occur when 
uncommitted physicians withdraw, such as in this study.  
Diagnosis, Treatment, and Management of Post-Treatment Lyme Disease Syndrome  
As stated in Chapter 1 and in this chapter, the term PTLDS (instead of CLD) it is 
more favorable used by the medical community (not the sick patients) (Delong, Hsus, and 
Kotsoris, 2019). Rebman et al. (2017) stated that 10 to 20% of patients after receiving 
treatment for LD experience multiple symptoms that sometimes the health professionals 
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find symptoms that vary from one patient to another) as prolonged fatigue, neurological 
dysfunction pains, that persist after being treated for LD (Delong et al., 2019a). There is 
no definite data collection or reporting it to the CDC as it is done for other infectious or 
chronic diseases. Nonetheless, Delong et al. (2019a) estimated an increase in the number 
of patients diagnosed with PTLDS from 2016 to 2020, with 68, 603 cases of PTLDS 
expected in 2020 (Delong et al., 2019a).  
Thus, as well as CLD, there is not much information about how to conduct a 
standardized diagnosis and treatment to cure such patients with PTLDS (Delong et al., 
2019). Rebman et al. (2017) stated the importance of investigating the clinical symptoms 
in patients living with PTLDS since it affects their quality of life. PTLDS bring financial 
burden to those patients with it; the problem is such a financial burden has never been 
investigated in the United States (Delong et al., 2019). But if PTLDS it turns out one day 
to be related to LD and CLD, it can cause more than a billion of dollars as it now the cost 
for health for patients known with LD (Delong et al., 2019). Therefore, in this study, 
although is investigating the validity of the finding founds by Johnson and Feder (2010) 
in regards to the diagnosis of CLD in Connecticut, it enhances insights about what would 
be the best implications or suggestions to recommends to PCPs in Connecticut to deal 
with cases of PTLDS (CLD). One clear objective recommendation is to have PCPs to 
accepts the term PTLDS to be able to create pathways to collect, document, and report 
possible cases of people sick with PTLDS (or CLD) that will eventually enable 
epidemiologists to how it is transmitted, what are the risk factors, and best treatment 
practices unknown presently. Further studies would be needed to find standardized 
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evidence based medical in regards to PTLDS to be substitute among professionals for 
CLD. Therefore, the term CLD/PTLDS was used concisely trough out the paper to 
recognized that is better for the future to recognized CLD/PTLDS as just “PTLDS”. More 
on this topic is presented in chapter 5. 
Summary and Conclusion 
Johnson and Feder (2010) found that there were significant differences in the 
KAPs of PCPs regarding the diagnosis, treatment, and management of LD and 
CLD/PTLDS. Ferrouillet et al. (2015) also found that there were significant differences in 
the knowledge and practices of physicians concerning how physicians diagnosed and 
gave antibiotic treatment to potential LD patients. However, Magri et al. (2002) 
determined that most physicians preferred to recommend the LD vaccine to patients. It is 
necessary to examine the gap to yield new opportunities for future research if the topic of 
research has not been addressed appropriately by other researchers.   
The study can help CT PCPs recognize PTLDS as a more appropriate diagnosis 
for those patients presumed has CLD. CT PCPs have difficulty dealing with the diagnosis 
and treatment of CLD/PTLDS patients. Thus, PTLDS can serve as a diagnosis for 
patients with CLD/PTLDS until more is known about it. Chapter 3 provides an overview 
of the research methods designed for the quantitative study and includes a discussion on 
the method of the study and the appropriateness of the design and data collection.  
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Chapter 3: Research Method 
Introduction 
Medical disagreements regarding CLD/PTLDS are caused by the unavailability of 
an acceptable standardized protocol to diagnose and treat it (Lantos, 2015a). Numerous 
medical doctors do not consider CLD/PTLDS an illness, which may be due to physician 
unawareness of evidence-based medical knowledge that corroborates the causal agent or 
the lack of surveillance systems that suggest that it is a new disease (Baker, 2008; 
Cameron, 2010; Feder et al., 2007; Johnson & Feder, 2010; Katz, 2007; Lantos, 2011, 
2015a; McClellan, 2012; Wormser & Shapiro, 2009). Consequently, the cause, origin, 
and diagnostic criteria of CLD/PTLDS are unclear because most medical practitioners do 
not have data to guide treatment for affected patients (Lantos, 2011, 2015a).  
The purpose of this quantitative nonexperimental, cross-sectional, comparative 
research was to validate Johnson and Feder’s (2010) study and determine whether there 
were significant differences between two Connecticut PCPs regarding their knowledge, 
diagnosis, and treatment of LD and CLD (PTLDS). Statistical comparisons were made 
between survey responses provided by Connecticut PCPs in Johnson and Feder’s study 
and the current study. I used the Connecticut knowledge, attitude, and practice (CT-KAP) 
survey, which was used by Johnson and Feder and was in the public domain for exact 
data comparisons.  
This study’s data may help physicians evaluate the current guidelines and 
methods for the diagnosis and treatment of CLD (PTLDS) patients. Within the limitation 
of having no approved case definition for CLD (PTLDS), in the survey mailed out, it was 
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defined “as the persistence (more than six months) of Borrelia burgdorferi infection, 
despite multiple standard courses of antibiotics).” Medical doctors are trained to conduct 
diagnosis using ICD codes, but in this study, an ICD code was not provided because it is 
not approved for CLD (PTLDS). This limitation accounts for the low response in this 
study, because some PCPs may not have felt comfortable to answer the KAP 
questionnaire or survey without knowing an ICD code with a definition associated for 
CLD/PTLDS, though I did provide a brief definition.   
This chapter presents the study’s methodology. The chapter begins with a 
summary of the research design and provides a rationale for its selection. The chapter 
continues with a discussion of the methodology with emphasis on the study population, 
sample, sampling procedures, participant recruitment and data collection procedures, the 
operationalization of study variables, the instrument and questions used to measure them, 
and the data analysis plan. Threats to validity of the study are then discussed, as are the 
ethical procedures of the study. A summary concludes the chapter. 
Research Design and Rationale 
I used a nonexperimental, cross-sectional, comparative (i.e., ex post facto) 
research design to examine whether there were significant differences regarding 
CLD/PTLDS KAPs between the sample of Connecticut PCPs who participated in 
Johnson and Feder’s (2010) research and those who participated in this study. The study 
included five research questions. The independent variable for all research questions was 
the PCP group in this study compared to those who participated in Johnson and Feder’s 
research. I used this the first research question  acted as a validity check to  examine 
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whether the two physician groups (the independent variable) had significant frequency 
distribution differences concerning the dependent variable of PCP types (i.e., family 
medicine, internal medicine, pediatric, other). The second research question helped 
examine whether the two PCP groups (the independent variable) had significant 
frequency distribution differences across three knowledge of LD categories (the 
dependent variable). The third research question helped examine whether the two 
physician groups (the independent variable) had significantly different frequency 
distributions across the knowledge of the four CLD (PTLDS) categories (the dependent 
variable). The fourth research question helped examine whether the two physician groups 
(the independent variable) significantly differed concerning the average number of 
patients they diagnosed as having CLD (PTLDS) within 3 years (the dependent variable). 
The fifth and final research question helped examine whether the two Connecticut PCPs 
(the independent variable) significantly differed concerning the average course of 
antibiotic treatment (in weeks) among the patients they diagnosed as having CLD/PTLDS 
within 3 years.  
The quantitative approach in this study was guided by the positivist paradigm, 
which states that a single, objective, and measurable reality exists (Bowling, 2014; de 
Villiers, & Fouché, 2015). Quantitative research involves the scientific method where 
researchers develop questions and hypotheses that pertain to the tested theory or theories, 
use valid and reliable measures to obtain numerical data, and perform statistical analyses 
of numerical data; researchers then use the results to determine whether to reject or 
accept the null hypotheses (Bowling, 2014; de Villiers & Fouché, 2015). I chose the 
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quantitative research method over the qualitative method because it involves the 
scientific method to answer research questions. Hypotheses for each research question 
were formulated, and numerically-based data from surveys that were given to study 
participants (i.e., Connecticut PCPs) were collected. Statistical analyses from the data 
gathered in this study were conducted. Direct adjustment was conducted with population 
proportion 2015 to allow the PCP categories subgroups rates to have the same general 
trend as the population-proportion of 2006 PCP categories (Pagano-Gauvreau, 2000) 
before the data analysis was conducted.  
Quantitative studies are delineated into three types: experimental, quasi-
experimental, and nonexperimental (Bowling, 2014; Patten & Newhart, 2017). The 
quantitative experimental research design is used in studies where the researcher 
randomly selects participants from the population and randomly assigns them into study 
conditions such as an intervention group that receives some treatment and a control group 
that does not. The quantitative experimental research design is most appropriate for 
examining whether one or more dependent variables differ across intervention and 
control groups of participants. Nonexperimental research designs pertain to studies where 
neither random selection of participants is conducted nor when random assignment to 
conditions is relevant or applicable.  
Further, nonexperimental research designs are commonly delineated into three 
types: (a) descriptive, in which the researcher presents and describes a phenomenon using 
descriptive statistics (as opposed to inferential); (b) correlational, in which the researcher 
wants to determine whether one or more independent variables (i.e., predictor variables) 
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are significantly associated with or related to one or more dependent variables (i.e., 
criterion variables) and utilizes inferential statistics such as correlational or regression 
models to determine the significance of these relationships; and (c) comparative, or ex 
post facto, in which the researcher wants to determine whether one or more naturally 
occurring groups (i.e., the independent variables) significantly differ in one or more 
dependent variables, which are also naturally occurring, and utilizes inferential statistics 
such as Chi-squares, t tests to determine if significant differences exist (Patten & 
Newhart, 2017; Reio & Reio, 2016). Naturally occurring refers to groups that cannot be 
manipulated. I did not choose a descriptive nonexperimental design because it does not 
involve inferential statistics (Reio & Reio, 2016). A correlational design was also not 
applicable because I did not determine temporal sequences or causal relationships 
between independent and dependent variables.  
A comparative quantitative research design was suitable for this study to assess 
the validity of Johnson and Feder’s (2010) study. I examined whether two naturally 
occurring groups of Connecticut PCPs (i.e., the independent variable) significantly 
differed among four dependent variables: (a) the type of PCP they identify as, (b) 
knowledge regarding LD and CLD(PTLDS), (c) the number of patients identified as 
having  LD and CLD (PTLDS) per PCPs, and (d) the average course of antibiotic 
treatment (in weeks). These dependent variables are also naturally occurring. This study 
differs from other comparative studies in that the data were gathered at the same time 
from the groups of the study’s focus. I compared the data collected from a new sample of 
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Connecticut PCPs to the archival proportion, frequency, and mean level data reported in 
Johnson and Feder’s study conducted with Connecticut PCPs. 
Finally, this study was designed to collect data from a single point in time and is 
therefore considered a cross-sectional study. Although data obtained in this study were 
compared to responses provided by Connecticut PCPs in Johnson and Feder’s (2010) 
study, this study is not longitudinal. These two naturally occurring groups of Connecticut 
PCPs were not comprised of the same physicians, and they were not followed over the 
past 10 years, as would be done in a longitudinal study. Therefore, it was necessary to 
assess whether each study group (2006 and 2015) was representative of the Connecticut 
PCP population at the time of each survey so the appropriateness of generalization of the 
results (external validity) could be assessed.  
Methodology 
A quantitative, cross-sectional, comparative study was implemented similar to 
Johnson and Feder’s (2010) study. The population of 2015 Connecticut PCPs was 
randomized using the same computer software (Excel) that Johnson and Feder used to 
obtain the 33% of PCP in the categories needed for the study to obtain the study sample. 
Participant recruitment and data collection procedures were also aligned. The study 
instrument was the CT-KAP 2006 questionnaire, and study variables were 
operationalized by survey item response coding. Further information is provided in the 




The population for this epidemiological investigation included 5,231 PCPs 
licensed to practice in the state of Connecticut as of 2015, based on information from the 
CT DPH (2015), which contained data on Connecticut physicians CT DPH MD/DO 
including physician work addresses for the 17,464 certified physicians who actively 
practiced medicine. Of these 17,464 physicians, 5,231 were classified as PCPs in the 
categories of primary health care practice specialties of pediatrics, primary/general/family 
medicine, and internal medicine as the main sampling frame needed to conduct the study 
(CT DPH, 2015). See Appendix F for the description of the sampling frame and PCPs for 
2006 (Johnson & Feder, 2010) and 2015 (the current study).  
The final population accountable for the data analysis in this study were 145 PCP 
survey responses (2015) and 285 PCP survey responses (2006). The total number of 
PCPs of 2006 was 15,424. Of these 15,424 physicians (MD/DO), 3,091 were classified as 
PCPs in the categories of primary health care practice specialties of pediatrics, 
primary/general/family medicine, and internal medicine as the main sampling frame 
needed to conduct the study (Benson & Eberle, 2009; CT DPH, 2006). The population 
proportion of 2006 was derived from the historical data in Johnson and Feder’s (2010) 
study. Adjustment to the population proportion of 145 was conducted to make the data 
analysis appropriate, and the adjustment factor was 1.97 (285/145, 1.9655 = 1.97, 1.97 X 
145 = 285). To be more specific, the 2006 population proportion derived from Johnson 
and Feder’s study consisted of 57 family physicians, 113 internal medicine physicians, 
107 pediatricians, and eight others (i.e., emergency physicians). In contrast, the 2015 
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population proportion in this study comprised 28 family physicians, 63 internal medicine 
physicians, 48 primary physicians, and six others (i.e., emergency physicians) before 
adjustments. After adjustments were made to bring the 145 PCP responses to be 
standardized for appropriate comparisons, the population proportion consisted of 55 
family physicians, 124 internal medicine physicians, 48 pediatricians, and 12 others (i.e., 
emergency physicians). See Table 6 for more details. 
Sample and Sampling Procedures 
The recruitment of a sample of Connecticut PCPs were intended to form a similar 
sample size and type as that of Johnson and Feder’s (2010) study. This study had the 
same inclusion/exclusion criteria for study participants as Johnson and Feder. Thus, 
adaption to the inclusion and exclusion criteria from those pages were applied (see Tables 
4 and 5). The 2006 PCP population made up of 285 survey responses in the categories of 
family medicine practitioner, internist, pediatrician, or other PCPs (i.e., emergency 
physicians) after accounting for inclusion criteria. In this study, there were 145  PCP 
survey responses (population proportion) in 2015 for the data analysis (in the following 
categories: family medicine practitioner, internist, pediatrician, or other primary care 
practitioners). Physicians with specialization in areas unrelated to the primary care 
categories of pediatrics, family medicine, or internal medicine as explicitly described in 
the CT DPH database were excluded from this study. In alignment with the previous 
study, in this study, the sample frame was limited to physicians who are certified and 
actively practice primary care in Connecticut.  
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Johnson and Feder (2010) did not describe how they conducted the validation of 
the 2006 CT-KAP survey, but I assumed that it was validated because they were medical 
doctors. This lack of validity criteria is a basis to conduct a validity check to see if the 
PCPs in Johnson and Feder’s study and in this study have changed after 10 years and to 
find the internal and external validity of the data for this study. Although the internal and 
external validity were not documented or not published, their survey will have a higher 
degree of internal validity because their response rate was 39.1 %, and the survey 
response rate with the 2015 population proportions in this study was 11.9%. In this study, 
the validation of data is presented in Chapter 4.  
The overall sample size had similar population proportion based on the z score 
test. However, I still adjusted the 145 sample of PCP survey responses to the 285 sample 
of PCP survey responses before the data analysis because “equivalence testing performs 
best when sample sizes are equal” (Rusticus & Lovato, 2014, p. 1). A G*Power (Faul, 
Erdfelder, Lang, & Buchner, 2007) power analysis for a one-sample t test was used to 
determine the sample size needed to achieve adequate power for this study. The 
significance (alpha) level was set to p < 0.05, and power was set to 0.80. Because 
previous literature on LD and related disorders have reported small effect sizes, the effect 
size was set to small (Cohen’s d = 0.165; Larsen, MacDonald, & Plantinga, 2014; Tonne, 
2017). Based on the power analysis result, a sample size of n = 300 PCPs working in 
Connecticut was needed for the study (see Appendix H). 
Because the 2015 PCP study population proportion did not achieve the sample 
size projected (N = 300), it was assumed that the margin of error in this study was greater 
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than the 285 PCP survey population proportion of 2006. The margin of error formula is 
margin of error = z * √p * (1 – p) / √n. The margin of error in this study was 0.01%, p = < 
0.05, 95% CI = 1.96. Further, under the expectation to receive 300 PCP survey responses 
and only receiving 145, the margin of error was ± 5.86%. Moreover, in this study when 
calculated for the 145 PCP survey responses with p < 0.05 (z score 1.96), the calculated 
margin error was ± 8.138%. In contrast, the margin of error for the samples in the 
Johnson and Feder (2010) 2006 population proportions of 285 was ±4.726%; therefore, 
the smaller sample size in this study had a larger margin of error. The larger the sample 
size, the smaller the margin of error. Thus, when the two cluster samples were added (i.e., 
n =145 for 2015 and n = 285 for 2006 = n = 430), the calculated margin of error was ± 
4.73% (see Appendix G).  
The sample was expected to be similar or greater in proportion to (with a response 
rate of 39.1%) Johnson and Feder’s (2010) study sample to achieve equal representation 
and accurate data analysis. However, because the 2015 PCP proportion sample consisted 
of 145 from 179 PCP survey responses, I assumed that this response rate might affect the 
representation (internal validity) of the population in this study. The 2015 PCP specialty 
categories also had dissimilar frequency proportions in contrast to the 2006 PCP specialty 
categories. Z scores as presented in Chapter 4 show the variations within the PCP 
categories (see also Tables 4 and 5). Therefore, the n = 145 sample proportion of 2015 
was adjusted for the data analysis stated the status of representation in this study before 
the data analysis was conducted. The adjustment was done using the larger number of P1 / 
P2. Thus, P1 (285) / P2 (145) = 1.97.  
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Regarding sampling procedures, Johnson and Feder’s (2010) sampling frame was 
from the CT DPH (2006) database of 3,091 PCPs licensed to practice in the state of 
Connecticut, which I also used for this study. Johnson and Feder used random sampling 
to select 33% of the 3,091 Connecticut PCPs (n = 1,034), whose data were available in 
the CT DPH database as the recruitment sample. The same random sampling strategy 
technique was also employed in this study. A randomization method was employed via a 
random number generator set between 1 and 5,231; these numbers corresponded to the 
numbered database entries of the 5,231 Connecticut PCPs. In this study, 1,726 physicians 
were randomly selected as the 33% of the Connecticut PCPs, whose data were available 
in the CT DPH (2015) database. These physicians made up the sample of participants 
necessary for this study (see Appendix E).  
I mailed a study materials packet that included an informed consent form, 
directions on completing the study survey, the survey itself, and a stamped and addressed 
envelope to the physicians at their work addresses. As per the directions in the packet, 
physicians were asked to return the completed CT-KAP questionnaire using the stamped 
envelope, which was mailed to a designated P.O. box address. The questionnaire 
directions and CT-KAP questionnaire itself were identical to those used by Johnson and 
Feder (2010). Additionally, two other questions were included on whether the physician 
participated in Johnson and Feder’s study (i.e., Yes or No) and to give consent to 
participate in this study (see Appendix A).  
The consent form included my professional contact information, the reason for 
conducting the study, and information about (a) the goals and purpose of the study, (b) 
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the role of the study participant (i.e., what the physician were required to do), (c) the 
benefits and risk of participating in the study, (d) the procedures employed in the study to 
maintain confidentiality and anonymity, and (e) the voluntary nature of the study (i.e., the 
right of the physician to not participate in the study and/or to refuse to answer any 
questions on the CT-KAP questionnaire). Participants were not asked to sign their name 
on the consent form or to mail it back to maintain physician confidentiality and 
anonymity; instead, they were asked to check Yes or No on the consent form that was 
found in the mail out. If any physician selected No or did not mark the answer on the 
question as consent to participate yet returned a completed questionnaire, their data were 
not used in the study. It was not possible to mail reminder notices to encourage 
participation.  
Johnson and Feder’s (2010) study reported that of the 1,034 study packets mailed 
to the PCPs, 191 (18.5%) were returned unopened due to an incorrect address, which 
reduced the recruitment sample to 843 Connecticut PCPs (Johnson & Feder, 2010). A 
similar percentage (or proportions) rate of the 1,726 study materials packets was expected 
to be returned due to incorrect address, resulting in a recruitment sample of 1,507 
physicians. Johnson and Feder (2010) reported that, of the 843 survey packets received 
by the physicians, only 330 surveys were returned (a 39% response rate; see Tables 4 and 
5). Johnson and Feder’s (2010) final response rate was 33.5%; 285 of the 843 surveys 
mailed to “Connecticut Primary Care Physicians 2018” were returned and had useable 
data. As response rates in health care and medicine studies using mailed questionnaires 
are notoriously low (i.e., approximately 30%), a response rate of 30% was anticipated (n 
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= 422) (Halbesleben & Whitman, 2013; Johnson & Wislar, 2012; Phillips, Friedman, & 
Durning, 2017).  
Additionally, the study survey included a question inquiring as to whether the 
physician participated in Johnson and Feder’s (2010) study. If a physician had 
participated, his or her response was used in this study. The likelihood that the same 
physicians in Johnson and Feder’s (2010) study would also be recruited into this study 
was low, mainly since they and the researcher employed random sampling to obtain the 
initial recruitment sample. The expected sample of 422 physicians was large enough to 
allow for the removal of any of these cases – as well as the removal of cases with 
incomplete or otherwise unusable data – while achieving the desired sample size of 300.  
Johnson and Feder (2010) did not seek to obtain equal numbers of PCPs per 
specialty category. Consequently, it was not sought in this study to align with Johnson 
and Feder’s (2010) previous approach. The first research question was developed to act 
as a validity check and determine if the proportion of physicians per primary care 
category in this study was significantly different from those reported by Johnson and 
Feder (2010). In this study, it was hoped that this study sought to identify no significant 
differences in the proportion of physicians per primary care category because a lack of 
significance indicates that the two samples were similar. 
The original data set used in Johnson and Feder’s (2010) study was not fully 
accessible to the researcher. Therefore, the proportion, frequency, or mean level data that 
were reported in Johnson and Feder’s (2010) study were also used in this study. The 
inability to access Johnson and Feder’s (2010) full study data set required that the 
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statistical analyses used to test study hypotheses also treated the proportion, frequency, or 
mean data reported in their study as the expected or population data.  
Instrumentation Operationalization of Study Variables 
The instrument used in this study was Johnson and Feder’s (2010) 9-item CT-
KAP 2006 questionnaire on LD and CLD/PTLDS (see Appendix A). Murray and Feder 
(2001) developed and validated the CT-KAP questionnaire, and it was further refined in 
the study by Magri et al. (2002). Murray and Feder (2001) reported a 56% response rate, 
receiving completed questionnaires from 320 out of 573 PCPs in Connecticut that were 
solicited to participate. Of the 320 physicians in Murray and Feder’s (2001) study, 267 
(83%) reported having diagnosed patients with LD, a valid percent in a geographical 
region with a high LD prevalence rate. Most physicians said that they followed the 
established clinical guidelines for treating patients with LD; for example, the average 
course of antibiotic treatment was 21 days (Murray & Feder, 2001).  
There is nearly a 20-year history of using the CT-KAP questionnaire in 
surveillance and epidemiological and clinical research studies on LD but little on CLD. 
Studies have provided evidence that the CT-KAP questionnaire provides a valid and 
reliable assessment of physicians’ KAP regarding LD and CLD/PTLDS (Brett, Hinckley, 
Zielinski-Gutierrez, & Mead, 2014; McKinney et al., 2008). There is evidence of 
construct validity of the CT-KAP; that is, it effectively measures the KAP of physicians’ 
clinical approach to CLD/PTLDS.  Magri et al. (2002) provide evidence of criterion-
related discriminant validity of the CT-KAP: they found that there was a significantly 
higher percentage (or proportions) of physicians with patients diagnosed with LD in high- 
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versus low-endemic areas (53.2% as compared to 29.1%, p = 0.0003). McKinney et al. 
(2008) note considerable overlap in KAP questions between the CT-KAP and related 
physician LD KAP questionnaires, providing evidence of the criterion-related concurrent 
validity of the CT-KAP.  
The independent variable of this study was the physician group that is, the group 
of Connecticut PCPs who participated in Johnson and Feder’s (2010) research and those 
who participated in this study. The inability to fully access and use Johnson and Feder’s 
(2010) data set precludes the ability to analyze data at the item level for the group of 
Connecticut PCPs who participated in Johnson and Feder’s (2010) study and those who 
participated in this study. Johnson and Feder’s (2010) group was treated as a population, 
allowing for the use of proportion, frequency, and mean level data reported in their study. 
The response codes for each and all the nine items on the CT-KAP questionnaire was the 
same, which allowed the comparisons between the group of Connecticut PCPs who 
participated in Johnson and Feder’s (2010) study and those who participated in this study 
to be made. The following section presents each dependent variable and its coding. 
Figure 5 presents a summary of the study independent and dependent variables, which are 




Figure 5. Study independent and dependent variables. 
Dependent variable 1: Primary care physician specialty. The first dependent 
variable of PCP specialty was measured using CT-KAP item two: “What is your 
specialty?”  This CT-KAP item two was coded as a categorical (nominal) item, where 1 = 
Family Medicine, 2 = Internist, 3 = Pediatrician, and 4 = Other Primary Care.  
Dependent variable 2: Physician knowledge of Lyme disease. The second 
dependent variable of physician knowledge of LD was assessed using CT-KAP item 3: 
“How would you describe your knowledge of Lyme disease?” This CT-KAP item 3 was 
coded as a categorical (nominal) item, where 3 = I know the symptoms and feel 
comfortable diagnosing it, 2= I know the symptoms but don’t feel comfortable 
diagnosing it, and 1 = I don’t know the symptoms and don’t feel comfortable diagnosing 
it.  
Independent Variable: 
CT PCPs 2006 and 2015                     
DV1: PCP Specialty
DV2: Knowledge of LD
DV3: Knowledge of CLD
DV4: N of patients with 
LD
DV4: N of patients with 
CLD




Dependent variable 3: Physician knowledge of chronic Lyme disease. The 
third dependent variable of physician knowledge of CLD (PTLDS)was assessed using 
CT-KAP item four: “How would you describe your knowledge of CLD (PTLDS)?”  This 
CT-KAP item four is coded as a categorical (nominal) item, where 4 = I know the 
symptoms and feel comfortable diagnosing it, 3 = I know the symptoms but don’t feel 
comfortable diagnosing it, 2 = I don’t know the symptoms and don’t feel comfortable 
diagnosing it, and 1 = I don’t believe it exists. 
Dependent variable 4: Mean number of patients diagnosed and treated with 
Lyme disease and chronic Lyme disease. The fourth dependent variable of mean 
number of patients diagnosed and treated with LD and CLD (PTLDS) was measured 
using CT-KAP item seven: “Over the past 3 years, approximately how many patients 
have you diagnosed and treated with Lyme disease? “Over the past 3 years, 
approximately how many patients have you diagnosed and treated with Lyme disease?” 
This CT-KAP item seven was a ratio-coded variable that ranged from 0 to n.  
Dependent variable 5: Average total course of antibiotic therapy (in weeks) 
for patients with chronic Lyme disease. The fifth dependent variable of average total 
course of antibiotic therapy (in weeks) was assessed using CT-KAP item seven a: “What 
has been the average total course (in weeks) of antibiotic therapy for patients with CLD 




Data Analysis Plan 
The statistical software used to conduct all data analyses was SPSS 24.0. The data 
analysis plan involved a sequential process. Study participants used a paper questionnaire 
that necessitated the entry of questionnaire data into an SPSS 24.0 data set. Before 
entering these data, the researcher reviewed the surveys received from the physicians. 
Questionnaires with incomplete or otherwise unusable data were discarded, as were 
surveys in which the participant did not provide consent in the study. The researcher 
denoted the number of discarded questionnaires and the reasons why they were discarded 
(see Chapter 4).  
The researcher assigned to each questionnaire an ID number and collated the 
questionnaires in order of the ID number. The data were documented and organized using 
SPSS 24.0 to create the data set, which was kept on a password-protected jump drive (not 
a computer hard-drive). The jump-drive was stored in a locked file cabinet at the 
researcher’s home office in a separate compartment from paper questionnaires. The 
researcher reviewed the data and data set before and after the data were entered, 
searching for any data entry errors. Frequencies were performed on all item responses 
and conducted unusual cases analytics to ensure that all data entry errors were addressed. 
Descriptive statistical analyses were conducted on all data, reporting responses for 
each of the first nine question items of the 2018 CT-KAP questionnaire. While certain 
CT-KAP 2018 items were used to measure dependent variables, descriptive statistics 
were used for all nine items. The researcher ran and reported the frequencies/percentages 
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of responses on categorical (nominal) variables as well as the mean, median, standard 
deviation, and minimum and maximum values for the ratio-coded variables.  
The first, second, and third research questions required conducting Chi-square (χ²) 
goodness-of-fit tests. The fourth and fifth research questions required one-sample t-tests. 
The appropriate effect size and power calculation results augmented the statistical 
findings for each research question.  
Cohen’s W is the indicator of effect size for a Chi-square (χ²) goodness-of-fit test 
(Cohen, 1988; Cunningham & McCrum-Gardner, 2007; NCSS, n.d.). The mathematical 
formula for Cohen’s W is ²̸ (Cohen, 1988; NCSS, n.d.). Cohen’s d is the indicator of 
effect size for a one-sample t-test (Cohen, 1988; Lakens, 2013). The mathematical 
formula for Cohen’s d for a one-sample test (i.e., Cohen’s dz) is [t]/√n, where [t] is the 
absolute t-value (i.e., no negative values used), and n is the sample size (Cohen, 1988; 
Lakens, 2013). Power was determined from the effect size and sample size values. 
Research Questions Hypotheses and Statistical Analyses 
The purpose of this quantitative comparative (i.e., ex post facto) study was to 
examine if significant differences regarding knowledge, diagnosis, and treatment of LD 
and CLD/ (PTLDS exist between two groups of Connecticut PCPs – those who 
participated in Johnson and Feder’s (2010) study and those who participated in this study. 
The study posed five research questions with associated null and alternative hypotheses. 




Research Question 1: Are the frequency distributions of the 2015 sample of 
Connecticut PCPs across the four primary practice specialty areas (i.e., family medicine, 
internal medicine, pediatrics, other) significantly different from the distributions of the 
2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?  
H01: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the four primary practice specialty areas (i.e., family medicine, internal medicine, 
pediatrics, other) are not significantly different from the distributions of the 2006 
(Johnson & Feder, 2010) sample of Connecticut PCPs. 
Ha1: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the four primary practice specialty areas (i.e., family medicine, internal medicine, 
pediatrics, other) are significantly different from the distributions of the 2006 (Johnson & 
Feder, 2010) sample of Connecticut PCPs.  
Analysis:  Chi-square (χ²) goodness-of-fit test. The researcher treated Johnson 
and Feder’s (2010) physician data as population data and used data from CT-KAP 
questionnaire item two. Chi-square (χ²) goodness-of-fit test was done by comparing the 
frequency/proportion distributions of physicians in each of the four specialty areas to the 
frequency/proportion distribution values reported in Johnson and Feder’s (2010) study. 
This research question was unique, as it is the only one in the study in which the null 
hypothesis was intended to be retained or failed to be rejected.  
Research Question 2: Are the frequency distributions of the 2015 sample of 
Connecticut PCPs across the two knowledge of LD categories (i.e., know symptoms of 
LD and feel comfortable diagnosing and treating LD vs. know LD but do not feel 
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comfortable diagnosing and treating LD) significantly different from the distributions of 
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs? 
H02: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the two knowledge of LD categories (know symptoms of LD and feel comfortable 
diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and 
treating LD) are not significantly different from the distributions of the 2006 (Johnson & 
Feder, 2010) sample of Connecticut PCPs. 
Ha2: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the two knowledge of LD categories (know symptoms of LD and feel comfortable 
diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and 
treating LD) are significantly different from the distributions of the 2006 (Johnson & 
Feder, 2010) sample of Connecticut PCPs. 
Analysis. Chi-square (χ²) goodness-of-fit test. In this study, Johnson and Feder’s 
(2010) physician data were treated as population data. Chi-square (χ²) goodness-of-fit test 
was conducted by comparing the distributions of responses on CT-KAP questionnaire 
item three in this study data to the distribution values reported by Johnson and Feder 
(2010).  
Research Question 3: Are the frequency distributions of the 2015 sample of 
Connecticut PCPs across the three knowledge of CLD/PTLDS categories (do not believe 
CLD exists, do not feel comfortable diagnosing and treating CLD/PTLDS, and feel 
comfortable diagnosing and treating CLD/PTLDS) significantly different from the 
distributions of the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs? 
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H03: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the three knowledge of CLD/PTLDS categories (do not believe CLD exists, do not feel 
comfortable diagnosing and treating CLD/PTLDS, and feel comfortable diagnosing and 
treating CLD/PTLDS) are not significantly different from the distributions of the 2006 
(Johnson & Feder, 2010) sample of Connecticut PCPs. 
Ha3: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the three knowledge of CLD/PTLDS categories (do not believe CLD/PTLDS exists, do 
not feel comfortable diagnosing and treating CLD/PTLDS, and feel comfortable 
diagnosing and treating CLD/PTLDS) are significantly different from the distributions of 
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.  
Analysis. Chi-square (χ²) goodness-of-fit test. The 2006 physician data were 
considered population data. Chi-square goodness-of-fit test was completed using the 
distribution data of physician responses per knowledge category for CT-KAP 
questionnaire item four and the distribution values reported by Johnson and Feder (2010).  
Research Question 4: Is the estimated average number of patients diagnosed as 
having CLD/PTLDS within a 3-year period by the 2015 sample of Connecticut PCPs 
significantly different from the average number of patients diagnosed as having 
CLD/PTLDS within a 3-year period by the 2006 (Johnson & Feder, 2010) sample of 
Connecticut PCPs?  
H04: The estimated average number of patients diagnosed as having CLD/PTLDS 
within a 3-year period by the 2015 sample of Connecticut PCPs is not significantly 
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different from the average number of patients diagnosed as having CLD/PTLDS within a 
3-year period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs. 
Ha4: The estimated average number of patients diagnosed as having CLD/PTLDS 
within a 3-year period by the 2015 sample of Connecticut PCPs is significantly different 
from the average number of patients diagnosed as having CLD/PTLDS within a 3-year 
period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs. 
Analysis. One-sample t-test. The 2006 (Johnson & Feder, 2010) physician data 
were considered population data. One-sample t-test was used to test the difference 
between the study sample mean score for CT-KAP questionnaire item seven and the 
mean of 3.00 CLD cases reported per physician by Johnson and Feder (2010). 
RQ5. Is the estimated average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs 
significantly different from the average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample 
of Connecticut PCPs? 
Research Question 5: Is the estimated average course of antibiotic treatment (in 
weeks) for patients diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut 
PCPs significantly different from the average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample 
of Connecticut PCPs? 
H05: The estimated average course of antibiotic treatment (in weeks) for patients 
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is not 
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significantly different from the average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample 
of Connecticut PCP. 
Ha5: The estimated average course of antibiotic treatment (in weeks) for patients 
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is 
significantly different from the average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample 
of Connecticut PCP. 
Analysis. One-sample t-test. The Johnson and Feder (2010) physician’s data were 
considered the population data. One-sample t-test was used to test the difference between 
the study sample mean score for CT-KAP questionnaire 2018 item seven a and the mean 
of 20 weeks of antibiotic treatment by physicians in Johnson and Feder’s (2010) study. 
The two primary statistics used to test the hypotheses were the Chi-square (χ²) 
goodness-of-fit test and the one-sample t-test. The non-parametric Chi-square (χ²) 
goodness-of-fit test was used to determine if the frequency distribution of responses on a 
categorical variable for a sample is significantly different from the expected or population 
distribution (Salkind, 2016). The primary assumption to be met for a Chi-square (χ²) 
goodness-of-fit test is that each variable category must have a sample size no smaller than 
five (Salkind, 2016). This assumption was met in this study. The smallest sample size per 
category was six, in reference to the number of PCPs who identified as other. 
The one-sample t-test was used to determine if a sample variable mean score is 
significantly different from a known population mean score (Treiman et al., 2015). The 
100 
 
two fundamental assumptions of the one-sample t-test were that the dependent variable 
was measured using a ratio or interval scale and that the dependent variable had a normal 
distribution (Treiman et al., 2015). In this study, one-sample t-tests were used with ratio-
coded dependent variables.  
The assumption of normality was addressed by examining the skewness of the 
variables by computing zskewness values (i.e., by dividing the variable skewness by the 
skewness standard error; Kim, 2013). For medium-sized samples – that is, samples 
between 50 and 300 – a zskewness greater than 3.00 indicates variable skewness and a 
violation of the normality assumption (Kim, 2013). The assumption of normality was 
further tested by (a) conducting Kolmogorov-Smirnov tests, (b) utilizing SPSS 24.0 
unusual cases function to identify outliers, and (c) computing box-plots.  
As stated by Cousineau and Chartier (2010), “there is no single solution” to 
dealing with outliers (p. 66). There are three standard options to address outliers: (a) 
winsorizing the outlier (i.e., replacing the outlier value with the next lowest or highest 
score), (b) transforming the variable (i.e., using loglinear or square root transformations), 
or (c) removing the outliers (Cousineau & Chartier, 2010; Kim, 2013; Pollet & van der 
Meij, 2017). However, Winsorization and transformation of values do not always solve 
outlier issues (Cousineau & Chartier, 2010; Kim, 2013; Pollet & van der Meij, 2017).  
The option for dealing with outliers selected for this study was removal of the 
outliers, especially as statistical findings may differ substantially based on whether 
“outliers are included or excluded” (Pollet & van der Meij, 2017, p. 54). A concern with 
removing outliers is that it may result in the loss of too many data points until the 
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statistical analysis cannot be conducted or is no longer applicable to the data set 
(Cousineau & Chartier, 2010; Kim, 2013; Pollet & van der Meij, 2017). However, one-
sample t-tests were conducted for the fourth and fifth research questions, as it was 
important in this study to replicate the analyses conducted by Johnson and Feder (2010) 
and to address the null and alternative hypotheses for them. 
Threats to Validity 
Three types of validity in quantitative research studies pertain to study limitations 
in relation to the research methodology and design: (a) internal validity, or the degree to 
which it can be stated that the observed effects on the dependent variable(s) are due to the 
independent variables and not to uncontrolled confounding variables; (b) external 
validity, or the ability to generalize study results to the population or other samples, 
settings, and times; and (c) construct validity, or how well a study instrument 
operationally captured the constructs under study (Patten & Newhart, 2017). The internal 
and external validity were assessed by comparing the number or proportions of PCP 
survey responses and the PCP categories of 2006 (from the official list of CT MD/DO, 
and the ones that responded to the survey) and 2015 (from the official list of CT MD/DO, 
and the ones that responded to the survey). The calculations for internal and external 
validity are presented in Chapter 4. The internal and external validity was measure in this 
study when answering Hypothesis questions. Quantitative studies have threats to internal, 
external, and construct validity, but they differ according to the type of quantitative 
research design employed in the study (Reio & Reio, 2016). Threats as they pertain to 
internal, external, and construct validity are discussed in the following sections.  
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Threats to Internal Validity 
Threats to internal validity are participant or study factors that compromise the 
ability to state that dependent variable effects were the result of the independent variable 
(Patten & Newhart, 2017). If a cross-sectional study has high level of internal validity 
will be measure in great part from the strength of the interferences of the study (Carlson, 
& Morrison, 2009). Most threats to internal validity concern experimental or quasi-
experimental studies, but there are threats to the internal validity of nonexperimental 
research studies as well (Patten & Newhart, 2017). These threats to the internal validity 
of nonexperimental research studies include the following: (a) bias due to confounding, 
(b) self-selection bias, and (c) social desirability response (Patten & Newhart, 2017).  
Bias due to confounding is the inability to conclude that the dependent variable 
effects are a result of the independent variable due to an unmeasured extraneous variable 
that was significantly associated with the independent and dependent variables (Bergman, 
2011). A potential source of confounding bias in this study is that physicians who 
participated in Johnson and Feder’s (2010) study may have been recruited into this study. 
There were a total of 14 PCP surveys responses of PCPs who believed they took the 
survey of 2006. Some of these respondents were not 100%, but they marked in the 
question 10 of the 2015 KAP survey used in this study as Yes.  
Self-selection or volunteer bias occurs in studies that rely on a convenience 
sample as opposed to a random selection of study participants; participants who volunteer 
for a study tend to differ in “relevant clinical characteristics” from those who do not 
participate (Tripepi, Jager, Dekker, & Zoccali, 2010, p. 98). The self-selection bias may 
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be minimized by focusing on a subset of physicians—namely, PCPs in the state of 
Connecticut—and utilizing random selection to obtain the study recruitment sample. 
Klabunde, Willis, and Casalino (2013) identified four primary reasons why physicians do 
not participate in survey studies: (a) “lack of time,” (b) perceptions that the study or study 
questionnaire has little value or importance, (c) confidentiality and anonymity concerns, 
and (d) views that the study questionnaire is “biased or not providing a full range of 
responses” (p. 286). Physicians who complete and mail the study survey may have more 
time in their schedule to complete the questionnaire and more positive attitudes about the 
study and/or study questionnaire and may be more assured that confidentiality will be 
maintained in the study than physicians who do not participate. 
Another threat to the internal validity of nonexperimental studies (as this cross-
sectional study) is social desirability response bias, or when the study participant 
provides answers to survey items that are socially acceptable irrespective of the truth 
(Bowling, 2014). As this study was a cross-sectional study, I am as the main researcher 
did not manipulate the independent variables and the random method used helped to 
control the present of extraneous variables. Nonetheless, social desirability response bias 
is more likely to occur when participants are asked sensitive questions – for example, 
questions about their weight, physical and mental health problems, and attitudes toward 
coworkers and supervisors (Klabunde et al., 2013). This study used a cross-sectional 
study (nonexperimental) to examine the physician’s (PCPS in the categories family, 
internal medicine, pediatricians) work-related KAPs regarding LD and CLD. While the 
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study survey inquiries about controversial topics, it does not ask about personal or 
sensitive topics. Consequently, social desirability bias may be lessened.  
The informed consent process wherein participants are informed about study 
confidentiality may further help reduce social desirability bias (Bowling, 2014). 
Conclusively, social desirability on self-reporting can affect the outcomes in the study in 
regard to the external and internal validity (Althubaiti, 2016). Althubaiti (2016) stated 
that an excellent way to eliminate the threat of social desirability not to affect the internal 
validity of a study is to validate the survey instrument before the data collection stage 
when possible. However, validating the survey instrument before the data collection stage 
is not applicable for cross-sectional study and better for experimental studies.  
Threats to External Validity 
External validity pertains to the ability to generalize study results beyond the 
study sample to the population (or other samples), to different points in time, and to other 
settings (Bowling, 2014). The external validity of a study is highly dependent upon the 
degree to which the study participants represent the population (Bowling, 2014). Random 
sampling to obtain the recruitment pool of physicians may increase the external validity 
of the study, as it can focus on a specific population of physicians. However, results from 
this study cannot be generalized to PCPs licensed to practice in states other than 
Connecticut, to physicians who are not PCPs, or to other health care workers (e.g., nurse, 
physician assistants), regardless of their specialty area. Results from this study cannot be 




Threats to Construct Validity 
Construct validity indicates that the study instrument is measuring the constructs 
it is intended to measure (Patten & Newhart, 2017). The inadequate explication of 
constructs, or the incorrect or inexact operationalization of study constructs, is a threat to 
construct validity (Patten & Newhart, 2017). The threat of inadequate explication of 
constructs is minimized in this study by a valid and reliable questionnaire. This study 
may be influenced by the construct validity threat of mono-method bias, or the use of a 
single type (vs. multiple types) of measurement (Patten & Newhart, 2017), primarily 
because individual items are used to measure study constructs. Conclusions from results 
can only be drawn concerning items on the CT-KAP questionnaire 2015.   
Ethical Procedures 
In conducting this study, the I adhered to the ethical standards for research with 
human subjects. I sought IRB approval from the Walden University IRB before 
implementing any part of this study. The study and data collection were approved by the 
Walden University IRB. Walden University’s approval number for this study was 06-05-
18-023461. I applied the highest level of ethical considerations to maintain the integrity 
of this study, especially with regard to informed consent and participant privacy and 
confidentiality, the management of data, data analyses, and the disposal of study 
materials (i.e., the checked consent forms, paper questionnaires, and data sets). 
Per ethical guidelines for human subjects research, I required that study 
participants read and sign an informed consent form. The informed consent form 
included information on (a) the goals and purpose of the study, (b) the role of the 
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participants in the study, (c) their rights as human subjects, and (d) benefits and risks of 
participating in the study. I included my contact information (i.e., email and phone 
number) as well as the contact information for the Walden University IRB administrator 
on the consent form to enable physicians who had questions or concerns about the study. 
Only three physicians called with some questions regarding the study, and I received no 
emails from any physicians. The physicians had to check Yes next to the informed 
consent form statement to indicate they consented to participate in the study. I discarded 
any returned surveys if the PCP did not provide consent by checking Yes.  
The CT-KAP questionnaire did not contain any questions that could identify the 
physician. While I knew names and work addresses of the 1,726 physicians of whom I 
mailed the survey packet, it was impossible to ascertain who did or did not complete and 
return the CT-KAP survey. I stored survey forms with the checked consent question mark 
from the CT-Survey of 2015 (conducted in 2018) in a locked file cabinet in a home work 
office.  
After I entered the data from the paper questionnaires into an SPSS 24.0 data set, 
the data were checked carefully to avoid errors in the data entry process. The data set was 
stored on a password-protected jump-drive (not a computer hard drive), which was kept 
in a locked file cabinet separate from the consent forms and paper questionnaires. The 
informed consent forms and surveys are to be shredded, and the jump-drive is to be 
destroyed five years after completion of this study. Data from the study were reported on 





This quantitative study utilized a nonexperimental, cross-sectional, comparative 
research design to determine if two groups of Connecticut PCPs significantly differ in 
their knowledge, diagnosis, and treatment of LD and CLD/PTLDS. CLD/PTLDS 
definition was stated in the cover letter of the consent letter, which was mailed with the 
survey for this study. Survey responses provided by 145 Connecticut PCPs who 
participated in this study were compared to the frequency, proportion, and mean level 
data reported by Johnson and Feder (2010) in their research with 285 Connecticut PCPs.  
The methodological practices, including the study participant recruitment and data 
collection procedures, were aligned with the practices outlined by Johnson and Feder 
(2010). The study used the CT-KAP questionnaire that Johnson and Feder (2010) 
utilized. One of two added questions (11) asked whether the physician took part in the 
previous study and was included on the questionnaire.  
Data from physicians who participated in the previous study were used. The 
information from this study was expected to update the PCPs positions on CLD/PTLDS 
(e.g., see Chapter 4 and 5) and help to inform the need for the development of 
CLD/PTLDS diagnosis and treatment protocols since it lacks a case definition, reliable 
laboratory tests, surveillance, and standardized treatment practices as most identified 
infectious diseases do (National Institute of Allergy and Infectious Diseases, 2019; 
Wharton et al., 1990). This chapter provided a comprehensive review of the study 




Chapter 4: Results 
Introduction 
CLD/PTLDS may be a new health condition (Marzec et al., 2017) that lacks a 
case definition, reliable laboratory tests, an ICD-10 code, data collection and 
surveillance, and standardized treatment practices (Infectious Diseases Society of 
America, 2006; Lantos, 2015a, National Institute of Allergy and Infectious Diseases, 
2019). Johnson and Feder (2010) addressed this confusion regarding CLD/PTLDS by 
examining the knowledge and practices of LD and CLD/PTLDS diagnosis and treatment 
in 285 Connecticut PCPs. However, there has not been assessment of Connecticut PCPs’ 
KAPs regarding LD and CLD/PTLDS since Johnson and Feder’s seminal study.  
In this study, I utilized a nonexperimental, cross-sectional, and comparative 
research design to validate Johnson and Feder’s (2010) study outcomes. The key element 
of this study was to determine whether there were any significant differences between the 
two groups of Connecticut PCPs (i.e., the 2006 and 2015 samples) regarding their KAP 
responses on the diagnosis, treatment, and management of LD and CLD/PTLDS. I 
followed the same participant recruitment and data collection procedures as Johnson and 
Feder. I also utilized their KAP survey, which can be validated by statistically similar 
findings between the two Connecticut PCP groups (using the CT DPH bases for 2006 and 
2015). Any significant differences between the two PCP groups suggest a need to 
conduct studies to further explore PCPs’ KAPs regarding CLD/PTLDS. The data 
obtained in this study from the PCP survey responses were compared to the data 
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published in 2010. For purpose of representation, the data in this study was adjusted to 
the factor of 1.97 (see Table 6).  
This study had five research questions. The first research question acted as a 
validity check to determine if the proportions of PCP specialties across this and the 2006 
study specialty were similar, which they were. The second research question focused on 
PCP knowledge differences on LD. The last three questions helped examine knowledge, 
attitude, and treatment differences regarding CLD/CLD. The research questions and 
hypotheses were as follows:  
Research Question 1: Are the frequency distributions of the 2015 sample of 
Connecticut PCPs across the four primary practice specialty areas (i.e., family medicine, 
internal medicine, pediatrics, other) significantly different from the distributions of the 
2006 (Johnson & Feder, 2010) sample of Connecticut PCPs?  
H01: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the four primary practice specialty areas (i.e., family medicine, internal medicine, 
pediatrics, other) are not significantly different from the distributions of the 2006 
(Johnson & Feder, 2010) sample of Connecticut PCPs. 
Ha1: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the four primary practice specialty areas (i.e., family medicine, internal medicine, 
pediatrics, other) are significantly different from the distributions of the 2006 (Johnson & 
Feder, 2010) sample of Connecticut PCPs.  
Research Question 2: Are the frequency distributions of the 2015 sample of 
Connecticut PCPs across the two knowledge of LD categories (i.e., know symptoms of 
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LD and feel comfortable diagnosing and treating LD vs. know LD but do not feel 
comfortable diagnosing and treating LD) significantly different from the distributions of 
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs? 
H02: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the two knowledge of LD categories (know symptoms of LD and feel comfortable 
diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and 
treating LD) are not significantly different from the distributions of the 2006 (Johnson & 
Feder, 2010) sample of Connecticut PCPs. 
Ha2: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the two knowledge of LD categories (know symptoms of LD and feel comfortable 
diagnosing and treating LD versus know LD but do not feel comfortable diagnosing and 
treating LD) are significantly different from the distributions of the 2006 (Johnson & 
Feder, 2010) sample of Connecticut PCPs. 
Research Question 3: Are the frequency distributions of the 2015 sample of 
Connecticut PCPs across the three knowledge of CLD/PTLDS categories (do not believe 
CLD exists, do not feel comfortable diagnosing and treating CLD/PTLDS, and feel 
comfortable diagnosing and treating CLD/PTLDS) significantly different from the 
distributions of the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs? 
H03: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the three knowledge of CLD/PTLDS categories (do not believe CLD exists, do not feel 
comfortable diagnosing and treating CLD/PTLDS, and feel comfortable diagnosing and 
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treating CLD/PTLDS) are not significantly different from the distributions of the 2006 
(Johnson & Feder, 2010) sample of Connecticut PCPs. 
Ha3: The frequency distributions of the 2015 sample of Connecticut PCPs across 
the three knowledge of CLD/PTLDS categories (do not believe CLD/PTLDS exists, do 
not feel comfortable diagnosing and treating CLD/PTLDS, and feel comfortable 
diagnosing and treating CLD/PTLDS) are significantly different from the distributions of 
the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs.  
Research Question 4: Is the estimated average number of patients diagnosed as 
having CLD/PTLDS within a 3-year period by the 2015 sample of Connecticut PCPs 
significantly different from the average number of patients diagnosed as having 
CLD/PTLDS within a 3-year period by the 2006 (Johnson & Feder, 2010) sample of 
Connecticut PCPs?  
H04: The estimated average number of patients diagnosed as having CLD/PTLDS 
within a 3-year period by the 2015 sample of Connecticut PCPs is not significantly 
different from the average number of patients diagnosed as having CLD/PTLDS within a 
3-year period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs. 
Ha4: The estimated average number of patients diagnosed as having CLD/PTLDS 
within a 3-year period by the 2015 sample of Connecticut PCPs is significantly different 
from the average number of patients diagnosed as having CLD/PTLDS within a 3-year 
period by the 2006 (Johnson & Feder, 2010) sample of Connecticut PCPs. 
Research Question 5: Is the estimated average course of antibiotic treatment (in 
weeks) for patients diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut 
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PCPs significantly different from the average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample 
of Connecticut PCPs? 
H05: The estimated average course of antibiotic treatment (in weeks) for patients 
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is not 
significantly different from the average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample 
of Connecticut PCP. 
Ha5: The estimated average course of antibiotic treatment (in weeks) for patients 
diagnosed as having CLD/PTLDS by the 2015 sample of Connecticut PCPs is 
significantly different from the average course of antibiotic treatment (in weeks) for 
patients diagnosed as having CLD/PTLDS by the 2006 (Johnson & Feder, 2010) sample 
of Connecticut PCP. 
This chapter starts with  information on the data collection procedures, the initial 
and final response rate, and the specialty description of the 145 PCPs in this study. As 
this is a validation of Johnson and Feder’s (2010) study, the discussion is focused on the 
similarities and differences found in this study with regard to study sample sizes and 
response rates. This chapter also provides a comprehensive examination of the 
descriptive and inferential statistical findings in this study. The presentation and 
discussion of these findings regarding the research questions comprise most of the 




The data collection period for this study was June 18, 2018 to August 20, 2018. 
The data collection methods aligned with those conducted by Johnson and Feder (2010; 
see Chapter 3). The two groups under examination are the 285 PCPs (from the PCP 
sample of 2006) study and the 145 PCPs (from the sample of PCP of 2015) in this study. 
As this was a validation study, it was important to replicate the same sampling frame 
used by Johnson and Feder’s research methodology, including the use of same survey 
instrument. Two extra questions were added to assess if the participants took the same 
survey before (Question 10) and to follow Walden University IRB requirements related 
to consent (Question 11) any relation with the variables in this study (see Appendix A). 
The first step of the study was to determine if the 2006 and 2015 samples of 
Connecticut PCPs similarly represented Connecticut PCPs, especially regarding specialty 
areas. The first step of the validity process was to determine if the 2006 and 2015 
samples adequately represented the population of Connecticut MDs/Dos as listed in the 
CT DPH database. The  CT DPH MD/DO database had contact information on 15,424 
PCPs for 2006 and 17, 464 PCPs for 2015. I mailed out CT-KAP surveys from the total 
list of MD/DO that were preselected of 2006 and 2015 populations proportions (see 





Figure 6. PCP Distributions from databases of CT DP MD/DO of 2006 and 2015. 
Database information was adapted from this study from the CT DPH List of Certified 
Medicare MD/DO. Database information were used to select the 33% of the PCPs in the 
list of 2006 (15,424) and in 2015 (15,464).  
  
Figure 7. Frequency of specialty groups within the PCP category in distribution 
databases of MD/DO of 2006 and 2015. A Chi-square test result indicated that the two 
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Therefore, the distribution of the three categories in year 2006 is not the same as the 
distribution in year 2015 taken from the original databases.  
To further investigate the similarities and differences of categories, z tests were 
used to test which category differed between 2006 and 2015. Table 3 shows the results of 
the z test for each category. The proportions of internal medicine were not significantly 
difference between 2006 and 2015. Similarly, the proportions of family medicine were 
not significantly difference between 2006 and 2015. However, the proportions of 
pediatrician category were significantly different between the two years (z = 2.492, p = 
0.012). Specifically, the percentage of pediatrician in 2006 (10.10%) was significantly 




Z Scores of Distributions from CT DPH Databases in 2006 and 2015 
Category z p Inference 
Internal medicine 3.463 < 0.050 Significant difference 
Family medicine 0.503 0.617 No significant difference 
Pediatrician 1.062 0.289  No Significant difference 
Other PCPs 10.05 < 0.050 Significant difference 
Note. Pediatrician specialty and family were similar in the two population proportions of 
2006 versus 2015, respectively (z = 1.062, p = 0.289; z = 0.0503, p = 0.617). The internal 
medicine specialty and the other PCPs specialty were no similar, respectively (z = 3.463, 
p < 0.050; z = 10.05, p < 0.050). 
Therefore, it was found that the CT DPH MD/DO of 2015 was independent but 
not 100% similar to the CT DPH MD/DO of 2006. These findings are important to 
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answer the hypotheses, especially for Research Question 1 where the values to from the 
PCP population proportions were received in both surveys. Though the fact that the PCPs 
distributions or proportions were not the same in this validity study may have affected 
some results, the same protocols were followed to avoid bias (selection, information bias, 
and confounding; Kukull & Ganguli, 2012). It is important to maintain the correct 
association of the variables under the study to avoid errors in outcome frequencies 
exposures (Kukull & Ganguli, 2012). The selection of participants using randomization 
gave equal participants the capacity to take part in the study, which allows for inferences. 
One of the main criteria for sampling was to take the 33% of the group (PCPs in 2006 
and PCPs in 2015). I also conducted a chi-square test to determine if this study was 
representative of the PCP sample or proportion found by Johnson and Feder (2010). The 
chi-square results indicated that the PCPs sample or proportion in this study was similar 
in terms of being representative of the PCPs of 2006. More of this discussion will be 
present when answering Research Question 1.  
Tables 4 and 5 provide a review of the survey dissemination data, including the 
total number of potential participants, the selected number of potential participants, and 
the number and percentages (or proportions) of surveys sent and received in both studies. 
Johnson and Feder (2010) used the CT DPH MD/DO of 2006, whereas this study 
included the CT DPH MD/DO of 2015. The total number of Connecticut PCPs denoted 
in the CT DPH MD/DO of 2006 DPH list was 3,091, and the total number in the CT DPH 
MD/DO of 2015 list was 5,231. As per their research methodology, Johnson and Feder 
(2010) randomly selected 33% of the PCPs, which was 1,034. In this study, 33% of the 
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PCPS were also randomly selected, which was 1,726. Johnson and Feder reported an 
initial response rate of 39.1%, or 330 PCPs who completed and returned a study survey. 
In this study the initial response rate was 11.9% or 179 PCPs who returned a completed 
study survey. Therefore, the response rate was lower than the previous study done 10 
years ago (see Table 4).  
Table 4 
 
Comparisons of Survey Dissemination Data 




z p Inference  
Total number of the PCPs from the 
CT DPH database 
15,424 17,464    
Number of PCPs on DPH-Certified 
list before randomization (original 
list). 
3,091 5,231 20.64 < .001 Dissimilar 
(see Figure 
8) 
Randomly selected PCPs who were 
sent the study survey packet (33% of 
the original categorical list).  
1,034 (33%) 1,726 (33%) 0.25 .804 Similar 
Study survey packets returned to 
researcher due to wrong address.  
191 (18.5%) 219 (12.7%) 4.06 < .001 Dissimilar 
PCPs who received study survey 
packets.  
843 (81.5%) 1,507 
(87.3%) 
3.75 < .001 Dissimilar 
PCPS who returned study survey 
packets.  
330 (39.1%) 179 (11.9%) 14.20 < .001 Dissimilar 
Final population (proportion) of the 
number of PCP responses used for 
data analysis  
285 145 1.59 0.118 Similar 
Note. The data show the similarities of the two PCP responses received of the two PCP 
distributions of 2006 and 2015. The additional parameters presented in this table were 
closely similar in percentages (or proportions) based on the nonsignificance z scores. 
The z-test procedure for testing the equality of two proportions was used to 
compare the responses to the survey between 2010 and 2015. The z-test statistic was 
computed as z = (p1 – p2) / SE (p1-p2) where p1 is the estimate of the proportion in of 
2006 (presented by Johnson & Feder, 2010) and p2 is the estimate of the proportion of 
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PCPs of 2015(in this study). SE (p1-p2) is the standard error of the difference in two 
proportions and can be estimated as:  SE (p1-p2) =  	1 − 	  +  where n1, and 
n2 are sample sizes in 2006 and 2015, respectively. 
The tests were performed at .05 level of significance which implies that the null 
hypothesis of equality of proportions will be rejected if the p value of the test is less than 
.05. The percentage of randomly selected PCPs of 2006 survey who were sent the study 
survey packet was 33.5% and it was very similar with the PCPs sample of 2015 (33.2%). 
Results of z test showed no significant difference in percentage of randomly selected 
PCPs who were sent the study packet between 2006 and 2015 (z = 0.427, p = .669). The 
percentage of study survey packets returned to the researcher due to wrong address was 
18.5% in 2010 and the corresponding percentage in 2015 was (12.7%). Results of z test 
showed a significant difference in the two percentages between 2006 and 2015 (z = 
4.198, p < .001). Specifically, the percentage of study survey packets returned to the 
researcher due to wrong address was significantly higher in 2006 sample compared with 
the 2015 sample (the difference in the proportions was 5.8%, 95% confidence interval for 
difference in percentage was 3.1% to 8.6% indicating that at 95% confidence, the 
difference in the percentage of survey packets returned due to wrong address was 
between 3.1% to 8.6%).  
The percentage of randomly selected PCPs who received the survey packets was 
81.5% od 2006 sample and the corresponding percentage of the 2015 sample was 87.3%. 
Results of z test showed a significant difference between the two proportions in 2010 and 
2015 (z = 3.748, p < .001). Specifically, the proportion of randomly selected PCPs who 
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received the survey packets was significantly lower in 2006 sample compared with 2015 
sample. The difference in the two proportions was – 5.3%, 95% confidence interval of 
the difference in proportions was -8.0% to -2.5% indicating that at 95% confidence, the 
difference in the proportion of randomly selected PCPs who received the survey packets 
in 2006 sample compared with the 2015 sample is between 2% to 8%.   
The percentage of PCPs who returned the survey packets was 39.1% of 2006 
sample and the corresponding percentage of 2015 sample was 11.9%. Results of z test 
showed a significant difference in the proportions between 2006 and 2015 samples (z = 
14.200, p < .001). Specifically, the proportion of PCPs who returned the survey packets 
of 2006 sample was higher compared with that in 2015 sample. The difference in the 
proportions was 21.6%, 95% confidence interval for difference in proportions was 18.6% 
to 24.6% indicating that at 95% confidence, the difference in the proportion of randomly 
selected PCPs who returned the survey packets in 2006 sample compared with that in 
2015 sample was between 18.6% to 24.6%.  More surveys were returned in this study due 
to wrong addresses than the one of 2006. This fact implies in this study the percent of 
nonresponse may be greater than in the previous study. Additionally, the facts of having 
more survey returned because wrong address may imply that fact maybe a greater 
number of PCPs moved out and maybe retired. Returned survey can increase the percent 







Comparison of Surveys Received and Discarded 





sample   
χ2 p Inference   
Number of 
Returned Study 
Surveys. (Similar).  
330 179 1.509 .219   
Number of 
Discarded Surveys 




  Z p   
Physician who 
completed survey 
was not a PCP. 
20 (44.4%)  16 (47.0 %) 0.231 .817 Similar  
PCP reported 
he/she was no 
longer in practice  
10 (22.2%) 10 (29.4 %) 0.727 .233 Similar  
PCP had not 
diagnosed patients 
within the last 3 
years.  
5 (11.1%) 3 (8.8%) 0.334 .739 Similar  
Undecipherable 
survey responses. 
8 (17.8%) 1 (2.9%) 2.055 .039 Dissimilar  
Health care 
provider other than 
PCP answered 
survey. 
2 (4.4%) 0 (0.0%) 1.245 .213  Similar  
Note. *Percentages (or proportions) are derived from the respective 45 or 34 discarded 
surveys. The 0.0% values could not be used for z tests using SPSS. Nonetheless, it was 




As illustrated in Table 5, A Chi-square (χ²) test of independence was used to test 
the difference in distribution of surveys received and discarded for 2006 versus 2015 
PCPs. In the study by Johnson and Feder, (2010) 86.4% of surveys were returned and 
13.6% were discarded. In the current study, 81% of surveys were returned and 19% were 
discarded. Results of the Chi-square (χ²) test for independence showed that there was no 
significant difference in the distribution of surveys returned or discarded between the two 
samples (2006 and 2015) (χ2 (1) = 1.509, p = .219). Z tests for testing the equality of two 
proportions was also used to compare which rationale of discarding the surveys was 
significantly different between 2006 sample and 2015 sample. Z-test statistic was 
computed as Z = (p1 – p2) / SE (p1-p2) where p1 is the estimate of the proportion of 
2006 sample and p2 is the estimate of the proportion in 2015 sample. SE (p1-p2) is the 
standard error of the difference in two sample proportions and can be computed using the 
following formulae: SE (p1-p2) =  	1 − 	  +  where n1, and n2 are the sample 
sizes in 2006 sample  and 2015 sample , respectively. This test was carried out at .05 
level of significance which implies that the null hypothesis of equality of proportions will 
be rejected if the p value of the test is less than .05.  
The percentage of surveys discarded because the physician who completed the 
survey was not a PCP was 44.4% in the 2006 sample and the corresponding percentage in 
the 2015 sample that was 47.1%. Results of the z test indicated no significant difference 
between the two proportions (z = 0.231, p = .817). 
The percentage of surveys discarded because the PCP reported he/she was no 
longer in practice was 22.2% for the 2006 sample and the corresponding percentage in 
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2015 sample was 29.4%. Results of the z test indicated no significant difference between 
the two proportions (z = 0.727, p = .233). This may suggest that medical doctors may had 
changed their medical specialty from PCPs to other types of medical doctors (i.e. in this 
study in the exclusion list two PCPs stated they were now cardiologists, others stated they 
were neurologists, etc.). This fact may imply LD and CLD are terms more popular among 
doctors and patients presently than in 2006 (i.e. as the CDC had documented how LD 
cases had increased after 2006; see Figure 3). 
The percentage of surveys discarded because the PCP had not diagnosed the 
patients in the last three years was 11.1% in the 2006 sample and the corresponding 
percentage in the 2015 sample was 8.8%. Results of the z test indicated no significant 
difference between the two proportions (z = 0.334, p = .739). 
The percentage of surveys discarded because of undecipherable survey responses 
was 17.8% in the 2006 sample and the corresponding percentage in 2015 sample was 
2.9%. Results of the z test showed a significant difference between the two proportions (z 
= 2.055, p = .039). Specifically, the proportion of surveys discarded because of 
undecipherable survey responses was significantly higher in the 2006 sample compared 
with 2015 sample. The difference between the two years was 14.8%, 95% confidence 
interval for difference was 0.7% to 28.9% indicating that at 95% CI, the difference in 
percentage of surveys discarded because of undecipherable survey responses between 
2006 sample and 2015 sample was between 0.7% to 28.9%.  
The percentage of surveys discarded because the health care provider other than 
PCP answered the survey was 4.4% in 2006 sample and the corresponding percentage in 
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2015 sample was 0%. Results of the z test indicated no significant difference between the 
two proportions (z = 1.245, p = .213). 
The percentage of surveys discarded because the PCP did not provide informed 
consent was 0%% for the 2006 sample, and the corresponding percentage in 2015 sample 
was 11.8%. Results of the z test showed a significant difference between the two 
proportions (z = 2.361, p = .018). Specifically, the proportion of surveys discarded 
because PCP did not provide informed consent was significantly lesser in 2006 sample 
compared with 2015 sample. The difference between the two samples was 11.8%, (95% 
CI:  -21.53% to -2.0% at 95% CI, the difference in percentage of surveys discarded 
because the PCP did not provide informed consent for the 2006 versus and 2015 sample 
was between -21.53% to -2.0%.  
For each research question, a post hoc power analysis was conducted after the 
analysis to determinate the degree of probability that the results could be said to be true. 
The post hoc effect size and power are reported in this study in those research questions 
needed.  
Descriptive statistics: PCP specialty. Table 6 provides the PCP specialty group 
frequencies and percentages, and Figure 8 details the frequencies per PCP specialty 
category. The largest group of PCPs in this study self-identified as internists (n = 63, 
43.4%). Forty-eight (33.1%) reported that they were pediatricians, while 28 (19.3%) were 
family physicians. Six (4.1%) reported having another primary care specialty (i.e., all six 
reported being in emergency medicine). The data was adjusted to present the 
representation of 2015 in contrast with 2006 population frequencies. The 2006 PCP 
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frequencies and percentages (or proportions) of 2006 specialty of n = 285 from the study 




Frequencies for Primary Care Physician Specialties in 2015 


















Internist 63 43.4% 124 43.4% 65.4% 
Pediatrician 48 33.2% 94 33.2% 19.1% 




6 4.1% 12 4.1% 5.1% 
Note. The 2015 PCPs of 2015 in the categories presented here internist, pediatrician, 
family physician, pediatrician and other were adjusted to present the representation status 
of it in this study. The percentages (or proportions) did not change, but the frequencies of 
PCPs did. The respective frequencies presented here from 2015 data were 63, 48,28, and 
6. When the data was adjusted by a factor of 1.97 (285/145) the frequencies of PCPs in 
this study are 124, 94, 55, and 12. Samples were similar after adjusted Samples had 
different frequencies (X2)   = 0.0017, p < 00001, no significant at p < 0.05. Therefore, the 






Frequencies for Primary Care Physician Specialties in 2006 









Internist 113 39.6 69* 
Pediatrician 107 37.5 20* 
Family physician 57 20   10* 
Other (i.e., Emergency 
Physicians) 
8 2.9 1* 
Note. * The whole data of MD/DO was not available to me. Therefore, estimation was 
adapted from figures from three sources (a) 
http://www.publichealth.uconn.edu/assets/primarycarereport_02_09.pdf, (b) 
https://portal.ct.gov/DPH/Practitioner-Licensing--Investigations/PLIS/Licensing-
Statistics, and (c) data from the Johnson and Feder (2010). Therefore, it was found that 
samples had different frequencies (X2  =  2706, p < 00001, significant at p < 0.05. Thus 
the 2006 population proportion who participated in Johnson and Feder study (n = 285) 
was not similar to the list of 2006 CT Md/DO of 2006. Therefore, the external validity is 
limited within these populations.  
Comparison of PCP specialty groups between the PCPs in this study and the 285 
PCPs from Johnson and Feder (2010) study is the topic of the first research question (see 
Figure 8). The percentages (or proportions) of PCPs by specialty were compared to the 
percentage of the 5,231 PCPs in the CT DPH (2015) database of active registered 
medical doctors (including PCPs) in Connecticut (see Table 6). The data in Table 6 
establish the true state of representation in this study when comparing the PCP data 
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obtained with the original CT DPH MD/DO of 2015. The CT DPH MD/DO keep 




Figure 8. Primary care physician specialty category frequencies from 2015 survey 
responses versus CT DPH List of Certified MD/Surgeons. The PCPs distribution in this 
study and the CT DPH (MD/DO of PCPs) were not similar. Therefore, the it may limit 
generalizations and the external validity of the data found in this study. The x-axis is the 
PCPs categories of 2015. The y-axis is the percentages of those PCPs categories.  
Results 
This section contains descriptive and inferential findings from the present study 
and opens with a summary of key descriptive statistics. The remaining sections are 
devoted to the statistical analyses and findings to address the study’s questions. The data 


























important to ensure that the 2006 and 2015 samples were equivalent. As presented in 
Figure 9, the two groups of PCPs had similar sampling frames. The z test was not 
significant (z =1.50, p = 0.118). There were no significant differences between the sample 
proportion of 2006 (n = 285 PCPs) and sample proportion of 2015 (n = 145 PCPs; see 
Figure 9).  
 
 
Figure 9. Data of primary care physician proportions from Johnson and Feder (2010). 
The proportions from Johnson and Feder had a population proportion of 285, and this 
study had 145 PCP responses. After adjustment of the data was done with a factor of 
1.97, the frequencies of 2006 PCP were similar to the 2015 PCP obtained in this study. 
Taking the responses more in detail when looking to the category data, the data 
frequencies showed to be similar. (X2   = 2.1871), p-value 0.534502. The result 
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Frecuencies of PCP categories found from the 2006 and 




Prior to hypothesis testing, descriptive statistics were computed for the five 
research questions in this study. Of the 145 PCPs in this study, 79.3 (n = 115) stated they 
knew LD symptoms and felt comfortable diagnosing LD. Almost half (n = 70, 48.3%) of 
the PCPs reported that they do not believe CLD/PTLDS exists. A third (n = 44, 30.3%) 
reported that they believe CLD/PTLDS may exist but are not comfortable diagnosing 
CLD/PTLDS. The smallest group of PCPs (n = 31, 21.4%) reported feeling comfortable 
diagnosing and treating CLD/PTLDS. Due to the substantial differences in responses for 
all three groups, which resulted in high variance and substantial skewness, the 
frequencies and proportions of responses are reported (see Figures10 through 13).  
Results for Physicians who Believe Chronic Lyme Disease Does Not Exist 
Of the 70 PCPs who reported not believing that CLD/PTLDS exists, 69 (98.6%) 
reported the number estimated patients they diagnosed and treated for LD. The mean 
number of patients diagnosed and treated for LD was M = 28.00 (Md = 15.00, SD = 
42.09). Figure 11 presents (as an asymmetrical bar chart that was converted) in a box plot 
of the estimated number of patients (cases) diagnosed with and treated for LD in the past 
3 years greatly differed across the individual PCPs who believed CLD/PTLDS does not 






Figure 10. Boxplot of number of estimated patients (cases) diagnosed with and treated 
for Lyme disease in past 3 years. Based on n = 69 PCPs who stated they did not believe 
CLD/PTLDS exists. Case #5 through Case #78 had between 50 and 100 patients 
diagnosed and treated for LD, while Case #63 had 300 patients diagnosed and treated for 
LD in the past 3 years. Scaling is asymmetric. 
In Johnson and Feder’s (2010) study, results showed that PCPs diagnosed a total 
of 11,970 cases for LD. Sixty-nine (24.2%) PCPs estimated they had diagnosed and 
treated 10 to 20 patients for LD in the past 3 years. Six (8.6%) PCPs estimated having 
diagnosed and treated no patients for LD in the past 3 years. Five (7.1%) PCPs each 
estimated having diagnosed and treated five or 25 patients for LD in the past 3 years. 
There were between one and three PCPs, who estimated the numbers of patients they had 
diagnosed with and treated for LD. Moreover, in the 2006 sample, the two (2) PCPs who 
believed CLD/PTLDS existed, had a mean average of 3.1 patients.   
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Results for Physicians who were Unsure and Uncomfortable Diagnosing Chronic 
Lyme Disease 
All 44 PCPs who felt uncomfortable diagnosing CLD estimated the number of 
patients they treated for LD in the past 3 years. The mean number of patients diagnosed 
and treated for LD for these 44 PCPs was M = 18.86 (Md = 10.00, SD = 23.19). Figure 13 
presents the estimated number of patients diagnosed and treated for LD for these 44 
PCPs. The estimated number of patients (cases) diagnosed with and treated for LD in the 
past 3 years by the 44 PCPs who were unsure that CLD exists and felt uncomfortable 
diagnosing CLD greatly ranged from no patients (cases) to 100 patients (cases). The 
largest groups of PCPs were eight (18.2%) and estimated having diagnosed and treated 
no patients for LD. The next largest groups of PCPs were 5 (11.4%) and estimated having 
diagnosed and treated 5 or 20 patients for LD in the past 3 years. Four (9.1%) PCPS 
estimated having diagnosed and treated 30 patients for LD in the past 3 years. There were 
between 1 and 3 PCPs who estimated the numbers of patients they had diagnosed with 






Figure 11. Boxplot of the number of patients estimated to have been diagnosed with and 
treated for LD in past 3 years. Based on n = 44 PCPs who stated they believe CLD may 
exist but felt uncomfortable diagnosing CLD. Case #38 had 80 patients diagnosed and 
treated for LD while Case # 113 had 100 patients diagnosed and treated for LD in the 
past 3 years.  
Results for Physicians who were Comfortable Diagnosing and Treating Chronic 
Lyme Disease 
Of the 31 PCPs who reported feeling comfortable diagnosing and treating patients 
for CLD, 28 (90.3%) provided the estimated number of patients they diagnosed as having 
LD in the past three years. The mean number of patients diagnosed and treated for LD for 
these 28 PCPs was M = 26.75 (Md = 20.00, SD = 23.47). Figure 14 presents the 
frequencies of the number of patients estimated to have been diagnosed and treated for 
LD, as reported by these 28 PCPs who responded. Responses as to the number of patients 
(cases) estimated to have been diagnosed with and treated for CLD/PTLDS in the past 3 
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years ranged from no patients (cases) to 100 patients (cases). Three (9.7%) of the PCPs 
each estimated having diagnosed and treated 20 or 30 patients for LD in the past 3 years. 
Between 1 and 2 PCPs each respectively estimated having diagnosed and treated between 
0 and 100 patients for LD in the past 3 years.  
 
Figure 12. Boxplot for estimated number of patients (cases) diagnosed with and treated 
for LD in past 3 years. Based on n = 28 PCPs who stated they diagnosed and treated 
patients for LD. Case #138 had 100 patients diagnosed with and treated for LD in past 3 
years.  
The estimated number of patients diagnosed with and treated for CLD in the past 
3 years were also calculated for the group of 31 PCPs who stated they diagnosed and 
treated patients for CLD/PTLDS. All 31 PCPs that provided an answer; the mean number 
of patients diagnosed and treated for CLD/PTLDS in the past three years was M = 5.84 
(Md = 3.00, SD = 10.15). Figure 15 provides the frequencies of patients diagnosed and 
treated for CLD/PTLDS in the past three years.  The range of estimated patients 
diagnosed with and treated for CLD/PTLDS in the past 3 years was from 0 to 51 patients. 
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The largest group was the 7 (22.6%) PCPs who estimated diagnosing 0 or 3 patients for 
CLD/PTLDS in the past three years, respectively. Four (12.9%) PCPs estimated having 
diagnosed and treated patient for CLD/PTLDS within the past three years. Three (9.7%) 
PCPs estimated diagnosing and treating 5 patients for CLD/PTLDS in the past three 
years. Two (6.5%) PCPs estimated diagnosing and treating 2 or 10 patients each for 
CLD/PTLDS in the past three years. One PCP each estimated having diagnosed and 
treated 4, 10, 11, or 51 patients for CLD/PTLDS in the past 3 years. 
 
 
Figure 13. Box plot of estimated number of patients (cases) diagnosed with and treated 
for CLD/PTLDS in past 3 years. Based on n = 31 PCPs who stated they diagnosed and 
treated patients for CLD/PTLDS. Case #129 had 20 patients, Case #122 had 25 patients, 
and Case #137 had 51 patients diagnosed with and treated for CLD/PTLDs in the past 
three years.  
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Dependent Variable Descriptive Statistics  
This study had two dependent variables: the estimated number of patients 
diagnosed and treated for CLD/PTLDS in the past three years and the estimated course of 
antibiotic treatment (in weeks), as reported by the PCPs who felt comfortable diagnosing 
CLD/PTLDS. Table 8 provides the descriptive statistics for the 31 PCPs who reported 
feeling comfortable diagnosing and treating patients for CLD/PTLDS. One (3.2%) PCP 
estimated diagnosing and treating 51 patients for CLD/PTLDS in the past 3 years (i.e., 
the maximum score). Twenty-four of the 31 (77.4%) PCPs who reported feeling 
comfortable diagnosing and treating CLD/PTLDS answered the question about average 
antibiotic treatment (in weeks). The descriptive statistics for the course of antibiotic 
treatment (in weeks) dependent variable were recorded (Table 8). The estimated average 
(mean) course of antibiotic treatment was 12.33 weeks (Md = 8.00, SD = 12.34).  Two 
(6.5%) PCPs reported an antibiotic treatment course of no weeks (i.e., the lowest value), 




Estimated Number of Patients Diagnosed and Treated by Primary Care Physicians who 
Reported Feeling Comfortable Diagnosing and Treating Chronic Lyme Disease 
 n M Md SD Min Max 
Number of patients 
diagnosed and treated 
for CLD 
31 5.84 3.00 10.15 0.00 51.00 
Course of antibiotic 
treatment (in weeks) 




Testing of the Normality Assumption  
An assumption of the independent samples t-test is that the data is normally 
distributed. Normality – must show a normal distribution= around the mean (Kim, 2013). 
Samples, Zskewness values, Kolmogorov-Smirnov (K-S) tests, and boxplots were calculated 
to test the normality assumption for the variables of CLD/PTLDS case numbers and 
course of antibiotic treatment (in weeks).  Zskewness values were computed by dividing the 
variable skewness value by the skewness standard error (see Table 9). The number of 
patients diagnosed and treated for CLD/PTLDS in the past three years had a zskewness value 
of 8.10, indicating a violation of the normality assumption. Thus, the normality 
assumption was not met and for the analysis of this data it was required to conduct a non-
parametric testing. The significant K-S test, shown in Table 9, provided confirmation of 
variable skewness and resultant non-normality for the course of antibiotic treatment (in 
weeks) variables. The assumption of normality was met. The zskewness value for the 
antibiotic treatment course variable was 3.57, also indicative of skewness.  
Table 9 
 
Test Values for Estimated Number of Patients Diagnosed and Treated by Primary Care 
Physicians Comfortable Diagnosing and Treating Chronic Lyme Disease 
 N Zskewness 
 
K-S Value (p) 
Number of patients 
diagnosed and treated for 
CLD 
31 8.10 0.32 (p = .001) 
Course of antibiotic treatment 
(in weeks) 




The SPSS unusual cases function indicated that the number of patients diagnosed 
and treated for CLD/PTLDS variable had three outlier cases with values of 20, 25, and 
51, respectively. Figure 14 presents the boxplot with outliers. Note that the case ID is 
presented in the boxplot not the actual variable score. SPSS output does not give the 
outlier values, but it does provide ID numbers of the cases. Case 15 had a score of 20, 
case 8 had a score of 25, and case 23 had a score of 51. The SPSS unusual cases function 
indicated that the course of antibiotic treatment (in weeks) variable had one outlier case. 
Figure 15 presents the boxplot with outliers. Case 123 had a score of 52 weeks.  
 
 
Figure 14. Course of antibiotic treatment in weeks (n = 24). The horizontal line in the 






Figure 15. Course of antibiotic treatment in weeks (n = 24). The horizontal line in the 
box interior represents the estimated median. Outlier 123 represents the score of 52 
weeks.  
The data collected in this study yielded a non-normal distribution of values for the 
estimated number of course of antibiotic treatment PCPs used with patients with CLD 
from the distribution of PCPs in 2018. Since the estimated samples mean came from a 
small sample size, it was necessary to eliminate outliers to make an estimated sample 
mean closer to the true value. 
The removal of the three outliers for the number of patients diagnosed and treated 
for CLD/PTLDS variable reduced the zskewness value to 2.93, which was lower than the 
critical value of 3.00. The removal of the outliers may result in the loss of data points in 
this study. It will also affect the mean and median values. When one is removing higher 
values, like it is the case here, the mean and the media will decrease, but the mean will 
decrease by more than the media. The K-S test remained significant (K-S (28) = 0.219, p 
=0.001). The removal of the one outlier for the course of antibiotic treatment (in weeks) 
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reduced the zskewness value to 1.87, which was below the zskewness critical value of 3.00. 
Moreover, the K-S test was marginally significant, (K-S (23) = 0.18, p = 0.054). The 
boxplot indicated no outliers for the number of patients diagnosed and treated for 
CLD/PTLDS variable (see Figures 16 & 17).  
Figure 16. Number of patients diagnosed and treated for CLD/PTLDS (n = 28). The 
boxplot indicated no outliers for the course of antibiotic treatment (in weeks) variable, as 




     
Figure 17. Course of antibiotic treatment in weeks (n = 23). The exclusion of outliers 
may cause the loss of data and may limited the finding in this study since the survey 
response was low. Results need to be taking with caution.  
 
Descriptive statistics for the estimated number of patients diagnosed and treated 
for CLD/PTLDS and course of antibiotic treatment (in weeks) variables with outliers 
removed are presented in Table 10. The estimated average (mean) number of patients 
diagnosed and treated for CLD/PTLDS was M = 3.04 (SD = 3.13), which is very similar 
to the median value of Md = 3.00. The estimated number of patients diagnosed and 
treated for CLD/PTLDS ranged from 0 to 11.  The estimated course of antibiotic 
treatment variable mean was M = 10.61 (Md = 8.00, SD = 9.19).  Antibiotic treatment 
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course ranged from 0 to 32 weeks. The non-skewed dependable variables with mean 




Descriptive Statistics for Estimated Number of Patients Diagnosed and Treated with 
Outliers Removed 
 n M Md SD Min Max 
Number of patients 
diagnosed and treated 
for CLD 
28 3.04 3.00 3.13 0.00 11.00 
Course of antibiotic 
treatment (in weeks) 
23 10.61 8.00 9.19 0.00 32.00 
 
Answers to the Research Questions 
Research Question 1 
The first research question posed in this study was as follows: “Are the frequency 
distributions of the 2015 sample of Connecticut PCPs across the four primary practice 
specialty areas (i.e., family medicine, internal medicine, pediatrics, other) significantly 
different from the distributions of the 2006 sample of Connecticut PCPs?” 
In this study, the sample was comprised of 28 (19.3%) family physicians, 63 
(43.4%) internists, 48 (33.1%) pediatricians, and 6 (4.1%) other PCPs (i.e., emergency 
medicine). As this study treated Johnson and Feder’s (2010) 2006 physician data as 
population data, a Chi-Square (χ²) goodness-of-fit test was conducted to address the first 
research question. A Chi-square (χ²) goodness-of-fit test computes the expected sample 
frequencies (numbers) per variable categories based on population category proportions 
and compares these computed frequencies to the actual observed sample group 
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frequencies (Sharpe, 2015). The expected frequencies (ns) denoted in the following chi-
square table represent the expected number of participants per category based on the 
2006 and 2015 survey proportions. A non-significant chi-square value (p > 0.05) 
indicates that the sample frequency distributions are similar between the 2006 sample 
(done in 2008) and the 2015 sample (done in 2018).  
The chi-square (χ²) test conducted for Research Question 1 was not significant (χ² 
(3, n = 145) = 1.41, p = .703) Therefore, the null hypothesis was accepted since there 
were no significant differences and the alternative hypothesis was rejected. The actual 
observed PCP group specialty proportions were similar for the 2006 and 2015 samples 
(see Table 11). This research question was unique, as it was the only one in the study in 
which the null hypothesis failed to be rejected. The non-significant findings indicate that 
the 2015 PCP specialty proportional distribution in this study was similar to the historical 




Chi-Square Test for Primary Care Physician Frequencies in 2006 Versus 2015 
 




Family Physician  28 29 
Internist  63 59 
      Pediatrician  48 52 
Other PCP  6 5 
    
Chi-Square (χ²) 1.410   
Df 3   
Significance (p) .703   




Research Question 2 
The second research question pertained specifically to LD: “Are the frequency 
distributions of the 2015 sample of Connecticut PCPs among the two knowledge of LD 
categories (i.e., know symptoms of LD and feel comfortable diagnosing and treating LD 
vs. know LD but do not feel comfortable diagnosing and treating LD) significantly 
different from the distributions of the 2006 sample of Connecticut PCPs?”  In the 2006 
study, 282 (98.9%) of PCPs reported knowing symptoms of LD and feeling comfortable 
diagnosing and treating LD while 3 (1.1%) PCPs reported knowing LD symptoms but not 
feeling comfortable diagnosing LD. The frequencies of PCPs per knowledge of LD 




























Figure 18. Frequencies of primary care physicians per knowledge of Lyme disease 
categories in this and the 2006 study. Chi-square (χ²) results were significant (χ² (df1, n = 
145) = 536.83, p < 0.001). 
The observed frequency of 30 PCPs in this study who reported knowing the 
symptoms of LD but not feeling comfortable diagnosing LD was significantly higher than 
the expected frequency of 2 PCPs who reported knowing LD but not feeling comfortable 
diagnosing LD. Moreover, the observed frequency of 115 PCPs in this study who 
reported knowing the symptoms of LD and feeling comfortable diagnosing LD was 
significantly lower than the expected frequency of 144 PCPs who reported feeling 
comfortable diagnosing LD. Results of the Chi-square(χ²) test were significant (χ² (1, n = 
145) = 536.83, p <.001). Due to the significant findings, the null hypothesis was rejected 
(failed to be retained) and the alternative hypothesis was retained for the second research 
question, denoting significant differences in the frequencies of PCPs who felt 




Chi-square (χ²) Goodness-of-fit Test: Observed and Expected Comfort in Diagnosing LD 
Categories (n = 145) 
 




Not comfortable diagnosing LD  30a 2a 
Comfortable diagnosing LD  115b 144b 
    
    
Chi-square (χ²) 536.83   
df 1   
144 
 
Significance (p) <0.001   
Note. *The expected frequencies are derived from the category percentages (or 
proportions) reported by Johnson and Feder (2010). They are not the actual frequencies.  
a The observed frequency of 30 is significantly higher than the expected frequency of 2.  
b The observed frequency of 115 is significantly lower than the expected frequency of 
144. 
 
Cohen’s w (Cohen, 1988; Cunningham & McCrum-Gardner, 2007; NCSS, n.d.) 
was calculated. The mathematical formula for Cohen’s w is ²̸ (Cohen, 1988; NCSS, 
n.d.). Cohen’s w was 1.9, a very large effect size (Cohen, 1988; NCSS, n.d.). Like 
Cohen’s d, Cohen’s w can be greater than 1.00, and it indicates a large magnitude in the 
frequency or proportion differences between the sample and population (Becker, 2000; 
Cohen, 1988). A post hoc power analysis using G*Power was conducted on the total 
sample of 145, with an effect size of 1.9, α err prob of .05, and df of 1. The output 
provided a noncentrality parameter λ of 523.45, critical χ² of 3.84, and the power was 
very high, 1- β= 1.00. 
 
Research Question 3 
The third research question was as follows: “Are the frequency distributions of 
the 2018 sample of Connecticut PCPs across the 3 knowledge of CLD/PTLDS categories 
(i.e., do not believe CLD exists, do not feel comfortable diagnosing and treating 
CLD/PTLDS, and feel comfortable diagnosing and treating CLD/PTLDS) significantly 
different from the distributions of the 2010 sample of Connecticut PCPs?”  Of the 145 
PCPs in this study, 70 (48.3%) PCPs reported that they do not believe CLD/PTLDS 
exists, 44 (30.3%) reported that they believe CLD/PTLDS may exist but are not 
comfortable diagnosing CLD/PTLDS, and 31 (21.4%) reported feeling comfortable 
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diagnosing CLD/PTLDS. Johnson and Feder (2010) reported that, of the 285 participants 
in their study, 142 (49.8%) PCPs reported that they felt CLD/PTLDS did not exist, 137 
(48.1%) stated that they believed CLD/PTLDS might exist but did not feel comfortable 
diagnosing CLD/PTLDS, and 6 (2.1%) PCPs reported that they felt comfortable 
diagnosing CLD/PTLDS. The frequencies of PCPs per knowledge of CLD categories are 
presented in Figure 19. 
 
Figure 19. Frequencies of primary care physicians per knowledge of chronic Lyme 
disease categories. Results from the Chi-square (χ²) goodness-of-fit test, were significant 
(χ² (2, N = 145) = 265.41, p < 0.001). 
A Chi-square (χ²) goodness-of-fit test was conducted to address the third research 
question. Results from the Chi-square (χ²) goodness-of-fit test were significant (χ² (2, n = 
145) = 265.41, p <.001) (see Table 14). The observed frequency of 44 PCPs in this study 





























diagnosing CLD/PTLDS was significantly lower than the expected frequency of 70 PCPs 
who reported that they believe that CLD/PTLDS may exist but do not feel comfortable 
diagnosing CLD/PTLDS, which was based on the population percentages (or 
proportions) derived from Johnson and Feder’s (2010) of the historical data. Moreover, 
the observed frequency of 31 PCPs in this study who reported feeling comfortable 
diagnosing CLD/PTLDS was significantly higher than the expected frequency of 3 PCPs 
who reported feeling comfortable diagnosing CLD/PTLDS, which was based on the 
population percentages (or proportions) derived from Johnson and Feder’s (2010) from 
the historical data. The observed frequency of 70 PCPs who believed that CLD/PTLDS 
does not exist was similar to the expected frequency of 72, which was also based on 
Johnson and Feder’s (2010) databased on the historical data. Due to the significant 
findings, the null hypothesis was rejected (failed to be retained), and the alternative 
hypothesis was retained for the third research question, indicating significant differences 





Chi-square (χ²) Goodness-of-fit Test: Observed and Expected Comfort in Diagnosing 
CLD/PTLDS Categories (n = 145) 
  Observed (n) Expected (n*) 
Do not believe CLD exists  70 72 
Not comfortable diagnosing CLD  44a 70a 
Comfortable diagnosing CLD  31b 3b 
Chi-square (χ²) goodness-of-fit test 265.41   
df 2   
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Significance (p) <0.001   
Note. *The expected frequencies are derived from the category percentages (or 
proportions) reported by Johnson and Feder. They are not the actual frequencies.  
a The observed frequency of 44 is significantly lower than the expected frequency of 70.  
bThere observed frequency of 31 is significantly higher than the expected frequency of 3. 
 
The Cohen’s was 1.35, a very large effect size (Cohen, 1988; NCSS, n.d.). Like 
Cohen’s d, Cohen’s w can be greater than 1.00, and it indicates a large magnitude in the 
frequency or proportion differences between the sample and population (Becker, 2000; 
Cohen, 1988). A post hoc power analysis using G*Power was conducted on the total 
sample of 145, with an effect size of 1.35, α err prob of .05, and df of 1. The output 
provided a noncentrality parameter λ of 264.26, critical χ² of 3.84, and the power was 
very high (1- β=1.00).  
 
Research Question 4 
The fourth research question was as follows: “Is the average number of patients 
diagnosed as having CLD/PTLDS within a 3-year period by the 2018 sample of 
Connecticut PCPs significantly different from the average number of patients diagnosed 
as having CLD/PTLDS within a 3-year period by the 2010 sample of Connecticut 
PCPs?” This research question required comparisons of data from the PCPs who reported 
feeling comfortable diagnosing CLD/PTLDS to data from the population of PCPs who 
reported feeling comfortable diagnosing CLD/PTLDS in Johnson and Feder’s (2010) 
study.  
A one-sample t-test, using data from the adjusted diagnosed or treated for 
CLD/PTLDS PCPC group mean (outliers removed) was conducted to address the fourth 
research question. In Johnson and Feder’s (2010) study, the average number of patients 
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diagnosed and treated for CLD/PTLDS in past years by these 6 PCPs was M = 3.10. 
Consequently, the test value mean was 3.10. Results from the first one-sample t-test were 
not significant (t (27) = -0.11, p = 0.914). The estimated mean number of patients 
diagnosed and treated for CLD/PTLDS in the past three years as reported by the 28 PCPs 
(M = 3.04) was not significantly different than the mean of 3.10, as reported in Johnson 
and Feder’s (2010) study.  
Research Question 5 
The fifth research question was as follows: “Is the average course of antibiotic 
treatment (in weeks) for patients diagnosed as having CLD/PTLDS by the 2018 sample 
of Connecticut PCPs significantly different from the average course of antibiotic 
treatment (in weeks) for patients diagnosed as having CLD/PTLDS by the 2010 sample 
of Connecticut PCPs?”  The fifth research question required comparing data from the 23 
PCPs (one outlier removed) that provided an answer to the antibiotic treatment course 
variable.  The population was the 6 PCPs who reported feeling comfortable diagnosing 
CLD/PTLDS in Johnson and Feder’s (2010) study.  
To address the fifth research question, a one-sample t-test, using the antibiotic 
course of treatment (in weeks) variable estimated mean of 9.74, was conducted. In 
Johnson and Feder’s (2010) study, the estimated average course of antibiotic treatment 
(in weeks) for the 6 PCPs who felt comfortable diagnosing and treating patients for 
CLD/PTLDS M = 20.00. Consequently, the test value mean was 20.00. Results from the 
second one-sample t test were significant (t (22) = -4.90, p < 0.001). The estimated 
average course of antibiotic treatment (in weeks) as reported by the 23 PCPs in this study 
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(M = 10.61) was significantly lower than the mean of 20.00 weeks, as reported in 
Johnson and Feder’s (2010) study.  Consequently, the null hypothesis was retained, and 
the alternative hypothesis was rejected. 
Summary 
The purpose of this nonexperimental cross-sectional comparative research study 
was to determine if two groups of PCPs working in Connecticut – the 285 PCPs in 
Johnson and Feder’s (2010) study and the 145 PCPs in this study – reported significant 
differences in their KAP in the diagnosis, treatment, and management of LD (LD) and 
CLD/PTLDS.  Data collection occurred in the summer of 2018, utilizing a USPS-mailed 
survey process.  Of the 1,726 survey packets mailed to the PCPs, 219 (12.7%) were 
returned due to an incorrect address. 1,507 (87.4%) PCPs received the study packet via 
USPS mail. The number of survey packets returned to the researcher was 179, resulting 
in an initial 11.7% response rate. The removal of 34 surveys from the data set for various 
reasons (e.g., the PCP not providing informed consent, PCP was retired) yielded a final 
sample of 145 and a final response rate of 11.9%.  
Due to the inability to obtain Johnson and Feder’s raw data, the comparison data 
were drawn from the information presented in Johnson and Feder’s (2010) their 
published study. The data from their study were treated as population data, and these data 
from the 285 PCPs were compared to the data from the sample of 145 PCPs in this study.  
The five research questions were answered using population-based statistical analyses, 
namely Chi-square (χ²) goodness-of-fit tests and one- sample t-tests. These inferential 
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analyses coupled with descriptive statistical analyses yielded pertinent information on 
key LD and CLD/PTLDS diagnosis and treatment factors.  
The first research question inquired as to whether the PCP specialty area 
frequency distributions (i.e., family medicine, internal medicine, pediatrics, other) of the 
145 PCPs in this study were significantly different from the PCP specialty area frequency 
distributions of the 285 PCPs in Johnson and Feder’s (2010) study. Results from a (χ²) 
goodness-of-fit test were not significant. This research question was unique, because it 
was the only one in the study in which the null hypothesis failed to be rejected. The 
nonsignificant findings indicated that the PCP specialty frequency distributions of family 
physicians, internists, pediatricians, and other PCPs (i.e., emergency medicine) in this 
study were similar to the PCP specialty frequency distributions in Johnson and Feder’s 
(2010) study.  
The second research question examined if the knowledge of LD category 
frequency distributions in this study significantly differed from the LD knowledge 
category frequency distributions in Johnson and Feder’s (2010) study. Results from the 
Chi-square (χ²) goodness-of-fit test, which was conducted to address the second research 
question, were significant. There was a significantly lower frequency of PCPs (n = 115, 
79.3%) in this study who reported that they knew LD symptoms and felt comfortable 
diagnosing LD than the frequency of PCPs (n = 282, 98.9%) who reported that they knew 
LD symptoms and felt comfortable diagnosing LD in Johnson and Feder’s study. Due to 
the significant findings, the null hypothesis was rejected (failed to be retained) for the 
second research question.  
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The third research question examined if the frequency distributions across the 3 
knowledge of CLD/PTLDS categories in this study were significantly different from the 
CLD knowledge category frequency distributions in Johnson and Feder’s study.  Results 
from the Chi-square (χ²) goodness-of-fit test conducted to address the third research 
question were significant.  There was a significantly higher frequency of PCPs (n = 31, 
21.4%) in this study who reported feeling comfortable diagnosing CLD/PTLDS as 
compared to the frequency of (2.1%) PCPs who reported feeling comfortable diagnosing 
CLD/PTLDS in Johnson and Feder’s (2010) study. There was a significantly lower 
frequency of PCPs (n = 44, 30.3%) in this study who believed CLD/PTLDS might exist 
but did not feel comfortable diagnosing CLD/PTLDS as compared to the frequency of 
137 (48.1%) PCPs in Johnson and Feder’s study who stated that they believed 
CLD/PTLDS might exist but did not feel comfortable diagnosing CLD/PTLDS. It should 
be noted, however, that the frequency distributions of PCPs who reported that they did 
not believe CLD/PTLDS exists were similar for both studies: 70 (48.3%) PCPs in this 
study and 142 (49.8%) PCPs in Johnson and Feder’s study reported that CLD/PTLDS did 
not exist. Due to the significant findings, the null hypothesis was rejected (failed to be 
retained) for the third research question.  
The fourth research question inquired as to whether the average number of 
patients diagnosed as having CLD/PTLDS within a 3-year period as reported by the PCPs 
in this study significantly differed from the average number of patients diagnosed as 
having CLD/PTLDS within a 3-year period as reported by those in the previous study.  
This research question required statistical comparisons of data from the 31 PCPs who 
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reported feeling comfortable diagnosing CLD/PTLDS to data from the population of 6 
PCPs who reported feeling comfortable diagnosing CLD/PTLDS in Johnson and Feder’s 
study. Statistical testing for skewness (i.e., computation of zskewness values and K-S test) 
revealed that the number of patients diagnosed and treated for CLD/PTLDS among these 
31 PCPs was considerably skewed. The removal of 3 outliers reduced the degree of 
skewness. While the zskewness value was acceptable, the K-S test remained significant. 
Results from the one-sample t-test conducted with 28 PCPs (outliers removed) were not 
significant. The 28 PCPs reported an average of 3.04 patients whom they had diagnosed 
as having CLD/PTLDS within the past 3 years, which was remarkably similar to the 
mean of 3.10 patients diagnosed with CLD/PTLDS in the previous study.  The null 
hypothesis for the fourth research question was retained (failed to be rejected).  
The fifth and final research question for this study assessed if the median course 
of antibiotic treatment (in weeks) range of response for patients diagnosed as having 
CLD/PTLDS significantly differed between 23 PCPs in this study and the PCPs in 
Johnson and Feder’s study. Statistical testing for skewness (i.e., computation of zskewness 
values and K-S tests) revealed that the course of antibiotic treatment (in weeks) variable 
was skewed. However, after the removal of one outlier, the zskewness value was acceptable, 
and the K-S tests was no longer significant. A one-sample t-test conducted for the fifth 
research question was significant. The approximately 10 week course of antibiotic 
treatment reported by PCPs in this study was significantly lower than the 20-week course. 
Is this consistent with your previous description of the answer to RQ5 reported by the 
PCPs in Johnson and Feder’s (2010) study. Due to significant findings, the null 
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hypothesis for the fifth research question was rejected (failed to be retained). The 
following chapter ends the dissertation study. It provides discussions in relation to the 
guiding theories of this and previous research studies as well as the study’s le limitations 
and recommendations for application or practice and future research.   
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
Due to the absence of a case definition, known biological agent, and lack of 
reliable laboratory testing, CLD/PTLDS remains a controversial diagnosis (Johnson & 
Feder, 2010; Lantos, 2015a; Maloney, 2016, Stricker & Fesler, 2018). The controversy 
and lack of clarity surrounding CLD/PTLDS have impeded understanding of health care 
providers’ diagnosis, treatment, and management of patients (Lantos, 2015a; Maloney, 
2016). Further research is necessary to understand and improve the health practices and 
methods for PCPs when addressing a diagnosis of CLD/PTLDS (Johnson & Feder, 2010; 
Lantos, et al., 2010; Lantos, 2015a; Stricker & Johnson, 2008).  
The purpose of this nonexperimental, cross-sectional, comparative study was to 
compare CLD/PTLDS knowledge, attitudes, and treatment/practice differences on the 
how frequently they diagnosed and treated (antibiotics used) patients for LD and 
CLD/PTLDS in the last 3 years. This study was a replication of Johnson and Feder’s 
(2010) seminal study, with the same sampling and methodological practices and survey 
instrument. The sampling frames for the two studies was the CT DPH database of 
MD/DOs, with Johnson and Feder (2010) using 2006 data and this study using 2015 data. 
As Johnson and Feder’s whole dataset could not be obtained, comparisons were made 
between the data in this study and the available data reported in their study, with their 
sample treated as the population. Additional data used to complement those in Johnson 




The initial data analyses was focused on assessing whether the survey 
dissemination and aspects of the two samples were similar. The response rate of 11.7% 
was significantly lower than the response rate of 39.1% reported by Johnson and Feder 
(2010). The survey dissemination factors were largely similar. Moreover, it was found 
that the two Connecticut PCPs were similar with regard to PCP specialty.  
This study had five research questions. Results for the first question were not 
significant, indicating that both studies had similar numbers of PCPs across specialty 
areas (i.e., family medicine, internal medicine, pediatricians, and other). The similarities 
between the two study samples allowed for an increased accuracy in statistical 
comparisons and enhanced the internal validity of the study. Results for the second and 
third research questions showed a smaller percentage of PCPs reported feeling 
comfortable diagnosing LD compared to the percentage of the 2006 sample of PCPs. In 
contrast, there was a much larger percentage of PCPs who reported feeling comfortable 
diagnosing CLD in this study compared to the percentage of the 2006 sample of PCPs. 
This finding shows the need for social change in the ways PCPs may be dealing with 
such patients versus the PCPs who do not believe in the diagnosis for CLD/PTLDS.   
The fourth research question required the use of a one-sample t test, using the 
adjusted sample mean value of 3.04. The population sample mean was 3.10 patients. The 
t test was not significant, indicating that the number of patients diagnosed and treated for 
CLD/PTLDS did not significantly differ across the two groups of PCPs. The fifth 
research question also involved a one-sample t test to determine if the adjusted mean of 
10.61 weeks found in this study was significantly different from the mean of 20 weeks 
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reported by Johnson and Feder. Results from the t test indicated that PCPs in this study 
reported a significantly lower course of antibiotic treatment (in weeks) compared to the 
2006 sample of PCPs. 
This chapter provides a comprehensive overview of the study findings. The 
chapter opens with an interpretation of findings section, which includes a review and 
discussion of findings concerning prior literature, especially Johnson and Feder’s (2010) 
study, and the guiding theories of the study. The chapter continues with a Study 
Limitations section, where recommendations for future health care practices and 
suggestions for future empirical study are denoted. The topics under discussion in the 
penultimate section of the chapter, Implications, pertain to the study’s potential for 
positive social change. Recommendations and a Conclusion section end the chapter. 
Interpretation of Findings 
The intent of this study was to validate Johnson and Feder’s (2010) seminal study 
to examine the differences between two groups of Connecticut PCPs regarding their 
diagnosis, treatment, and management of LD and CLD/PTLDS (health professionals tend 
to prefer to use PTLDS instead of CLD, and PTLDS is a term accepted by the CDC). This 
study emphasized the potential differences in the responses provided by the PCPs 
regarding their knowledge and attitudes about LD and CLD/PTLDS when Johnson and 
Feder conducted their study using PCPs distributions in 2006 and PCP distributions in 
2015 (the data in this study). In alignment with Johnson and Feder, I focused on PCPs 
who work in the state of Connecticut, as this type of physician is most likely to engage 
with patients who demonstrate symptoms of LD and CLD/PTLDS (Ali et al., 2014; 
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Johnson et al., 2014). The emphasis on differences required a guiding theory that 
suggests why a medical idea or concept is adopted by the medical community. The 
diffusion of innovations theory provided the lens to examine potential differences 
between the two groups of PCPs in this study, which aligned with the KAP approach of 
this study. In the following sections of the chapter, I present and discuss the findings in 
relation to prior research, especially Johnson and Feder’s study and the diffusion of 
innovation theory. 
This study was a replication of Johnson and Feder’s (2010) study conducted with 
285 PCPs working in the state of Connecticut. The first research question acted as a 
validity check to determine if the PCP specialty area frequency distributions were similar 
in this study and Johnson and Feder’s study. The lack of significant findings indicated 
that both studies had similar numbers of PCPs across specialty areas (i.e., family 
medicine, internal medicine, pediatricians, and other). The similarities between the two 
study samples allowed for an increased accuracy in statistical comparisons and enhanced 
the internal validity of the study. 
The second and third research questions helped examine whether there were 
significant differences in the frequency distributions of PCPs who felt comfortable 
diagnosing LD or CLD in this study as compared to Johnson and Feder’s (2010) study. In 
this study, a smaller percentage of PCPs reported feeling comfortable diagnosing LD 
(79.3%) compared to the percentage of PCPs who reported feeling comfortable 
diagnosing LD (98.9%) in Johnson and Feder’s study and the percentage (99%) in a 
previous study by Ferrouillet et al. (2015). In contrast, there was a much larger 
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percentage of PCPs who reported feeling comfortable diagnosing CLD (12.6%) in this 
study compared to the percentage of PCPs who reported that feeling comfortable 
diagnosing CLD (2.1%) in Johnson and Feder’s study. The significant findings for the 
second and third research question suggest that PCPs in Connecticut may feel 
increasingly comfortable diagnosing and treating CLD. However, there are still many 
gaps in implementing a common case definition for CLD using evidence-based research, 
something that is limited at this time.  
The diffusion of innovation theory provided the framework to understand these 
findings. In this study, the innovative health care practice was the diagnosis and treatment 
of CLD/PTLDS. The diffusion process pertained to changes in PCP knowledge, attitudes, 
and practices regarding CLD/PTLDS over a 10-year period (i.e., between 2008 and 
2018). Study findings support diffusion of innovation’s theoretical intent regarding the 
diagnosis and treatment of CLD/PTLDS. The six (2.1%) PCPs in Johnson and Feder’s 
(2010) study can be considered innovators, rare physicians who felt that CLD/PTLDS 
was a meaningful, real, and diagnosable disorder. The increase from 2.1% to 21.4% of 
PCPs who felt comfortable diagnosing CLD in the past 10 years suggests that 
CLD/PTLDS diagnosis and treatment has gone from the innovation stage to the early 
adoption stage.  
The diffusion of innovation theory also has implications for the findings regarding 
the average course of antibiotic treatment. The average course of treatment reported by 
the 17 PCPs who felt comfortable diagnosing and treating CLD in this study was 
significantly lower than the course of treatment reported by the six PCPs in Johnson and 
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Feder’s (2010) study. However, when considering this finding within the context of 
diffusion of innovation, it could be that the change from the innovation to adoption stage 
of CLD diagnosis and treatment has resulted in an improved treatment procedure. That is, 
being wary of the problems associated with antibiotic treatment (e.g., over-prescribing. 
Increasing resistance, side effects), the PCPs in this study may have learned that a shorter 
effective antibiotic treatment course was as effective as a longer one.  
The diffusion of innovation theory has less clear implications for the findings 
regarding the number of patients diagnosed and treated for CLD/PTLDS in the past 3 
years. The mean of 3.10 patients reported by Johnson and Feder (2010) and used in 
analyses is an adjusted value. Johnson and Feder removed one outlier to obtain this value. 
The number of patients diagnosed as having CLD/PTLDS was twice as high in this study 
as compared to Johnson and Feder’s study when the two outliers were retained in the data 
set (i.e., 6 to 3). In contrast, the adjusted mean value of 3.04 patients—obtained by 
removing two outliers—was similar to the 3.10 patients reported by the six PCPs in 
Johnson and Feder’s study. However, the course of antibiotic treatment (in weeks) was 
significantly lower in this study compared to Johnson and Feder’s study. These differing 
findings suggest that, despite an increase in the number of PCPs who report feeling 
comfortable diagnosing and treating CLD in the past 10 years, PCPs are hesitant to 
diagnose and treat their patients for CLD and are cautious about prescribing a long course 
of antibiotic treatment for CLD. Although the acceptance of CLD diagnosis and 
treatment has gone from the innovation to the adoption stage, the actual diagnosis and 
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treatment of CLD remains in the innovation stage. There were limitations in this study 
that likely influenced the findings in this study, which are discussed in the next section.  
Limitations of the Study 
This study had some limitations. One weakness was the small response rate of 
11.9 %, especially when comparing it to the response rate of 33.9% reported by Johnson 
and Feder (2010). Although 179 surveys were returned by the PCPs, 34 surveys had to be 
discarded for a variety of reasons, most notably that the physician who completed the 
survey was not a PCP or that the physician was a PCP but no longer practiced or did not 
provide informed consent. When comparing both distributions with and without the 34 
omitted surveys untabulated in this study, the loss of data did not seem to affect the 
frequency distributions of the PCP specialty areas, as they were similar across this study 
and Johnson and Feder’s study. Related problems were the small sample size of 31 PCPs 
who reported feeling comfortable diagnosing and treating CLD/PTLDS. In addition, there 
were missing data or outliers in the responses related to the number of patients diagnosed 
and treated for CLD/PTLDS in the past 3 years and the average course of antibiotic 
treatment for them. Therefore, the results from the one-sample t test regarding the 
number of patients diagnosed and treated for CLD/PTLDS should be interpreted with 
caution. 
Other limitations concerned the PCPs’ survey answers and the survey itself. 
Despite being asked to provide a numerical value when answering the questions 
regarding the number of patients diagnosed and treated for LD or CLD/PTLDS, a small 
number of PCPs provided answers such as “many, many” or “a few.” These responses 
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made it difficult to interpret the exact number of diagnosed and treated patients. 
Moreover, when answering the question regarding the average course of antibiotic 
treatment for patients with CLD/PTLDS, some PCPs provided answers in months or days 
instead of weeks, and a small number of PCPS provided a range of values (i.e., 3 to 6 
months). These types of responses resulted in having to estimate values. Additionally, 
there was limitation with the survey because of a small inconsistency in the language 
used with the term CLD, which should have been consistently stated as CLD/PTLDS. 
Nonetheless, the questions used in the survey were the same Questions 1-9 used by the 
previous researchers, so it should not affect much the construct validity of the study.  
Another limitation of this study concerned methodological biases that may have 
influenced study findings. The percentage (or proportion) of PCPs who were comfortable 
diagnosing CLD/PTLDS (21.4%) in this study was significantly higher than the 2.1% of 
the PCPs reported in Johnson and Feder’s (2010) study. The participation bias may play a 
role in this finding. PCPs who believe that CLD/PTLDS exists may have been more 
likely to participate in this study, so the 21.4% value may not reflect the actual population 
percentage (or proportion), which is an issue when considering the low response rate. 
Alternatively, the 21.4% value may be a result of the social desirability bias. That is, 
some PCPs may not have reported their actual belief—that CLD/PTLDS exists—as this 
belief contradicts the current mainstream medical opinion.  
Another potential concern in this study was recall bias. PCPs were asked to recall 
the number of patients they diagnosed and treated for LD and CLD/PTLDS in the past 
three years. A 3-year span is quite long, especially considering the number of patients 
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that PCPs see daily. As such, the PCPs may have under- or over-reported the number of 
patients they diagnosed as having LD or CLD/PTLDS.   
Another limitation of the study pertained to the study recruitment period as it 
relates to the mailing of the survey packets. Recruitment and the mailing of survey 
packets occurred during summer. The summer is a difficult season to recruit study 
participants, especially physicians, as professionals often take extended time off for 
vacations and traveling (Johnston et al., 2010). Physician recruitment seems to improve 
during the spring and winters (Johnston et al., 2010; PRA, n.d). Moreover, the survey 
packets were mailed on Mondays or Saturdays, with physicians receiving the packets 
early or late in the workweek. Study survey completion rates contribute to be higher on 
Tuesdays or Wednesdays (Bowling, 2014; PRA, n.d.). These two-timing factors may 
have contributed to the poor return rate response. It is possible that an electronic survey 
would be better, as other researchers have suggested that they are faster and cheaper to 
reach to PCPs through their medical societies or in conferences that they will be attending 
(Dobrow et al., 2008). However, due to the increase of cyberattacks, PCPs may be 
reluctant to take part in electronic surveys because they care about keeping their patient 
records safe. For example, out of 10 medical doctors, eight had experienced a cyberattack 
in practice (American Medical Association, 2017).  
Lastly, the study database used in this study have limited information about the 
participants in this study. This kind of database only keeps the license number, first 
name, last name, address (most of the time is work), city, state, zip code, issue date, 
expiration date, degree type, and specialty. This type of MD/DO database does not have 
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information about gender, age, or race, meaning certain data descriptive data from the 
participants to describe the populations under the study were unavailable. Thus, it was 
challenging to provide evidence that the samples of the two surveys (2006 vs. 2015) were 
comparable, and it is not possible to make inferences about the gender, age, and race 
presented in this study from the PCPs who responded to the surveys.  
Recommendations 
There is a 10-year gap between this and Johnson and Feder’s (2010) seminal 
study. There remains a relative absence of contemporary studies—quantitative or 
qualitative—on physicians’ knowledge, attitudes, and treatment of CLD/PTLDS. 
Moreover, both this and Johnson and Feder’s study were conducted with Connecticut 
PCPs, with contact information gathered from the CT DPH MD/DO databases for 2006 
and 2015. Thus, the findings can only be generalized to the PCPs who responded and 
whose contact information is listed in the CT DPH MD/DO databases. These two factors 
emphasize the need to conduct more epidemiological/public health empirical work to 
refine knowledge and understanding of the CLD/PTLDS diagnosis rates among PCPs and 
physicians in general.  
As findings in this study can only be generalized to PCPs in Connecticut, a need 
exists for replication studies that extend beyond the Connecticut PCP population to 
include state and preferably national samples of PCPs. There is a need for cross-state 
studies on whether KAP differences regarding PTLDS/CLD occur across PCPs practicing 
in different geographical regions, states, or even countries. Studies that compare 
PTLDS/CLD KAPs among PCPs who practice in states with low versus high rates of 
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PTLDS/CLD would be especially beneficial. Other types of needed studies are (a) causal 
comparative studies that examine PTLDS/CLD KAP differences between PCPs that 
differ with regard to demographics (gender, age), education, and training experience; (b) 
correlational studies that examine if significant relationships exist between PCPs’ 
attitudes toward PTLDS/CLD diagnosis, primary symptomatology, and perceived 
severity/health impact and the number of patients diagnosed with and treated for 
PTLDS/CLD; and (c) longitudinal studies that follow one set of physicians/PCPs over 
time and measure changes in PTLDS/CLD (and LD) diagnostic and treatment practices. 
Qualitative empirical work, such as phenomenological studies that capture PCPs’ 
experiences diagnosing and treating PTLDS/CLD and case studies on PTLDS/CLD 
diagnostic and treatment modalities, would complement the quantitative research on the 
study topic.   
As this was a validation study of Johnson and Feder’s (2010) work, it utilized 
these authors’ survey. There exists a need for validation studies that assess the 
psychometric quality of Johnson and Feder’s (2010) study. Do to the controversy 
surrounding the term CLD and the lack of a case definition for this disease (Borcher et 
al., 2015), it would be interesting to see if differences emerge if different groups of PCPs 
answer questionnaires that have the same questions but use the terms CLD, PTLDS, or 
PTLDS/CLD. There is also a need to develop and psychometrically test more 
comprehensive questionnaires that inquire not only about PCPs’ demographics (e.g., age, 
gender) and education and training, but also delve into PCPs knowledge about 
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PTLDS/CLD, its diagnostic criteria, and recommended treatment protocols, as well their 
actual treatment protocols for their own patients diagnosed with PTLDS/CLD.  
Specific aspects of this study and study findings provide a guide for future 
studies. Findings in this study indicated that a lower percentage (or proportions) of PCPs 
reported feeling comfortable diagnosing LD as compared to the PCPs in Johnson and 
Feder’s (2010) study. This finding is intriguing and suggests that studies examining 
changes in LD diagnostic rates among PCPs and physicians would be beneficial. The 
estimated course of antibiotic treatment (in weeks) for patients with CLD/PTLDS was 
similar in this and Johnson and Feder’s (2010) study.  It is unknown whether the course 
of treatment reported by the PCPs in this and Johnson and Feder’s (2010) study is typical 
among Connecticut PCPs and PCPs in general. Additional work is needed to obtain a 
better understanding of PCPs’ reported average course of antibiotic treatment for 
CLD/PTLDS as well as the type and dosage of antibiotic prescribed for CLD/PTLDS, as 
this type of information is currently unknown. Finally, CLD/PTLDS antibiotic treatment 
efficacy studies are warranted, especially experimental studies that examine the effects of 
different antibiotic types, dosages, and course lengths on CLD/PTLDS symptomatology. 
However, it would unethical to conduct clinical trials when there is not a known 
etiological agent to understand its susceptibility to antibiotics. Conducting epidemiology 
research would be an appropriate starting point.  
The uncertainty regarding the cause, origin, and specific diagnostic criteria of 
CLD/PTLDS is concern among physicians (Greenberg, 2017; Halperin, 2015). Olson, 
Graber, and Singh (2018) stated the difficulty that medical doctors may have when 
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coming across “undesirable diagnostic events (UdesF)” due in significant part to the lack 
of standardization making impossible to have health professionals to make an accurate 
and timely diagnosis. The majority of the PCPs in Connecticut, as well as the CDC, and 
the National Institute of Allergy and Infectious Diseases may want to adopt a 
reconciliation position that will eventually help CLD/PTLDS patients indirectly since 
they may feel the same way as Olson et al. (2018). One way to adopt a reconciliation 
position is by utilizing a new practice diagnosis as PTLDS.  
By adopting a new practice diagnosis as PTLDS, the CDC, the National Institute 
of Allergy and Infectious Diseases, and the PCPs in Connecticut can do and document 
PTLDS diagnosis. At the same time, it will be a good thing for the patients because they 
can get most of their medical bills accepted by their health insurance, which is not a 
perfect solution to alleviate the tensions between PCPs and presumed CLD/PTLDS 
patients. However, it is a position in the middle that may unite PCPs from that belongs to 
the Infectious Diseases Society of America and ILADS.  
It would also be beneficial if CT DPH, the Connecticut Medical School, 
Connecticut Convergence Institute for Translation in Regenerative Engineering would 
initiate “blood serum clinics” from those people or patients who are feeling afflicted with 
PLTDS/CLD. In the past, serological surveys and clinics have generated new insights for 
the discovery and cure of infectious agents that became new diseases in the United States 
(e.g., AIDS, syphilis) and nowadays, there are a standardized diagnosis and acceptable 
treatment protocols (Metcalf et al., 2016). Additionally, parallel applications should be 
dedicated to finding more about CLD/PTLDS. Without a CLD/PTLDS’s case definition, 
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it would be unfair to assess what are the best PCP practices to diagnose and treat patients 
for CLD/PTLDS. There should be resources to find more important issues pending and 
presently unsolved pertinent to the uncertainty of CLD/PTLDS as new disease (if this is 
the case) as: (a) aids in the identification, if applicable, of a known biological agent 
involved in CLD/PTLDS; (b) reconcile concerns regarding Borrelia burgdorferi 
exposure studies that refine the laboratory testing of LD and CLD/PTLDS agents; and (c) 
move toward a medically-informed consensus of CL/PTLDS symptomatology and 
diagnostic indicators (Greenberg, 2017).  
Implications 
Epidemiological studies that will assess CLD/PTLDS prevalence/incidence rates 
and LD-CLD/PTLDS correspondence rate (i.e., how many patients diagnosed with LD go 
on to develop CLD/PTLDS) would be especially worthwhile. Epidemiological studies 
that will assess CL/PTLDS prevalence/incidence rates and LD-CLD/PTLDS 
correspondence rate will help to minimize the current polarized understanding regarding 
CLD/PTLDS that has created a dispute among many medical professionals, including 
mainstream community PCPs (Marzec et al., 2017). Since there is not a case definition 
for CLD/PTLDS, PCPs in Connecticut should compromise to accept PTLDS and start 
collecting information about PTLDS.  
The comparative findings found between this study and Johnson and Feder’s 
(2010) study presented in this cross-sectional investigation contradict and complement 
one another within the same alignment of the literature review presented in chapter 2. 
This study and Johnson and Feder’s (2010) study have similar findings to affirm the need 
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for more studies to find (a) the identification (if any) of a biological agent involved in 
CLD/PTLDS; (b) associations between LD and CLD/PTLDS (d) CLD/PTLDS diagnostic 
criteria; and (e) CLD/PTLDS treatment ‘best practices. It would be improper for PCPs to 
have an effective standardized treatment if they do not know if the agent causing 
CLD/PTLDS is infectious or not. Moreover, there is the pressing need for more studies to 
find if there are any relationships between LD biofilms and late antibiotic treatment, 
associated the prevalence of CLD/PTLDS, that at this time is unknown. 
Moreover, without any doubts, the study findings affirm the need for new 
conversations between PCPs, government officials (local, state, and federal), and patients 
to allocate financial resources for further medical and epidemiological investigations 
regarding CLD/PTLDS. In addition, the study findings will help to create universal 
guidelines for the best optimal treatment for patients affected by CLD. Additionally, 
results from this study suggest that medical doctors may find it challenging to treat 
patients potentially suffering from CLD/PTLDS.  
It is hoped that the knowledge generated in this study can be applied by 
physicians to understand their pursuit of eliminating and minimizing morbidity and 
mortality among their patients. Facing the need to force better practices for the 
CLD/PTLDS diagnostic and treatment acumen will promote their sensitivity and 
understanding when dealing with patients who report CLD/PTLDS symptoms. The 
increasing rate of PCPs who diagnose and treat CLD/PTLDS, as evidenced in this study, 
denotes a need for change in medical policies to make the CLD/PTLDS diagnosis more 
cost-effective, and legitimate to be documented in a new electronic surveillance system. 
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Additionally, the results of the study may help federal and state government health care 
organizations (e.g., CT DPH, CDC) to urgently fund more studies to find the etiological 
agents of CLD/PTLDS, to consequently develop and implement educational programs, 
new policies and services that equip PCPs to have a standardized diagnosis and treatment 
system across all medical doctors’ categories.  
It is the intent of the researcher to develop, complete, and publish empirical 
manuscripts from this study. Attention will be given to publishing in peer-reviewed 
epidemiology and public health journals, in partnership with the previous researchers 
(i.e., Johnson & Feder, 2000) and Walden University mentors. The study data set is 
robust enough to publish results noted in this study as well as findings on additional 
information gleaned from the data set. The dissertation manuscript will be published 
through ProQuest and made available to Walden University professors and students.  
Conclusion, Future Research, and the Need for Social Change 
As posited by Johnson and Feder (2010), the diagnosis and subsequent treatment 
of CLD/PTLDS remain challenging and controversial issues for PCPs in Connecticut. 
PCPs, such as internists, pediatricians, family, and emergency medicine physicians, are 
often the first to diagnose and treat LD. Nonetheless, in this study it was found that LD is 
not as straightforward diagnosed and treated as in the previous study done 10 years ago 
or maybe not as many physicians feel comfortable diagnosing regular LD anymore. This 
is an interesting point to move the message in this research to create social change and it 
is interesting since it looks like especially LD has strong scientific evidence to back it up. 
Nonetheless I think physicians may prefer evidence-based medicine, but when a disease 
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emerges that they do not know how to treat or have treated unsuccessfully using the 
standard of care, they resort to case based reports or expert opinions, lower levels of 
evidence.  Thus, the data from this study process show how PCPs diagnose and treat 
CLD/PLTSDS as an emerging disease that still requires a scientific explanation and more 
research is needed. PCPs must remain attentive to the possibility that 3 to 28% of these 
patients may develop CLD/PTLDS. Often, PCPs do not have the means or the time to 
explore and investigate the causes of CLD/PTLDS symptoms, nor are they able to 
provide a holistic and ongoing evaluation and treatment protocol for CLD/PTLDS 
patients. Patients with CLD/PTLDS, both self-diagnosed or diagnosed by a PCP, 
frequently suffer in silence. Ultimately, CLD/PTLDS patients’ health-related quality of 
life and daily functioning may be impaired due to these controversies. 
Despite the substantially higher number of 285 PCPs in the previous study, the 
proportional distributions of internists, pediatricians, and family and emergency medicine 
physicians were similar to those in this study (Figure 20). It can be accounted that in 
Connecticut, the numbers of PCPs grow or diminish not more than 20% of any previous 
year. The mean number of patients diagnosed for CLD/PTLDS by PCPs and the 
estimated average course of antibiotic treatment (in weeks) did not significantly differ 
between this study and Johnson and Feder’s (2010) study. However, significantly fewer 
PCPs were comfortable diagnosing and treating LD in this study. This study and Johnson 
and Feder’s (2010) study may collectively provide insight regarding PCPs’ KAP on 
CLD/PTLDS based on their survey responses. 
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Figure 20. Percentages (or proportions) of the total numbers of primary care physicians 
in the categories used in this study. Total numbers did not change more than 20%. This 
type of information is very limited to be share. Thus, it would be more meaningful to be 
able to show how the how the PCPs increase or decrease in such specialty, but such 
information is well protected by at the CT DPH.  
Moreover, this manuscript points out how the substantial majority of PCPs voice 
discomfort and concern when diagnosing and treating LD and CLD/PTLDS. Some 
patients diagnosed with LD, much less CLD/PTLDS, may never have reported a tick bite 
or show the EM rash (Allen et al., 2016; Gasmi et al., 2017). There are existing PCP 
customary practices (meaning PCPs want to diagnose their patients adopting an evidence-
based approach); PCPs and other health care providers want to diagnose and treat all 
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assessment on their patients to find why they are sick (Ebell, Sokol, Lee, Simons, & 
Early, 2017). There may be some limitations when requesting an exact diagnostic test for 
CLD/PTLDS patients because there is no known biological agent, which prevents 
potential medical tests for CLD/PTLDS (Lantos, 2015c). Therefore, PCPs may not be 
comfortable with CLD/PTLDS diagnosis because there is no cost-effective clinical 
testing to back it up and recommended treatment (Ebell et al., 2017; Lantos, 2015a). 
Consequently, the lack of a consensus on a CLD/PTLDS case definition among 
leading medical organizations will continue until there are further discoveries related to 
this condition (Stanek et al., 2010; Stricker & Fesler, 2018). The lack of a case definition 
has important implications. The World Health Organization (2016) who developed ICD 
classification codes (see Table 2) to identify a patient’s specific health condition, as well 
as the respective billing code to health insurance companies, has not assigned an ICD 
classification code for either CLD/PTLDS (CDC, 2017; World Health Organization, 
2016). PCPs may be highly reticent in diagnosing a patient with CLD/PTLDS if they 
cannot follow standardized protocols to have their patients be reimbursed by their 
insurance companies or non-coverage policies.  
This study may instigate a consciousness of how difficult it may be for a PCP to 
better assist patients with CLD/PTLDS; this may be because the existing guidelines for 
infectious diseases do not consider CLD a disease that affects people in Connecticut 
(where LD was discovered) or in the United States. For example, the American Academy 
of Pediatrics presently (as 2017) stated that they do not consider CLD/PTLDS a medical 
diagnosis (Korioth, 2017). It is necessary for organizations (i.e., World Health 
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Organization, CDC, National Institute of Health, and the CT DPH) to hold conversations 
that contribute to future innovations and practices. However, to accomplish this, they 
need a consensus on the most recent data collected from the care given to patients with 
CLD/PTLDS.  
In the study, the survey was random and anonymous, so there was limited 
opportunity for the participants to exchange an active dialogue with the researcher of this 
study. Nonetheless, there was at the end of the survey space for PCPs to write comments 
(see Appendix A). This chapter ends with a list of specific gaps in knowledge as well as 
applied practice recommendations:  
• The current treatment data lack specificity since the previous data on 
standardized “treatments” (including alternative treatments) can be applied to 
persons under specific CLD/PTLDS clinical conditions. 
• The present CLD/PTLDS data published up to 2019 cannot be well 
characterized and it will be not useful for surveillance, prevention, or control 
of disease to eliminate mortality and morbidity. 
• In the future, it helps to determinate the geographical locations of patients 
afflicted by CLD/PTLDS, but the reporting of cases will need to meet the 
specific case definitions (possible, probable, confirmed) – without this, 
geographical mapping can be misleading so that future researchers can 
determine the incidence and prevalence of CLD/PTLDS. 
• There is still lack of knowledge to find or corroborate if environmental factors 
play a role in the symptomatology and developmental pathophysiology of 
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such patients with CLD/PTLDS, because it is meaningless without beginning 
with well pedigreed data – that is, data developed with careful forethought and 
scientific objectivity, including the development and use of standardized 
definitions and establishment of a representative surveillance and monitoring 
system. 
• There is the need for more studies to find their effects of climate change on 
tick-borne diseases (Connecticut Agricultural Experimental Station,2017; 
Dumic & Severnini, 2018), notably when the CDC reports that the ticks 
population keeps increasing in the last decades (CDC, 2015b) 
• There is no confirmation of the etiological agent of CLD/PTLDS thus, clinical 
testing is limited, and the use of the term “CLD/PTLDS” implies the present 
LD diagnostic tests have very low sensitivity and can produce many false 
negatives. 
• There is a need for new innovative technologies that can help identify vector-
borne diseases from non-vector bone disease since most scientists think that 
CLD/PTLDS is a vector borne disease related with B. Burgdorferi (the 
spirochete that causes LD). 
• There is a need for organizations such as the CDC, World Health 
Organization and the Infectious Diseases Society of America to investigate if 
patients with CLD/PTLDS are related to LD because LD has a standardized 
case definition, and clinical care guidelines exist to develop an ICD code for 
CLD/PTLDS and better medical guidelines that PCPs can follow (see Table 2) 
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• If CLD/PTLDS becomes established as an infectious disease, the Institute of 
Medicine and National Center for Complementary and Integrative Health may 
wish to review the applications of the Koch’s Postulates in the 21st Century 
through a rigorous scientific approach and to decide what would be the best 
for patients with it. 
• According to Ali at al. (2014), and Johnson et al. (2014), patients that 
presumed to have CLD/PTLDS is a problem at the national level since, in 
their studies, patients were recruited at large. Thus, it is necessary for some 
legislation to benefit both presumed patients with CLD/PTLDS and PCPs. To 
develop such legislation (local and Federal), the health organizations such as 
the World Health Organization, CDC, Council of State and Territorial 
Epidemiologists, International Society for Disease Surveillance, and state and 
local health departments need to identify what will be the next step towards 
such legislative changes. If this legislative process will be met, patients can 
get their health insurance to pay for the treatments needed, and PCPs do not 
need to be afraid about the care given to such presumed CLD/PTLDS patients.  
• From the biotechnological point of view, there is a need to conduct more 
studies in the fields of molecular biology, immunology, and genetics to 
determine the role of Borrelia burgdorferi and other Borrelia species, as well 
as other bacteriological agents found in deer ticks to find potential 
relationships with patients afflicted by CLD/PTLDS.  
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Medical education for PCPs will continue to be a challenge and will be limited 
until scientists, health professionals, organizations like the World Health Organization, 
CDC, Council of State and Territorial Epidemiologists, and Infectious Diseases Society 
of America resolve present existing disagreements for a standardized case definition and 
ICD code for CLD/PTLDS (Id one day will have the merit to be identified as disease 
alone). Once a case definition and an ICD code will be established, PCPs can follow the 
same protocols and guidelines to diagnose and treat patients with CLD/PTLDS (or in 
some cases with PTLDS). The main limitation for PCPs for not having a standardized 
case definition for surveillance is because patients with CLD/PTLDS do not exhibit 
specific symptoms for their illness like with other infectious or not infectious diseases.  
While the global disease burden has been shifting towards chronic conditions, 
health systems, and moreover, including primary health systems, it is crucial to have the 
system that evoked the concept of CLD/PTLDS. In addition, new opportunities for 
research, as well for CLD/PTLDS and LD studies, should further continue to be funded 
in the United States to benefit both PCPs and their patients (World Health Organization, 
2003). Finally, for CLD/PLTDS or just CLD or PTLDS, definitions usually have to come 
from the medical literature and evolve over time. In this study, it is expected that the 
information presented here most likely will help PCPs to come together to help that 
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Appendix A: CT-KAP Johnson and Feder’s (2010) questions 1-9, update CT KAP 2018 
(questions 10 and 11) 
1. Are you in clinical practice seeing patients?  
 Yes   No 
2. What is your specialty? 
     Family Physician    Internist      Pediatrician    Other (please indicate) _____ 
 
3. How would you describe your knowledge of Lyme disease? 
  I know the symptoms and feel comfortable diagnosing it.  
  I know the symptoms, but I don’t feel comfortable diagnosing it. 
  I don’t know the symptoms and I don’t diagnose it. 
 
4. How would you describe your knowledge of Chronic Lyme disease?  
  I know the symptoms and feel comfortable diagnosing it. 
  I know the symptoms, but I don’t feel comfortable diagnosing it. 
  I don’t know the symptoms and I don’t feel comfortable diagnosing it.  
  I don’t believe it exists. (Go to question #6.) 
 
5. In your experience Chronic Lyme disease includes which of the following? Check 
all that apply; you may check none, or more than one.  
 Following the treatment for Lyme disease, a patient has persistent symptoms like 
headache, trouble concentrating, fatigue, myalgias, and/or arthralgias. Some of these 
patients have Chronic Lyme disease and require prolonged antibiotic therapy. 
 
 A patient has never previously been diagnosed with Lyme Disease but has 
persistent headache, trouble concentrating, fatigue, myalgias, and /or is seropositive 
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for Borrelia burgdorferi antibodies. Some of these patients have Chronic Lyme 
disease and require prolonged antibiotic therapy. 
 
 A patient has never been diagnosed with Lyme Disease but has persistent 
headache, trouble concentrating, fatigue, myalgias, and/or arthralgias is seronegative 
for Borrelia burgdorferi antibodies. Some of these patients have Chronic Lyme 
disease and require prolonged antibiotic therapy. 
 
 Other-please describe _____________________________________________ 
 
6. Over the past 3 years approximately how many patients have you diagnosed and 
treated with Lyme disease? __________ 
 
7. Over the past 3 years approximately how many patients have you diagnosed and 
treated with Chronic Lyme disease? _________________________ (if “0”, please go 
to question 8.) 
 
a. What has been the average total course of antibiotics therapy for these patients 
with Chronic Lyme disease? __________________________ 
 b. In your opinion, have these patients diagnosed with patients with  
    Chronic Lyme disease been helped by the antibiotics? 
 
     Yes      No     I don’t know 
 
8. Over the past 3 years approximately how many patients have you diagnosed and 
treated with Chronic Lyme disease (or PTLDS) by other physicians?  
____________________________ 
 
8a. In your opinion have these patients diagnosed with Chronic Lyme disease 
been helped by antibiotics? 
 
 Yes      No     I don’t know 
 
9. In your opinion, how frequently does Chronic Lyme disease occur in 
Connecticut?  
  Commonly      Uncommonly     Never      I don’t know 
 
10. Did you participate in the same previous same mailed survey done in 2006 by 
Johnson& Feder (2010).  
 
  Yes           No  
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11. I should understand that the fact that you mailed the survey back to me is the 
corroboration that you have given me consent to use your anonymous data in this 
study?  
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Appendix D: Frequencies of Primary Care Physicians in Connecticut from 2005 to 2016 
Table D1 
 
Frequency of Primary Care Physicians  













Note. Adapted from the Connecticut Department of Health (2019). The year before 2006 
and after 2015 have minimal changes in the total frequencies of PCPs. The PCP 
population in Connecticut shows stable growth. 
 








Data on Primary Care Physicians Based on Category 
PCP Category or 
Specialty 
CT DPH of total 
data of PCPS of 
2006 (original) 
in %.  
CT DPH of total 
data of PCPS of 
2006 proportions.  
CT DPH of 
total data of 
PCPs 2015 
(original) in %. 
CT DPH of total data 
of PCPS of 
2017proportions.  
Total number of MD/DO 
from original data 
15,424  17,464  
Family physicians *69% 10643 65.4 11422 
Internal Medecine *20% 3085 19.1% 3336 
Pediatricians *10% 1542 10.4% 1816 
Other  1155  890 
Total  1524  17464 
Total number of PCPs 
selected to participate in 
this study taking a 33% 
1034 (33 % of 
3091)  
 






Frequency Results Based on Category 
Results 
  Family MD Internal Medicine Pediatricians Other  Row Totals 
Frequencies 
of 2006 PCPs 
before 
randomization 
3085  (3011.36)  [1.80] 10643  (10348.17)  [8.40] 1542  (1574.85)  [0.69] 154  (489.62)  [230.06]  15424 
Frequencies 
of PCPs of 
2015 before 
randomization 
3336  (3409.64)  [1.59] 11422  (11716.83)  [7.42] 1816  (1783.15)  [0.61] 890  (554.38)  [203.18]  17464 
        
Column 
Totals 
6421 22065 3358 1044  
32888  (Grand 
Total) 
Note.* Adapted from three sources (a) 
http://www.publichealth.uconn.edu/assets/primarycarereport_02_09.pdf, (b) 
https://portal.ct.gov/DPH/Practitioner-Licensing--Investigations/PLIS/Licensing-
Statistics and (c) the data from the Johnson and Feder (2010). 
The chi-square statistic is 453.7446. The p-value is < 0.00001. The result is significant 
at p < .05.  
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Appendix F: Distribution of the Population Used in this Study (2006 vs. 2015) 
Population 2006 Population 






z Score  p value  
 Total number of the original 
population of PCPs from the 
databases from CT Public Health 
Department years (2006 vs. 
2015) 
15424 17464   
Population (proportion)  after the 
selection of  PCP in the 
categories (F,IM, P) needed for 
the study  from  Original 
population of PCPs from the CT 
DPH MD/DO list. 
3091 5231 20.6351 p < .0001 
p < .05 
Significant  
Dissimilar 
Population (proportion) within  
the pre-selection of the 33 % 
from the population of PCPs 
from the CT DPH MD/DO list   
randomized to receive the 
survey.  
1034 1726 0.4273 p < .0001 
p <. 05 
Not Significant  
Similar 
Population (proportion) of the 
Number of PCPs that responses 
were received successfully from 
the  survey and were mailed   
back to the researchers.  
843 1507 4.1353 p < .0001 
p < .05 
Significant  
Dissimilar 
Population(proportion) of the 
number of PCP that responses 
were received before exclusions 
were applied in the studies.  
330 179 -15.3912 p < .0001 
p < .05 
Significant  
Dissimilar 
Final Population (proportion) of 
the number of PCPs that 
responses were received used for 
data analysis in the studies.  




Note. The population proportions for this study were similar (2006 vs. 2015). 
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Appendix G: The Margin of Error Calculated for this Study 
    
The margin of error (with finite population expected of 300, but I only got 145 (2015P) is 
±5.86%  
Where: z = 1.96 for a confidence level (α) of 95%, p = proportion (expressed as a 
decimal), N = population size, n = sample size. 
z = 1.96, p = 0.5, N = 300, n = 145 
margin of error = 1.96 * √0.5 * (1 - 0.5) / √ (300 - 1) * 145 / (300 - 145); margin of error 
= 0.98 / 16.725 * 100 = 5.86% 
The margin of error (with finite population correction) is ±5.86% 
The margin of error 145 (2015) PCP survey responses received is ±8.138%   
Where: z = 1.96 for a confidence level (α) of 95%, p = proportion (expressed as a 
decimal), n = sample size. 
z = 1.96, p = 0.5, n = 145 
margin of error = 1.96 * √0.5 * (1 - 0.5) / √145= margin of error = 0.98 / 12.042 * 100 = 
8.138% 
The margin of error is ±8.138% 
The margin of error (145 PCP survey responses only) is ±5.805% 
Where: z = 1.96 for a confidence level (α) of 95%, p = proportion (expressed as a 
decimal), n = sample size. 
z = 1.96, p = 0.5, n = 285 
margin of error = 1.96 * √0.5 * (1 - 0.5) / √285; margin of error = 0.98 / 16.882 * 100 = 
5.805% 
The margin of error is ±5.805% 
The margin of error for the whole population of 2006(285 & 145 PCP survey) 430 PCP 
survey responses is ±4.726% 
The margin of error is calculated according to the formula: margin of error = z * √p * (1 - 
p) / √n 
Where: z = 1.96 for a confidence level (α) of 95%, p = proportion (expressed as a 
decimal), n = sample size. 
z = 1.96, p = 0.5, n = 430 
margin of error = 1.96 * √0.5 * (1 - 0.5) / √430 = margin of error = 0.98 / 20.736 * 100 = 
4.726% 





Appendix H: Representation of the Two Population Proportions After Adjustment 
 
Results 






 Row Totals 
Frequencies of PCPs of 
2006 in the study of J&F 
57  (56.00)  [0.02] 113  (118.50)  [0.26] 107  (100.50)  [0.42] 8  (10.00)  [0.40]  285 
Frequencies of 2015 
adjusted in this study 
55  (56.00)  [0.02] 124  (118.50)  [0.26] 94  (100.50)  [0.42] 12  (10.00)  [0.40]  285 
        
        
        
Column Totals 112 237 201 20  
570  (Grand 
Total) 
The Chi-square statistic is 2.1871. The p-value is .534502. The result is not significant at p < 





Appendix I: G*Power Analysis Findings 
 
t-tests  :Means: Difference from constant (one sample 
case) 
Analysis: a priori: Compute required sample size 
Input: Tail(s) = two 
Effect size (d)= 0.1625 
α err prob = 0.05 
Power (1-β err prob)= 0.80 
Output: Noncentrality parameter δ = 2.8145826 
Critical t= 1.9679297 
df=299 
Total sample size = 300 
Actual power = 0.8011039
 
 
Note. Source from Erdfelder et al. (2007). Retrieved from 
https://link.springer.com/article/10.3758/BRM.41.4.1149 
 
